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Summary
In this thesis I present my attempt to further the knowledge on early human development 
with emphasis on trophoblast lineage, using RNA-Sequencing (RNA-Seq) technology. 
RNA-Seq leverages on high throughput next generation sequencing to profile entire 
transcriptomes with extreme sensitivity  and resolution, providing data superior to that of 
conventional methods available for measuring gene expression.
Three major RNA-Seq datasets are presented in this thesis.
The first dataset contains information on transcriptomic dynamics of poly A mRNA from 
a time-course experiment with five time-points (day 0, 2 4 6 and 8), where human 
embryonic stem cells were differentiated along the trophoblast lineage using an improved 
differentiation protocol. 
The second dataset contains transcriptomic data of smallRNA (all RNA transcripts less 
than 200 nucleotides) during the first three time-points of the above mentioned 
differentiation protocol.
The third dataset is on mouse early development and contains information on the 
transcriptomes of the 8-cell stage embryo, E3.5 blastocyst, E4.5 blastocyst and E4.5 
inner cell mass. This mouse preimplantation dataset is used in a comparative capacity to 
find molecular mechanisms which are specific to the human system. 
As an early adapter of the RNA-Seq technology during a time where there were no 
proper analysis software available, I created a series of programatic workflows in the 
form of scripts, written using the python programming language, meant to simplify  the 
analysis of RNA-Seq data and to easily  identify transcriptomic events such as alternative 
ix
splicing, novel exon - exon junctions, exon extensions and expression of novel 
transcripts. These workflows together with the results they provide are also presented in 
this thesis.
Using RNA-Seq datasets and results of programatic workflows mentioned above, this 
thesis presents a comprehensive view on the transcriptomics of early human trophoblast 
differentiation.
When comparing human and mouse preimplantation data, it was evident that  the two 
systems have considerable differences at the transcriptome level concerning both the 
expression pattern and expression level of genes. This observation supports the hourglass 
model of development, where the species of the same animal phylum, for a brief period 
in their developmental timeline known as the phylotypic stage, show a remarkable 
similarity with each other, but show considerable differences during the rest of the 
developmental timeline. Trophoblast development occurs much earlier than the 
phylotypic stage and therefore shows great divergence in transcriptomics between mouse 
and human. This is important because it  advocates the cautious extrapolation of 
biological observations made in the mouse system into human - as in the case of most 
data available for trophoblast differentiation. 
Looking at novel (i.e. unannotated) transcribed regions of the human genome identified 
by RNA-Seq, it was evident that trophoblast differentiation induces the expression of a 
large number of endogenous retroviral sequences. There are instances where these 
retroviral elements modify transcripts by acting as extra exons or as new promoters 
resulting in the expression of new transcripts. Therefore this thesis argues that retroviral 
x
elements are a major component responsible for the human / primate specific 
transcriptomic events in early development. Thus they  are responsible for the interspecies 
diversity seen during the pre-phylotypic stages of development in human and mouse.
xi
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1.1 Preimplantation development: from zygote to blastocyst
Fertilization occurs in the fallopian tube, 24 - 48 hrs after ovulation, leading to the 
production of the zygote, the new organism’s first developmental stage. Then for 3 - 4 
days in mouse and for 5 - 7 days in humans, it  travels through the fallopian tube 
moving towards the uterus while producing new cells - the blastomeres, through 
mitotic division. During these cleavage stages the actual size of the embryo remains 
the same even though the number of cells within the structure increases.  During the 
8-cell stage of the embryo, the blastomeres are totipotent, clearly identifiable and are 
topologically symmetrical. The polarization events that take place during compaction 
create the morula, giving rise to two ‘classes’ of cells - inner blastomeres and outer 
blastomeres. The inner blastomeres are fully surrounded by the outer blastomeres 
while the outer blastomeres have a part of their cell surface exposed to the external 
environment. Maturation of the outer blastomeres into a functional epithelium 
combined with further cell divisions leads to the formation of the blastocoel, the 
defining feature of the blastocyst.
The blastocyst  is composed of an outer layer of cells making the trophoectoderm 
(TE), which marks the perimeter of the blastocyst, and the inner cell mass (ICM), 
which initially  exists as a small group of cells attached to the TE layer facing the 
blastocoel. At around E4.5 in mouse, the ICM  differentiates into the primitive 
endoderm, which will produce the extraembryonic tissues and the epiblast which will 
create the embryo proper. Formation of trophoectoderm (TE) and inner cell mass 
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(ICM) during the genesis of blastocyst marks the first lineage segregation event of the 
embryo. The TE goes on to form the fetal component of the placenta.
1.2 Development of the placenta
The placenta is a complex organ which acts as the interface between two (partially) 
genetically  diverse individuals. It is composed of both fetal and maternal tissue. The 
placenta is essential for the transport of nutrients, gases and waste products between 
the fetus and mother and acts as an endocrine organ facilitating the growth of the 
fetus. Though poorly understood, the placenta also plays an important  role in maternal 
immune modulation preventing the mother from rejecting the semi-allograft embryo.
Placenta development gets underway  just after implantation which takes place at 
around 8 - 9 days post fertilization in humans when the embryo is made up of around 
107 - 256 cells (Benirschke, Kaufmann et al. 2006). Implantation is composed of 
three stages, apposition, adhesion and invasion.
During apposition the blastocyst orients itself so that its embryonic pole gets attached 
first. This is preceded by  complex crosstalk between the blastocyst and the uterine 
wall. After attachment, the invasion phase begins when the trophoblasts in the 
attachment surface proliferate and produce cytotrophoblast cells and a 
syncytiotrophoblast layer. Syncytiotrophoblasts are a multi-nucleated layer of cells 
produced by the fusion of mono-nucleated cytotrophoblasts. Cytotrophoblasts have an 
active proliferative rate which enables them to increase their number while producing 
the syncytiotrophoblast. After some time, vacuoles start to appear in the 
syncytiotrophoblast layer. As development progresses these expand and forms a 
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system of lacunae, separated by ‘walls’ of syncytiotrophoblast - the trebaculae. At 
around day 12 the embryo is completely engulfed by the uterine epithelium, and due 
to the proliferation of trophoblasts, the embryo is completely covered by a syncytial 
layer of syncytiotrophoblasts and cytotrophoblasts. Physical and hormonal pressures 
put on the endometrium by trophoblasts causes the endometrium to form decidua.
Trophoblast proliferation together with lacunar formation divides the trophoblast 
layer into three layers - in the direction of fetus to maternal tissues - primary  chorionic 
plate which is composed of cytotrophoblasts, the lacunary system and the 
trophoblasic shell made by syncytiotrophoblasts. Here the cytotrophoblasts which 
form the chorionic plate, invade the syncytiotrophoblast and continue their migration 
to the maternal endometrium. The invading trophoblasts penetrates maternal blood 
vessels. In the mature placenta this connection results in filling the lacuna with blood. 
These lacuna act as mini reservoirs enabling the diffusion of nutrients and gas to the 
fetus. The endometrium-invading trophoblast cells form villi, where each villus is 
composed of a column of cytotrophoblasts and a surrounding layer of 
syncytiotrophoblast. From the earliest  stages of the placenta to the most mature stage, 
a layer of trophoblastic and fetal tissues, termed the placental barrier, separates 
maternal and fetal bloodstreams.
As the fetus grows and its demands for oxygen and nutrients increases, the maternal 
circulation system and the placental barrier get adapted, so that the blood flow to the 
placenta is enhanced and the efficiency of transfer through the placental barrier is 
maximized. Due to the plugging of maternal spiral arteries by trophoblasts, there is no 
detectable uteroplacental blood flow during the first trimester (Hustin and Schaaps 
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1987) which leads to a low oxygen environment. At around the twelfth week the plugs 
are removed and the maternal blood flow is increased.
1.3 Genes involved in the formation of the trophoectoderm (TE)
The vast majority of functional studies to determine essential gene function in 
preimplantation development and formation of trophoblast lineage relies mainly on 
data from the mouse. Currently Tead4 is considered to be the earliest transcription 
factor involved in TE lineage determination (Yagi, Kohn et al. 2007). Tead4 
homozygous mutants die even before the formation of the blastocoel (Nishioka, 
Yamamoto et  al. 2008). Even though Tead4 is expressed ubiquitously in the embryo 
(Nishioka, Yamamoto et al. 2008), its activity  is modulated through the components 
of the Hippo signaling pathway (Nishioka, Inoue et al. 2010). Hippo signaling is 
made active by  cell to cell contact, which results in phosphorylation of the Tead 
coactivator protein Yap. Yap protein inhibits the nuclear localization of Tead, 
essentially  preventing it from acting as a transcription factor. Since cell to cell contact 
is high on the inside cells, Hippo signaling is more active there, leading to 
inactivation of Tead4. This is supported by the fact  that Yap protein shows different 
sub-cellular localization in ICM  versus TE (Nishioka, Inoue et al. 2010). In Lats 1/2 
homozygous mutants, which are negative regulators of Yap, Yap accumulates in the 
nucleus and Cdx2 expression increases (Nishioka, Inoue et al. 2010). Even though 
Tead4 is expressed in the ICM it is not essential for the ICM (Yagi, Kohn et al. 2007; 
Nishioka, Yamamoto et al. 2008).
Activation of Tead4 in TE leads to the up-regulation of Cdx2 (Yagi, Kohn et al. 2007). 
Cdx2 is recognized as an essential factor for the ICM/ TE lineage segregation and acts 
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by the repression of Oct4 and Nanog in the TE. It has been shown that Cdx2 
homozygous mutant embryos, even if they  produce the blastocyst, die before 
implantation due to the collapsing of the blastocoel, and that in these embryos there is 
no differential expression of Oct4 and Nanog between the TE and ICM (Strumpf, 
Mao et al. 2005). The reciprocal relationship between Cdx2 and Oct4 has been further 
shown by  the over-expression of Cdx2 in mouse ES cells, which down-regulates Oct4 
leading to the differentiation of cells into TE lineage (Niwa, Toyooka et  al. 2005). 
Cdx2 is first expressed in a nonspecific manner and then gets up-regulated in the 
outside cells which are the precursors of TE, suggesting that Cdx2 is not the trigger 
for lineage segregation (Ralston and Rossant 2008; Guo, Huss et al. 2010).
Apart from Tead4 and Cdx2 which based on current understanding, act as the main 
regulators of lineage shift to TE, there are other transcription factors which help  in the 
maintenance and progression of TE state. Among these, Eomes is considered to be an 
important factor in trophoblast development and mesoderm formation (Russ, Wattler 
et al. 2000). Even though Eomes is expressed throughout early development 
(McConnell, Petrie et al. 2005), it is believed to be at least partially regulated by Cdx2 
(Nishioka, Yamamoto et al. 2008).
 
Tcfap2c has been reported to differentiate ES cells into the trophoblast lineage 
independent of Cdx2, even though both Cdx2 and Tcfap2c are required for the up-
regulation of Elf5 which helps in trophoblast cell maintenance (Kuckenberg, Buhl et 
al. 2010). Additionally Ets2 has been shown to be important in trophoblast 
development (Georgiades and Rossant 2006) and trophoblast  stem cell self renewal 
(Wen, Tynan et al. 2007).  Elf5 acts downstream of TE formation and aids in the 
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robust expression of Cdx2 and Eomes (Ng, Dean et al. 2008). Gata3, which is highly 
expressed in trophoblast cell lines, is expressed from the 8-cell stage but gets 
restricted to TE and is thought to regulate TE expression (Home, Ray et al. 2009; 
Ralston, Cox et  al. 2010). Gata2 is also expressed in the blastocyst and is restricted to 
the TE. Thus redundancy  between Gata 2/3 may explain why neither is early 
embryonic-lethal in the mouse. 
1.4 Genes involved in the formation of the placenta
Even though placental mammals (and the placenta) came into being relatively 
recently  compared to the timeframe of vertebrate evolution, the placenta as an organ 
is highly diverse among different species both at the tissue / cellular level and the sub 
cellular level (Rawn and Cross 2008). Surprisingly, this diversity is not caused mainly 
by new placenta-specific genes, as the number of such known genes are low. Instead 
placenta development involves genes with multiple functions in both placenta and in 
other tissues / organs (Cross, Baczyk et al. 2003). For example HAND1 is involved in 
heart and blood vessel formation along with placenta development (Riley, Anaon-
Cartwight et al. 1998). Similar examples include both DLX3 (Beanan and Sargent 
2000) and FGFR2 (Xu, Weinstein et al. 1998). However this lack of placenta specific 
genes is compensated mainly by transcriptional regulation. There are several 
examples of genes which undergo alternative splicing or have alternative start sites - 
regulated by  placenta specific enhancers / promoters - thereby producing a placenta-
specific or placenta-enriched isoform. Some of the placenta-specific promoter activity 
has been derived from historical retroviral infections. 
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1.4.1 GCM1 (Glial cells missing 1)
GCM1 is considered to be an essential transcription factor for placental development 
due to its ability  to make active fusogenic and proangiogenic gene expression in the 
placenta, thereby leading to vasculogenesis and formation of the syncytiotrophoblast 
(Anson-Cartwright, Dawson et al. 2000; Lin, Chang et al. 2010).  GCM1 is reported to 
positively regulate Syncytin (Yu 2002), placental growth factor (PGF) (Chang, 
Mukherjea et al. 2008) and Aromatase (CYP19A1) (Yamada, Ogawa et al. 1999), all 
genes essential for placental function. GCM1 acts as a regulator between the 
proliferative state and the cell cycle arrest / fusion of trophoblast cells (Baczyk, 
Drewlo et al. 2009). GCM1 has a highly  placenta-specific expression and is known to 
be regulated at the post transcriptional level. GSK3B causes GCM1 to be 
phosphorylated which leads to it being detected by FBW2 and ultimately resulting in 
GCM1 degradation (Chiang, Liang et al. 2009). DUSP23 on the other hand has a 
protective effect, since it is involved in the dephosphorylation of GCM1 thereby 
preventing it from being degraded (Lin, Chang et al. 2010).
1.4.2 Chorionic gonadotropin (CG)
CG is a member of the glycogen hormone family  where the rest of the members 
consist of the luteinizing hormone (LH), Follicle stimulating hormone (FSH) and the 
thyroid stimulating hormone (TSH) (Pierce and Parsons 1981). The CG protein is 
dimeric, consisting of an alpha subunit, encoded by CGA, which is shared among all 
the members of the glycogen hormone family and a beta subunit  which is specific for 
CG. CG is only found in primates and horses and is expressed exclusively in the 
placenta (Nilson, Bokar et al. 1991; Rawn and Cross 2008). The beta subunit  of CG, 
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derived from duplications of the gene encoding the beta subunit of LH, has 6 copies 
in the human genome. CG is involved in inducing progesterone secretion from the 
corpus lutem and preparing the uterus endometrium for pregnancy (Cameo, Srisuparp 
et al. 2004) and is essential for the maintenance of human pregnancy.
1.4.3 Growth Hormone cluster
The human growth hormone cluster is composed of five genes - GH1, GH2, CSH1, 
CSH2 and CSHL1. Among these, all except GH1 is placenta specific, while GH1 is 
expressed both in the placenta and the pituitary (Su, Liebhaber et al. 2000). GH2 
protein induces maternal lactogenic and growth promoting activities (Macleod , 
Worsley et al. 1991; Alsat, Guibourdenche et al. 1998).
1.4.4 ELF5 (E74-like factor 5)
ELF5 is believed to act as a “gatekeeper gene”, to maintain the trophoblast  lineage 
after the initial lineage commitment (Senner and Hemberger 2010) and is under 
epigenetic regulation (Hemberger, Udayashankar et al. 2010). In mouse, it has been 
reported that Elf5 is methylated and repressed in the embryonic lineage and 
hypomethylated and expressed in the trophoblast lineage, and enforces maintenance 
of the trophoblast lineage through a positive feedback loop with Cdx2 and Eomes 
(Ng, Dean et al. 2008). In humans, ELF5 expression is found in the villous 
cytotrophoblast cells of the placenta (Hemberger, Udayashankar et al. 2010). On the 
other hand, human embryonic stem cells, and the trophoblast cells derived either 
through spontaneous differentiation or BMP4 treatment have a hypermethylated and 
non - expressed ELF5 (Hemberger, Udayashankar et al. 2010). This raises an issue 
with the conventional trophoblast differentiation protocols since ELF5 is an important 
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regulator of the trophoblast lineage and the conventional differentiation protocols do 
not induce ELF5 expression similar to the actual system.
1.5 Transposable elements in the human genome
Transposable elements are mobile DNA sequences in the genome. They  are able to 
change their location within the genome by using either a “cut  - paste” or a “copy - 
paste” strategy. Transposable elements are divided into two classes - Retrotransposons 
(Class I) and DNA transposons (Class II). It has been estimated that 45% of the 
human genome is composed of sequence derived from transposable elements 
(Griffiths 2001) though many of these sequences are no longer “transposable”.
Under the copy-paste strategy used by retrotranposons in the “migration” across 
genome, the element is first transcribed into an RNA intermediate, which then 
changes the original locale and  finally gets reverse transcribed back into genomic 
DNA. Because of this mechanism they leave behind their original DNA footprint in 
the genome thus effectively amplifying their number over time. Endogenous retroviral 
elements (ERVs) belong to this class. 
DNA transposons on the other hand do not have an RNA intermediate stage as they 
follow a cut - paste strategy. Their movement involves the excision of the transposon 
from the genomic DNA, movement to a new location and then the integration back 
into the genome. 
9
1.5.1 Endogenous retroviral elements (ERVs)
Endogenous Retroviral Elements (ERVs) are the modern day genomic remnants of 
ancient germline infections of exogenous viruses. ERVs alone make up for around 8 - 
10% of the human genome (Griffiths 2001; Goodier and Kazazian 2008; Black, 
Arnaud et al. 2010).
ERVs have the same genomic structure as their active exogenous counterparts. This 
includes the four viral genes, gag, pro, pol and env, sandwiched between two long 
tandem repeat (LTR) regions. The gag gene codes for structural components of the 
viral particle while pro and pol genes code for the enzymatic machinery. The env gene 
codes for viral capsid and envelope protein. The two LTR regions contain regulatory 
elements which could regulate the expression and the function of the ERV element 
(Black, Arnaud et al. 2010).
Previously, ERVs together with other members of the repeat elements group  were 
thought to be nonfunctional and were labelled as “junk DNA”. In fact, most  if not all 
human endogenous retroviral elements (HERVs) have acquired point mutations in the 
coding sequences, which disrupt the original function. That said the mere existence of 
these genes, with their original gene structure intact, indicates that they may  still serve 
a biological purpose. If ERVs were truly  “junk DNA” then at least  the majority of 
them would simply cease to exist, removed through natural selection.
Creation of new ERVs by the integration of new retroviruses to the germline has 
happened throughout evolution. The recent ERVs known as modern ERVs still have 
functional viral pathogens such as the Jaagsiekte sheep retrovirus (JSRV), mouse 
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mammary  tumor virus, feline leukemia virus and the avian leukemia virus which 
closely resemble their (i.e. ERV’s) genomic structure and sequence (Black, Arnaud et 
al. 2010).  However the common consensus is that most of the ERVs, due to point 
mutations, have completely lost one or more functional genes of the original viral 
particle. 
1.6 Human genes originating from human ERVs which are highly 
expressed in placenta
The genes HERV-W (ERVWE1), HERV-FRD and ERV-3 have intact env genes and are 
expressed in the human placenta (Venables, Brookes et al. 1995; Blond, Besème et al. 
1999; De Parseval, Lazar et al. 2003).
1.6.1 ERV-3
This was the first retroviral protein to be associated with a physiological function. 
(Rote, Chakrabarti et al. 2004). ERV-3 is coded by  the env gene, which has a long 
open reading frame, and is expressed in syncytiotrophoblasts but not in villous 
cytotrophoblasts (Lin, Xu et al. 1999). In isolated cytotrophoblasts, the ERV-3 
expression was up-regulated upon differentiation (Boyd, Bax et al. 1993). It has also 
been reported that its expression is associated with increased expression of hCG and 
cell cycle arrest prior to syncytiotrophoblast formation (Rote, Chakrabarti et al. 2004).
A mutation which introduces a stop codon in the ERV-3 coding env  gene has been 
observed (Rasmussen and Clausen 1998; De Parseval, Lazar et al. 2003). The 
functional importance of ERV-3 has been questioned since 1% of the population 
which has this as a heterozygous mutation are healthy. However there is a chance that 
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ERV-3 still might be active due to a variety of reasons including the truncated protein 
retaining function, ERV-3 function being restored by other retroviral elements 
expressed during early  development, and the stop codon being bypassed (Rote, 
Chakrabarti et al. 2004). However based on the structure of the full length ERV-3 
protein, it has been reported that it lacks fusogenic ability  and the ability for 
immunosuppression (Lin, Xu et al. 1999; Lin, Xu et al. 2000; Mi, Lee et al. 2000). 
1.6.2 HERVE1 / Syncytin 1
Protein coded by  the env open reading frame of HERV-W is known as Syncytin 1. 
HERV-W expression is restricted to syncytiotrophoblast (Rote, Chakrabarti et al. 
2004). Syncytin 1 entered the primate genome 25 million years ago after the split of 
the new and old world monkeys which happened 40 million years ago (De Parseval, 
Lazar et al. 2003).
Interaction between Syncytin 1 and the D type mammalian retrovirus receptor leads to 
the formation of the syncytium (Blond, Besème et al. 1999; Handwerger 2009). It is 
believed that Syncytin 1 is involved in the fusion of mononuclear cytotrophoblasts to 
produce syncytiotropblasts.  Syncytin 1 causes cell fusion in cell lines and this 
activity is reversed by  an anti Syncytin 1 antibody (Blond, Lavillette et al. 2000; Mi, 
Lee et  al. 2000) . Conversely when BeWo Cell fusion is induced by forskolin, 
Syncytin 1 is up-regulated (Mi, Lee et al. 2000).  In addition Syncytin 1 contains a 
putative immunosuppressive region suggesting an immunological function as well 
(Black, Arnaud et al. 2010).
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1.6.3 HERV-FRD / syncytin 2
Syncytin 2 was identified by a genome-wide screen for fusogenic retroviral envelopes 
(Blaise, de Parseval et al. 2003).  Both Syncytin 1 and Syncytin 2 are structurally 
similar. Like Syncytin 1, Syncytin 2 is also reported to induce cell fusion and is 
believed to have immunosuppressive properties (Mangeney, Renard et al. 2007). 
1.7 Functional implications of the existence and expression of ERVs
Despite their origins from infective exogenous retroviruses, ERVs have been 
associated with positive effects on their host’s biology. 
Most retroviruses contain an immunosuppressive region in their env  protein which 
enables the viral particle to bypass the host immune defenses. While this is certainly 
detrimental to the host in the case of a retroviral infection, it could be considered as a 
benefit in rare instances where temporary immunosuppression is required. During 
implantation, the mother’s reproductive system must accept the embryo, which is of a 
different genomic composition (i.e. a semi-allograft) to that of the maternal genome. 
An immune rejection at any stage of early development would be fatal to the fetus 
highlighting the requirement for immunosuppression. 
While modulation of immunosuppressive effects has been argued as a main function 
of ERVs they have also been implicated in imparting antiviral resistance, maintaining 
genomic plasticity  and introducing novel regulatory elements via LTRs (Nelson, 
Carnegie et al. 2003). 
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1.8 Genes which produce placenta-specific / placenta-enriched 
transcripts due to insertion of retroviral elements in their regulatory 
regions
Long terminal repeat (LTR) sequences flank retrotransposons and have their own 
promoters and enhancers. Therefore if an insertion of a retrotransposon occurs close 
to an existing gene there is a chance that the expression of the gene is influenced by 
the LTR promoters and enhancers. Several such examples have been reported and 
more instances were identified from the data presented in this thesis.
1.8.1 CYP19A1 (Cytochrome P450, family 19, subfamily A, polypeptide 1)
CYP19A1 codes for the protein Aromatase, which is a key  enzyme in estrogen 
biosynthesis (Simpson, Mahendroo et al. 1994). It is involved in placental 
development as well as preparation for parturition (Fürbass, Selimyan et  al. 2007). 
RefSeq annotation shows that aromatase has two isoforms, where the splice selects 
either the first or the second in a mutually exclusive manner. The isoform which 
encompasses the first exon is reported to be placental specific and this isoform is 
regulated by  a placenta-specific promoter (Kamat and Mendelson 2001). The 
particular promoter exists in an LTR region, suggesting that its origin is retroviral 
(van de Lagemaat, Landry et al. 2003).
1.8.2 EDNRB (Endothelin receptor type B)
EDNRB has an active LTR region, derived from an HERV-E family retrovirus, as an 
alternative promoter, which produces a placental specific isoform (Medstrand, Landry 
et al. 2001).  The LTR promoter is located ~52kb upstream of the “standard” promoter 
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of the gene. Unlike in the case of CYP19A1, the placental specific isoform of EDNRB 
accounts for only around 15% of the total transcripts in placenta (Sakurai, Yanagisawa 
et al. 1990).
1.9 MicroRNAs in early development
MicroRNAs are short non coding regulatory  RNA, which regulate the translation of 
target mRNAs either by mRNA degradation or by translational repression (Lewis and 
Steel 2010). The microRNAs carry  out their function by  binding to the 3’ UTR of the 
target mRNA and they add an additional layer of complexity  to the transcriptome 
(Bartel 2004). 
MicroRNA biogenesis consists of several steps. First, microRNA genes are 
transcribed by RNA polymerase II which produces a primary  microRNA (pri-
miRNA). Primary microRNA has a stable secondary stem loop  structure consisting of 
a ~33 nucleotide stem. Then it is cleaved by the microprocessor complex consisting of 
Drosha and DGCR8 to produce a pre-microRNA. Pre-microRNA maintains the stem 
loop structure of pri-miRNA but has a shorter stem consisting of ~22 nucleotides. 
This stable stem loop  structure is a key feature of microRNAs and can be used in 
microRNA prediction workflows. The pre-miRNA is then transported out of the 
nucleus by Exportin - 5 transporter protein, where the RISC loading complex subjects 
it to a further cleaving step  by removing its loop thus resulting in a ~22 nucleotide 
double stranded RNA (Lee, Ahn et al. 2003). The double strand then gets separated 
where one goes on to act as a mature microRNA while the other (known as the “star” 
strand) gets degraded.
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The expressed cohort of microRNA of a particular tissue / cell type has been shown to 
be highly  specific (Bartel 2004). This implies that microRNA regulation is at least 
partially involved in defining the “state” of the tissue / cell type. Therefore the 
identification of microRNA expression dynamics during early development is very 
important.
Involvement of microRNA in early  development has been reported. Mouse Oocytes 
with nonfunctional microRNA biogenesis machinery do not survive beyond the first 
cell division (Murchison, Stein et al. 2007; Tang, Kaneda et  al. 2007) indicating that 
maternally derived microRNAs are essential for the very first steps of mammalian 
development (Lewis and Steel 2010). Mouse miR-125a expression has been shown to 
begin at the 2 cell stage, and is believed to regulate developmental timing (Byrne and 
Warner 2008). Mouse miR-92 has been shown to be specific for trophoectoderm and 
primitive endoderm (Takeda, Noguchi et al. 1997; Byrne and Warner 2008; Foshay 
and Gallicano 2009). In the case of human ES cells, mir-145 is reported to regulate 
POU5F1, SOX2 and KLF4 showing the importance of microRNA in regulating 
pluripotency  (Xu, Papagiannakopoulos et al. 2009). It has been shown that placenta 
too expresses a unique set of microRNA and some even enter the mother’s blood 
stream (Gilad, Meiri et al. 2008). Thus defining microRNAs in the human trophoblast 
lineage will not only provide resources for understanding the basic biology of 
placental formation but may also potentially provide biomarkers for placental 
function in maternal blood.
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1.10 Epithelial - mesenchymal transition (EMT)
Epithelial-mesenchymal transition (EMT) is the process in which polarized epithelial 
cells convert themselves into a mesenchymal phenotype through structural and 
biochemical changes (Zeisberg and Neilson 2009). EMT transition, or its reverse 
(Mesenchymal to epithelial transition - MET) is dependent on the activity  of 
specialized transcription factors, cell surface proteins, enzymes and even microRNAs. 
While epithelial cells are polar and stationary, mesenchymal cells show an increased 
capability for migration / invasion (Kalluri and Weinberg 2009). 
EMTs are divided into three types. Type 1 includes EMT events that  take place during 
implantation embryogenesis and organ development while type II includes EMT 
events during tissue regeneration and organ fibrosis (Kim, Kugler et al. 2006; 
Zeisberg, Tarnavski et al. 2007; Potenta, Zeisberg et al. 2008). EMTs which take place 
during cancer progression and metastasis are classified under type III (Hanahan and 
Weinberg 2000; Thiery 2002).
During trophoectoderm formation, cells of the morula undergo a transition to an 
epithelial phenotype. Furthermore, during implantation cytotrophoblast cells undergo 
an epithelial to mesenchymal transition which enable them to invade the maternal 
endometrium and act as an anchor and form an interface for gas and nutrient 
exchange (Aplin and Kimber 2004; Bischof, Aplin et al. 2006). These EMT events 
come under type I and are the least studied events among all EMT events. Most of the 
biochemistry  relating to type I EMT comes from the studies done on embryogenesis 
or organ development, an event which occurs after the formation of the TE lineage.
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When EMT events during embryogenesis is considered, canonical Wnt signaling is 
believed to be a critical factor, as embryos deficient in Wnt3 are unable to undergo 
EMT during gastrulation (Liu, Wakamiya et al. 1999; Skromne and Stern 2001). 
Formation of the primitive streak, which is the subsequent EMT event, requires 
Wnt8c (Popperl, Schmidt et al. 1997). Wnt proteins together with FGF receptors 
(Ciruna and Rossant 2001; Perea-Gomez, Vella et al. 2002) and the transcription 
factors Snail, Eomes and Mesps regulate gastrulation (Nieto 2002; Arnold, Hofmann 
et al. 2008; Lindsley, Gill et al. 2008; Kalluri 2009) .
1.11 Involvement of microRNA in the regulation of EMT
Using madin darby canine kidney (MDCK) clones, it has been shown that members 
of the microRNA 200 family (mir - 200a/b/c, miR- 141 and mir - 429) and mir - 205 
are up regulated during EMT and regulate EMT through ZEB1 and ZEB2 (Gregory, 
Bert et al. 2008). mir-200b and 200c down-regulate the expression of ZEB1 and ZEB2 
(Hurteau, Carlson et  al. 2007; Nanna 2007). When expressed, ZEB1 and ZEB2 inhibit 
the expression of E-cadherin transcription, preserving the epithelial phenotype 
(Comijn, Berx et al. 2001; Eger, Aigner et al. 2005).
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1.12 Importance of studying the development and function of 
trophoblast lineage
Trophoectoderm formation marks the first lineage commitment in early  development. 
It also marks the creation of the first epithelial cell type of the new organism. The 
trophectoderm also plays a major role in implantation which is one of the most crucial 
steps for a successful pregnancy. The trophoblast create a majority  of cells / tissues in 
the placenta, a unique organ which acts as the interface of two genetically  different 
organisms (the mother and the child). Problems in trophoblast / placental biology are 
believed to contribute to poor pregnancy outcomes such as preeclampsia (incidence 
rate of 7 - 8%) and preterm labor (10%) (Goldenberg and Andrews 1996). Besides 
providing a better understanding of placental disorders, studying placental biology 
may provide an additional model to study cancer as there are similarities in the 
biology  of the two systems. For instance, during the transformation of villous 
cytotrophoblasts to their extravillous state, trophoblasts change their morphology 
from that  of epithelial to invasive mesenchymal type. This epithelial to mesenchymal 
transformation is seen in several types of cancer and studying trophoblast 
differentiation would shed more light on the underlying mechanisms. Therefore the 
study of trophectoderm is of vital importance not only from an early development 
stand point, but also from a clinical point of view.
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1.13 Model systems currently available to study the trophoblast 
lineage
The study  of trophectoderm formation and trophoblast differentiation, particularly  in 
the human system, presents the researcher with a number of obstacles. Apart from the 
ethical issues raised by early human embryo research, TE formation takes place at an 
extreme early time point of embryo formation making it difficult to obtain clinical 
samples. Samples earlier than 6 weeks of gestation are not available (Golos, 
Giakoumopoulos et al. 2010). The available clinical samples from aborted fetuses are 
difficult to come by  (Enders 2000). When available, the information obtained is 
limited  to the later differentiation stages of the trophoblast. Therefore to circumvent 
the above mentioned issues, different  types of model systems have been developed for 
the study of the early differentiation stages of the trophoblast.
1.13.1 Animal models to study trophoblast biology
One of the ways to study  human trophoblast differentiation is to use a model system 
such as the mouse. Even now, the mouse and in some instances the primate system, 
are been used to study the TE formation and the differentiation of the trophoblasts. 
This approach while informative, has an inherent weakness, due to the genetic and 
biochemical differences between the model system (mouse) and human (Carter 
2007) . 
1.13.2 Cell lines to study trophoblast biology
Primary  trophoblast cultures obtained from aborted placenta and a number of 
choriocarcinoma derived cell lines are available to study trophoblast biology  (King, 
Thomas et al. 2000; Shiverick, King et al. 2001). Carcinoma cell lines are easy to 
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maintain and study  as opposed to the primary cell cultures. However, the latter 
provides a more realistic view of the trophoblast biology (Genbacev and Miller 2000) 
as the cancer like properties of cell lines can be a handicap when using them to study 
trophoblast biology (Khoo, Bechberger et al. 1998). Since the primary trophoblast 
cells have been obtained from early pregnancy placenta or term placenta, they belong 
to a time point much later than the initial lineage commitment, making it difficult to 
use them to study TE formation and early TE differentiation.
1.13.3 Embryonic stem cells
The derivation of embryonic stem cells, specially human stem cells, from the inner 
cell mass of the blastocysts has enabled the study of pluripotency and differentiation, 
without using valuable and rare clinical samples. While trophoblast  stem cells - stem 
cells derived from the trophoblast - are available for mouse, they are still not available 
for humans.
Under right conditions, stem cells can be differentiated into the trophoblast lineage, 
creating a model system, which starts from the earliest time points of trophoblast 
differentiation. Human embryonic stem cells, have been shown to spontaneously 
differentiate into the trophoblast lineage (Thomson, Kalishman et al. 1995; Thomson, 
Itskovitz-Eldor et al. 1998). However since this differentiation is not uniform, a 
variety of differentiation protocols, including controlling of gene expression, using 
chemical mediators and imparting physical stresses has been proposed to increase the 
efficiency of the differentiation.
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It has been reported that ES cells can be differentiated along the trophoblast lineage 
by preventing the expression of pluripotency factors. This has been done by ‘active’ 
methods such as knocking down (Niwa, Miyazaki et al. 2000; Velkey and O'Shea 
2003; Hay, Sutherland et al. 2004) or silencing POU5F1, NANOG or SOX2 by 
siRNA (Hough, Clements et al. 2006; Ivanova, Dobrin et al. 2006; Loh, Wu et al. 
2006) or through inducing ES cells to form embryoid bodies (EBs) and then selecting 
for trophoblast like cells (Gerami-Naini, Dovzhenko et al. 2004; Golos, Pollastrini et 
al. 2006) .
When it comes to the study of human trophoblast lineage, using these approaches on 
ES cells are preferred, due to its ability to show extreme early events in TE formation 
and differentiation. Since the differentiation starts from human stem cells, the 
observations obtained can be considered more realistic than what is gained when 
using materiel from different species.
1.13.4 Differentiating human embryonic stem cells to the trophoblast lineage 
through modification of hES media
ES cells grown in the presence of BMP4 differentiates into the trophoblast lineage 
(Xu, Chen et al. 2002; Liu, Dovzhenko et al. 2004). A similar observation has been 
done when BMP4 treatment was done without FGF2 (Schulz, Ezashi et al. 2008) . 
While these differentiation protocols do induce the expression of trophoblast related 
genes and suppress the expression of pluripotency  factors they have certain flaws. For 
example it has been reported that the efficiency of BMP4 differentiation is cell line 
dependent and that certain IVF derived stem cell lines had poor trophoblast 
differentiation and that formation of endoderm / yolk sac like structures was also 
involved (Reubinoff, Pera et al. 2000; Pera, Andrade et al. 2004).
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The BMP4 differentiation of human embryonic stem cells to the trophoblast lineage 
has been improved upon by Dr. Luo Wenlong  under the supervision of Dr. Paul 
Robson (Dr. Luo Wenlong’s thesis - https:// scholarbank.nus.edu.sg/handle/
10635/18805, (Wenlong 2008)). This protocol used BMP4 treatment together with 
SU5402, an FGF receptor inhibitor, to produce a rapid, uniform differentiation of hES 
cells to the trophoblast  lineage. This improved protocol works on multiple hES cell 
lines, and results in a more robust and rapid down-regulation of pluripotency factors 
and an up-regulation of trophoblast markers, compared to the standard BMP4 
treatment (Wenlong 2008). My thesis relies on this particular improved differentiation 
protocol to study the transcriptome of the trophoblast lineage.
1.14 RNA-Sequencing as a tool for high-throughput transcriptomics 
From the early Sanger sequencing methods, to the current high-throughput 
sequencing platforms, DNA sequencing technology has come a long way. The modern 
“Next generation” sequencing machines with their efficient chemistries and 
miniaturized technologies have the capacity to sequence millions of DNA reads per 
run. RNA-Sequencing (RNA-Seq) technology exploits this high-throughput 
sequencing capability, to sequence cDNA fragments from RNA extracts to study 
transcriptomes in great detail. 
An RNA-Seq experiment has three main steps. The wet lab portion is where the RNA 
of the particular sample is extracted and the sequencing libraries generated. Then 
comes the sequencing part which results in a large amount of data describing all the 
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sequences of the libraries. The final step  involves mapping the sequenced “fragments” 
to their original genes to identify the transcriptome.
 The wet lab portion of an RNA-Seq experiment has several major steps. 
1) Extraction of RNA and selecting for the RNA component of interest. The RNA 
extraction method should ensure the extraction of the RNA of interest, for example 
to study small RNA, the method used should be able to efficiently extract  the 
smallRNA available in the sample. 
2) Removal of rRNA. In an extracted RNA sample (unless the extraction was done so 
that only small RNA was extracted), ribosomal RNA would be the major 
component. Since rRNA show limited change in biology, they need to be removed 
to better use the available sequencing depth. For this reason commercial kits which 
deplete rRNA or extract mRNA using their polyA tail are available.
3) Fragmentation - Current sequencing technologies have a limited sequencing length. 
Therefore to accommodate this requirement the RNA (or in some cases the reverse 
transcribed cDNA) needs to be fragmented. Sonication methods as well as 
enzymatic methods are used in fragmentation.
4) Reverse transcribing of RNA. Depending on the protocol used, this step comes 
before or after fragmentation.
5) Adapter ligation. For the sequencing machine to process a particular read, it should 
contain two adapters either side of it (This is so that the reads can be incorporated 
into the specific sequencing chemistry used by the sequencer). In some protocols 
one of the adapters is used as a “barcode” for multiplexing of samples.
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1.14.1 Available sample preparation strategies
Since RNA-Seq technology has been around for some time now, there are different 
protocols available for different samples. Choice of protocol is mainly determined by 
the amount of RNA available and the segment of the transcriptome which is of 
interest. 
If the sample amount is not an issue, then the most common sequencing method is the 
fragment sequencing, which (if ABI sequencers are used) gives strand specific reads. 
There is also another protocol by Nugen (http://www.nugeninc.com/nugen/index.cfm/
products/amplification-systems/ovation-rna-seq-system/), which uses a lesser amount 
of sample, and which does rRNA depletion and sample amplification within the same 
protocol. If the sample amount is really  low there is also a single cell RNA-Seq 
protocol (Tang, Barbacioru et  al. 2010) which takes in a single cell’s worth of RNA 
and amplifies it so that sufficient material is obtained to construct RNA-Seq libraries.
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1.14.2 Applied Biosystems (ABI) SOLiD Sequencing
When we were selecting technologies for RNA-Seq, ABI offered the best sequencing 
depth and fragment length combination. SOLiD technology  provides 50bp reads 
which are most importantly, strand specific, i.e. one can take a sequenced read and not 
only say  which portion of the genome it came from but also say  which strand it 
originated from. In the case of transcriptomics this feature is extremely useful.
SOLiD technology has a different method of “reading” bases when it sequences a 
read compared to other available technologies. Instead of reading one base at a time 
(base space), the SOLiD method reads two bases at the same time and this is done in a 
staggered manner so that each base is read twice. This results in increased accuracy of 
the read and higher mappable reads. However the disadvantage of this is that, 
compared to standard FASTA-like sequence outputs given by other sequencing 
technologies, the SOLiD platform results in sequence data encoded in “color space”, 
where each base pair is represented not by their actual names (e.g. ATGC) but a 
number representing two neighboring bases, determined by each base pair. This adds 
another layer of complexity to the data. As a result there are fewer tools available to 
analyze color space data compared to standard base space data.
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1.15 Results from RNA-Seq compared to traditional methods
Compared with traditional transcriptomics techniques such as real time PCR and 
microarray, RNA-Seq experiments tend to cost more, require a greater effort both 
during sample preparation and data analysis and requires specialized and expensive 
equipment. However despite these drawbacks the quality and depth of information 
provided by an RNA-Seq experiment is far superior to that obtained from any other 
conventional transcriptomics method.
In contrast  to hybridization-based methods such as microarrays, RNA-Seq is a 
sequencing method. Therefore the technique is highly  accurate and sensitive and not 
confounded by  cross-hybridization effects. The technology is now mature enough to 
make available different protocols for different sample amounts (cell lines to 
embryos) which looks at different RNA types (mRNA to smallRNA). 
Furthermore, unlike a microarray or a qPCR experiment where the sequence of the 
gene is critical to measure its expression level, RNA-Seq data is independent of 
known annotations. Due to this, RNA-Seq technology provides information on the 
entire transcriptome including both known and unknown entities. This enables the 
easy identification of new transcripts / genes. In addition, since RNA- Seq data 
contains information on all the exons of the transcripts, accurate expression levels can 
be calculated and also alternative splicing and alternative start events can also be 
studied.
Moreover, depending on the protocol, the RNA-Seq data can be strand specific. This 
means that in addition to the expression level of a particular transcript, its coding 
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strand can also be identified. All the data except the mouse embryo RNA-Seq data is 
strand specific. 
Due to these advantages RNA-Seq is currently  the best tool available for the study  of 
transcriptomes.
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2 Materials and Methods
2.1 Cell culture
Only the cells grown in feeder free conditions were used in the study to prevent the 
samples from being contaminated by mouse embryonic fibroblasts (MEFs). The 
WiCell H1 human embryonic stem cell line (WiCell research institute) was grown on 
conditioned hES media, at 37 ºC, in a humidified atmosphere with 5% CO2 . The cells 
were routinely passaged every 7 days.
2.1.1 Preparation of conditioned human embryonic stem cell (hESC) media
Human embryonic stem cell (hESC) media was prepared by  combining 800 ml of 
DMEM  F12 (Gibco, #11330-032), 200 ml (or 20%) of Knockout serum (Invitrogen 
#10828028), 10 ml of 100 mM L- Glutamine (Gibco, #25030) with 7 !l of 2 - 
mercaptoethanol (Gibco, #21985-023), 10ml of non essential amino acid (Gibco, 
#11140) and 45 !l of 10%  bFGF (Invitrogen, # 13256-029).
A 15 cm cell culture plate was coated with 0.1% gelatin (Stem cell technologies, 
#07903) overnight, and the plate was seeded with 4 million inactivated MEFs in MEF 
media.  
On the second day, the MEF media was replaced with hES media, and from the third 
day to the tenth day the conditioned hES media was collected, and a new volume of 
hES media added daily. Finally the collected conditioned media was filter sterilized 
and 90!l of bFGF added for a final bFGF concentration of 4 ng / ml.
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2.1.2 Passaging cells
First, the plates to which the split cells were to be added, were coated with Matrigel 
(BD, #354234) diluted with knockout DMEM  (Gibco, #10829) to a dilution ratio of 1: 
30. 
During passaging, the cells were first  incubated with a 1 mg / ml solution of type IV 
collagenase (Gibco, #17104019), for 5 - 7 minutes at 37 ºC . After the incubation and 
after ensuring that the edges of the cell colonies appear to be curled, the collagenase 
solution was replaced by hES medium. Then using a sterile 5 ml pipette, the cells 
were gently scraped and the cell suspension was centrifuged (Eppendorf, #5810R) at 
800 rpm, for 1 minute at room temperature. After the centrifugation step the 
supernatant was removed and the cells were resuspended in conditioned media. The 
suspension was gently pipetted up and down to break the large cell clumps and the 
cells were added to the Matrigel coated plates.
2.1.3 Treatment of cells
SU5402 (Calbiochem, #572630) was dissolved in DMSO ( Sigma, #D2650) before 
diluting in conditioned hES media for a final concentration of 20 !M and BMP4 (R & 
D Systems, # 314-BP /CF) was diluted in DPBS (Gibco, #14190 ) to a concentration 
of 100 !g / ml before being diluted to a concentration of 100 ng / ml. The media 
containing 20 !M of SU5402 and 100 ng / ml of BMP4 was added to cells during 
treatment and the media was changed daily.
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2.1.4 RNA extraction
Extraction of RNA was done by using a combination of standard TRIzol (Invitrogen, 
#15596-018)  method and the RNA extraction using RNAeasy mini kit (Qiagen, 
#74106). Please note that unless otherwise stated the centrifugation steps and 
incubation steps were done at room temperature.
Each 15cm dish containing H1 hESC colonies were first washed twice with 10ml of 
PBS (Gibco, 14190 - 144 ) followed by  the addition of 6 ml TRIzol. After incubating 
for 5min with TRIzol, the lysed cells were mixed well by pipetting up and down and 
divided, 1 ml each, into 1.5 ml micro-centrifuge tubes (Eppendorf, MCT-175-C). For 
each tube (containing 1 ml of TRIzol), 200 !l of chloroform was added and incubated 
for 3 minutes. This was followed by a centrifugation step at  4 ºC for 15 minutes at 
12,000 rpm (Eppendorf, #5415R). After the centrifugation the aqueous layer was 
carefully  placed into another 1.5 ml micro-centrifuge tube and 500 !l of isopropanol 
was added to it. This was incubated for 10 minutes and centrifuged at 12,000 rpm for 
4 ºC for 10 minutes. The supernatant was discarded and the remaining pellet was 
washed by adding 1 ml of 75% ethanol followed by a centrifugation step at 10,000 
rpm for 5 minutes at  4ºC. The remaining washed pellet was dissolved in 100 !l of 
RNase free water (Ambion, #AM9937) and the Qiagen mini RNAeasy kit (Qiagen, # 
74106) was used to process the resulting RNA solution.
350 !l of Buffer RLT (with 1%, 2- mercaptoethanol (Gibco, # 21985 - 023)) was 
added to the 100 !l RNA solution followed by 250 !l of 100% ethanol. The resulting 
solution was mixed by gently  pipetting up and down and then applied to a RNeasy 
mini column. This was then centrifuged for 30 seconds at 12,000 rpm and the flow-
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through was discarded. After changing the collection tube, 500 !l of buffer RPE was 
added to the spin column and centrifuged for 30 seconds at 12,000 rpm and the flow-
through discarded. Then the spin column was again centrifuged for 1 minute at 12,000 
rpm. The RNeasy mini column was placed in a new sterile 1.5 ml micro-centrifuge 
tube. The RNA was eluted out by adding 20 !l of RNase free water directly  onto the 
filter membrane of the spin column, incubating for 1min and centrifuging for 12,000 
rpm for 1 minute. This step  was repeated once to elute the remaining RNA from the 
membrane. 
2.1.5 Checking RNA concentration, purity and integrity
RNA concentration and purity was measured by the NanoDrop spectrophotometer 
(Thermoscientific, #ND-1000). The NanoDrop uses absorbance at 260nm wavelength 
to predict the RNA concentration based on the Beer - Lambert law. The 260 / 280 
absorbance ratio was used as a measure of RNA purity  and a value above 2.0 was 
considered to be pure.
The RNA integrity  was evaluated by performing a Agilent RNA 6000 pico assay 
(#5067-1513) on the Agilent bioanalyzer. The RNA integrity number (RIN) gives the 
integrity  of the RNA sample in a scale of 0 - 10 where 10 is the highest. All samples 
used had a RIN value of more than 9.
2.1.6 Poly (A) RNA purification
The Poly (A) Purist MAG kit (Ambion,  #AM1922) was used for extracting RNA 
transcripts with a poly A tail from the total RNA extract. The poly (A) purist mag kit 
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uses oligo (dT) magnetic beads and a magnet to capture RNA transcripts with a poly 
A tail. The capture process involves placing the micro-centrifuge tube with the 
sample / wash solution in the holder of the magnet for 2 minutes letting the magnetic 
beads attach to the surface closest to the magnet and carefully  removing the liquid 
portion. 100 !g of total RNA was used for the mRNA extraction for each sample. 
The total RNA concentration was adjusted to 600 !g / ml by adding RNase free water 
and to this diluted RNA solution,  an equal volume of  2X binding buffer was added 
and mixed. 10 !l of oligo (dT) beads were used per 100 !g of RNA. The beads were 
first washed twice with wash solution 1 prior to use. The RNA in binding buffer was 
then mixed with the beads and the mixture was incubated for 5 minutes at 70 ºC. After 
this it was incubated for 60 minutes on a shaker ( Labnet, #S2030 - RC - 220) at room 
temperature, with gentle rocking. The beads were captured and washed twice with 
wash solution 1 and wash solution 2, respectively. The volume of wash solutions used 
was equal to the volume of the initial diluted total RNA. The poly (A) RNA was 
eluted from the beads by two 200 !l washes of the RNA storage solution heated to 
75ºC. The RNA was then precipitated using an incubation step of 1 hour at -80ºC with 
0.1 volumes of 5M ammonium acetate, 1 !l Glycogen and 1.1 ml of 100% ethanol. 
After incubation the poly (A) RNA pellet was isolated by a centrifugation step of 30 
minutes at 12,000 g  at  4ºC. The pellet was then washed with 1ml of 70% ethanol 
followed by a centrifugation step for 10 minutes at  4ºC . Finally the poly  (A) RNA 
pellet was resuspended in 30 !l of RNase free water.
The concentration and the efficiency of poly  (A) extraction was measured using a 
bioanalyzer trace.
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2.1.7 Whole transcriptome library preparation for SOLiD sequencing
The whole transcriptome library preparation consisted of fragmenting the poly (A) 
RNA, adapter ligation, reverse transcription, size selection and amplification. For 
these steps the contents of the ABI whole transcriptome library preparation kit (ABI, 
#4425680 ) was used.
2.1.7.1 Fragmentation
750 ng of poly (A) RNA diluted in 8 !l of RNase free water was used for 
fragmentation. 1 !l each of 10X RNase III reaction buffer and RNase III was added to 
the  diluted poly (A) RNA solution. It  was mixed by gently pipetting up  and down and 
incubated for 10 minutes at 37 ºC in a thermocycler (BioRad, tetrad 2). Immediately 
after the incubation 90 !l of nuclease free water was added to the reaction mix.
Following the fragmentation step  an RNA cleanup step was performed using the 
Ribominus concentration module (Invitrogen, #K155005). 100 !l of binding buffer 
L3 and 250 !l of 100% ethanol was added to the fragmentation reaction mix with 
water. The mixture was placed in a spin column and centrifuged for 1 minute at 
12,000 g. After discarding the flow-through, 500 !l of buffer W5 was added to the 
spin column and it was centrifuged for 1 minute followed by  another 2 minute 
centrifugation, after removing the flow-through. To elute the RNA, the spin column 
was then placed on a recovery tube. The elution was done by two 20 !l wash steps 
using RNase free water, an incubation step of 1 minute,  and a centrifugation of 1 min 
at 12,000 g.
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The Nanodrop spectrophotometer was used to quantify the resulting fragmented RNA 
and the Bioanalyzer was used to measure the size distribution.
2.1.7.2 Hybridization
75 ng of fragmented RNA in 3 !l of RNase free water, 2 !l of adapter mix A and 3 !l 
of the hybridization solution was mixed on ice. The resulting mixture was incubated 
65 ºC for 10 minutes and 16 ºC for 5 minutes, using a thermocycler with a heated lit. 
After the two incubation steps 10 !l of 2X ligation buffer and 2 !l of the ligation 
enzyme mix was added and the resulting ligation mix was incubated for 16 hours at 
16 ºC on a thermocycler with the heated lid turned off.
2.1.7.3 Reverse transcription
The reverse transcription master mixture (per sample), was prepared by  mixing 
together 13 !l of Nuclease water, 4 !l of 10X RT buffer, 2 !l of 2.5mM dNTP mix 
and 1 !l of array  script  reverse transcriptase enzyme, on ice. This RT mix was added 
to the 20 !l ligation mix after the 16 hour incubation. After gently mixing, the reverse 
transcription was carried out in a thermocycler at  42 ºC with a heated lid for 30 
minutes. 
2.1.7.4 cDNA purification
For cDNA purification the Qiagen PCR purification kit was used (cat #28106). The 
centrifugation steps were carried out at room temperature.
35
The resulting cDNA from the reverse transcription was transferred to a 1.5ml micro-
centrifuge tube and was mixed with 60 !l of RNase free water and 500 !l of Buffer 
PB. The resulting 600 !l solution was added to a mini elute column and centrifuged 
for 13,000 g for 1 minute. The followthrough was discarded and the spin column was 
placed on a new centrifuge tube followed by another centrifugation step of 1 minute 
at 13,000 g. The spin column was placed on another clean micro-centrifuge tube and 
10 !l of buffer EB was added to the spin membrane. After an incubation of 1 minute 
the purified cDNA was extracted by a centrifugation step of 13,000 g for 1 min.
2.1.7.5 Size selection
The size selection of the cDNA is done using a gel purification step which uses Novel 
reagents and NuPage gels (Invitrogen, # EC6865BOX).
5 !l of purified cDNA was run on a Novex 6% TBE-Uread gel (using 1X TBE 
running buffer on the Xcell surelock mini-cell electrophoresis system (Invitrogen, 
EI0001)). Once the gel has run for 15 minutes it was stained with SYBR gold nucleic 
acid stain (Invitrogen, #S11494) and the gel band corresponding to the range 100 - 
200bp was excised and cut into four equal sized vertical bands.
2.1.7.6 cDNA amplification
The PCR mastermix was made by adding 171.6 !l of Nuclease free water, 22 !l of 
10X PCR buffer, 4.4 !l of SOLiD PCR primer 1, 17.6 !l of 2.5mM  dNTP and 4.4 !l 
of Amplitaq DNA polymerase, per sample. Two of the gel pieces cut in the above step 
were individually put on 2 PCR tubes and 100 !l of the PCR master mix was added to 
each. The program for the PCR was set as follows. A holding step of 95 ºC for 5 
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minutes. 15 cycles of  of 95ºC for 30 seconds, 62 ºC for 30 seconds and 72 ºC for 30 
seconds. And a final holding step of 72 ºC for 7 minutes.
2.1.7.7 Purification of the amplified cDNA
The Purelink PCR micro kit (Invitrogen, #A11199 ) was used for the purification of 
the amplified cDNA. All centrifugation steps were done at room temperature.
The PCR reaction solution in both of the tubes were pooled into a 1.5ml 
microcentrifuge tube and mixed with 800 !l of binding buffer B2. This was added to 
a Purelink column, centrifuged for 1 min at 10,000 g and flow through discarded. The 
centrifugation step  was repeated and then the purified cDNA was eluted with two 
washes of 10 !l of elution buffer by incubating for 1 minute and spinning for 14,000 g 
for 1 minute.




2.2.1 Extraction of smallRNA enriched RNA
The mirVana miRNA Isolation kit (Ambion, # AM1560) was used for the extraction 
of RNA, enriched with small RNA.  This kit allows the extraction of RNA less than 
200 nucleotides. The treated cells and the control cells were lysed with 600 !l of 
Lysis / Binding buffer, inside the culture dish and the cell lysate was collected. 1/10 
volume of miRNA homogenate additive was added to the lysate and it was incubated 
for 10min on ice. An equal volume of Acid-Phenol:Chloroform was  then added to the 
mixture, and it was centrifuged at 10,000 g for 5 minutes. After the centrifugation the 
upper (aqueous) phase was carefully transferred to a new tube and mixed with 1/3 
volumes of 100% ethanol. The mix was then transferred to a filter cartridge and after 
a centrifugation step  (10,000g,~15sec) the filtrate was collected. A 2/3 volume of 
100% ethanol was added to the filtrate, and it was again filtered using a filter 
cartridge. The flow through was discarded and the filter was washed with 700 !l of 
miRNA wash Solution 1 followed by two washes of 500 !l of wash solution. The 
RNA enriched with small RNA was then eluted with 100!l of heated (95ºC) nuclease 
free water. 
The RNA integrity and the size distribution of the RNA was evaluated by using the 
Agilient bioanalyzer.
2.2.2 Library preparation
For the library preparation for smallRNA RNA - Seq, the SOLiD Total RNA-Seq kit 
for small RNA libraries protocol (ABI, # 4452439)  was used. This protocol is in 
principal similar to the standard RNA-Seq library preparation, but excludes the 
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enzymatic fragmentation step. 200ng total RNA enriched for smallRNA was directly 
hybridized with SOLiD adaptors and the library generation was done as per the above 
stated protocol. The  library generation steps are omitted here to avoid repetition with 
the standard RNA-Seq library preparation section.
2.2.3 RNA-Seq library generation system with the Ovation system
The standard ABI RNA-Seq library preparation protocol requires a minimum of 
100ng -  200ng of rRNA depleted or poly A RNA. This RNA requirement becomes an 
issue when limited samples such as mouse embryos are concerned. Therefore to 
analyze the transcriptome of the mouse embryos, which yield very  little RNA, the 
Ovation RNA-Seq system by  Nugen (Nugen, # 7100-08) was used. The Ovation kit 
can amplify RNA (in a linear manner) starting from as little as 500 pg and produce 
around 3!g of RNA. Apart from the impressive amplification the other advantage of 
this method is that its amplification does not solely depend on the poly  A tail of the 
transcripts. It uses random priming for amplification, where the primers are 
specifically designed to bind to all RNA except ribosomal RNA. The amplified 
product from the Ovation kit was further processed using the ABI fragment library 
preparation protocol to produce the libraries.
2.2.4 RNA extraction
RNA extraction of mouse embryos was done using the pico pure RNA extraction kit.
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2.2.5 RNA amplification by the Nugen Ovation kit
2.2.5.1 First strand cDNA synthesis
500 pg of RNA in a 5!l solution was mixed,on ice, with 2!l of A1 solution, 2.5!l A2 
solution and 0.5!l A3 solution. The mix was then put in a thermocycler and the 
following program was run - (4ºC 1 min, 25ºC 10min, 42ºC 10min, 70ºC 15min, 4ºC 
hold ).
2.2.5.2 Second strand cDNA synthesis
9.7!l of B1 solution and 0.3!l of B2 solution was added to the products of the first 
strand cDNA synthesis step. It was then placed in a thermocycler and the following 
program was run (4ºC 1 min, 25ºC 10min, 50ºC 10min, 80ºC 20min, 4ºC hold ).
2.2.5.3 Purification of double stranded cDNA
RNAClean beads were used for this step. The beads were first resuspended and 
allowed to return to room temperature. 32!l of the bead mix was added to the 
products of the previous step and incubated for 10 min at room temperature. The 
beads were then aggregated using a magnet and 42!l of the cleared buffer was 
removed. Then the beads were washed three times  with 200!l 70% ethanol and air-
dried for 20 min. 
2.2.5.4 SPIA Amplification
The SPIA mastermix was prepared by mixing on ice 20!l of C2 solution, 10!l of C1 
solution and 10!l C3 solution. This was added to the air dried RNAClean beads 
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containing the cDNA. The mix was then put in a thermocycler and the following 
program was run (4ºC 1 min, 47ºC 60min, 95ºC 5min, 4ºC hold). 
2.2.5.5 Post SPIA Modification
The RNAClean beads were aggregated using a magnet and the supernatant (35!l) was 
put into a new tube.  To the supernatant 5!l of E1 primer was added and the mix was 
incubated for 3 min at 98ºC in a thermocycler. After the incubation, 5!l of E2 solution 
and 5!l of E1 was added and the resulting mix was put in the thermocycler and the 
following program was run (4ºC 1 min, 30ºC 10min, 42ºC 15min, 75ºC 10min, 4ºC 
hold). This produces the final amplified cDNA. The cDNA was purified using 
QIAquick PCR purification kit ( Qiagen, # 28104).
2.2.5.6 Library preparation
The SOLiD fragment library kit (ABI, #S3100101) was used to prepare the small 
RNA-Seq libraries using the amplified cDNA. 
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2.3 Bioinformatic analysis of RNA-Seq
During an RNA-Sequencing run, the sequencer records the nucleotide sequence of all 
the sequenced reads. In order to make biologically relevant interpretations these 
sequenced reads must be first mapped to the genome to identify the region it 
originated from, and then the reads should be counted so that the expression level of 
the particular region they map  to, can be measured. For these above mentioned steps 
Bioscope software (version 1, ABI) was used.
2.3.1 Alignment / mapping
Bioscope uses the software - mapreads (also known as, SOLiD system colour space 
mapping tool)(http://solidsoftwaretools.com/gf/project/mapreads/) for the alignment 
of reads to the genome. Mapreads uses a seed and match strategy  for mapping. In this 
approach, the software first tries to find an initial alignment of 25 bases between the 
read and the genome (the seed) with a maximum of 2 mismatches. Once it finds such 
a place the alignment is extended to the entire length of the read, and an alignment 
score is calculated by giving a score of +1 for each correctly aligned base and -2 for 
each misaligned base. During alignment the mapreads software looks at up to ten 
positions each read aligns to and only considers a read as uniquely aligned if the read 
maps to only one position or if the difference in score between the best alignment and 
the next best is more than 4. During the mapping step  the reads are mapped to the 
filter sequences (described below), splice junctions and the genome in parallel. 
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2.3.2 Mapping to filter sequences
If the reads which originate from the repeat sequences of the genome is used for the 
genomic alignment they can cause unnecessary computational overhead and incorrect 
results, as they would match to multiple locations of the genome with virtually the 
same alignment score. To counter this problem, the reads are mapped to a database of 
known repeat sequences which in effect filter them out and prevent them from being 
mapped to the genome. In our case the repeat database contained ribosomal 
sequences, tRNA sequences and other common repeat sequences. By looking at the 
total number of reads mapping to rRNA sequences, the efficiency  of the rRNA 
removal method can be validated. 
2.3.3 Mapping to the reference genome
This is the single most computationally intensive and most time consuming process of 
the RNA-Seq data analysis. The data described here were aligned to the hg18 build of 
the human genome. This step enables the identification of the genomic regions which 
are being transcribed, and since the alignment is done to the whole genome even the 
unannotated but transcribed regions can be identified. 
2.3.4 Mapping to the splice junctions
The seed and extension method used by  mapreads works well for a majority of reads, 
which originate from exon bodies. However the reads which originate from splice 
junctions do not get mapped to the genome due to the presence of introns in the 
genome which in this case is the reference sequence. To counter this problem 
Bioscope tries to map the reads to a database of all possible exon exon junctions 
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within a given RefSeq gene. This step  manages to recover the splice junction reads. 
Normally splice junction reads are much less in number as compared to the number of 
reads which mapped to their corresponding exons. This is understandable as the splice 
junction reads represent only a small portion of the entire footprint of the transcript. 
However they are important in identifying and quantifying the alternative splicing 
events of genes, as they act as markers of linkages between two exons.
2.3.5 Counting known transcripts
The counting step quantifies the reads which map to a particular transcript or a gene. 
It should be noted that the final counts file shows read counts per exon. Post 
processing is needed to obtain the total number of reads which map to a particular 
exon or a gene. During counting the reads which get  aligned to the genome get 
counted if they have less than 3 bases outside the given exon. As for reads which get 
mapped to splice junctions, they contribute to the count of the exon if it starts or ends 
at the boundary of the exon. 
2.3.6 File formats
Bioscope software produces several files in several formats which contain the RNA-
Seq data.
Counts file : This is a tab delimited text file which contains the total number of reads 
mapping to individual exons of RefSeq annotation.
wig file format: These files contains data on the expression level of each base in the 
genome. These can be uploaded to the UCSC genome browser for visualizing the 
data.
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GTF file format: This contains the sequence and the mapping location of each and 
every read which  align to the genome.
Filter files: Contains statistics on the number of reads which align to the repeat 
sequences.
2.4 Calculating expression levels
The simplest measure of the  expression level of a particular gene is the total number 
of reads which align to it. However the raw read count is not a good indicator of 
expression level as it  is dependent on  the length of the sequence as well as the 
sequencing depth.  (i.e. longer the transcript, the higher the total read count, the higher 
the total sequenced reads, the higher the read count). The RPKM value (Mortazavi, 
Williams et al. 2008) was introduced to nullify the effects of these two factors on the 
expression level of a particular transcript or a gene. The RPKM value was calculated 
by normalizing the total number of reads which fall on all the exons of the gene, with 
the length of all its exons and the sequencing depth. Total mapped reads for the entire 
genome was used as a representative value for the sequencing depth. 
RPKM value for a particular gene was calculated using the following equation:
= [ "(read counts of exons) /{ " (exon length)/1000 X total mapped reads} ] X 
1000000
2.4.1 Microarray Data
The Illumine Single Color Human Ref-8 Version 2 microarray data was first imported 
into GenomeStudio (Illumine) for background correction. Then the data was imported 
into GeneSpring GX (Version 11.0, Agilent Technologies Inc.) where it was 
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normalized (Shift to 75 percentile, Baseline transformation - median of all samples) 
and analyzed.
2.4.2 Comparing expression levels of RNA-Seq data and microarray data
To compare the expression levels obtained by RNA-Seq and microarray, the fold 
change of all the RefSeq genes (day 0 vs day 8 of treatment) were calculated using 
RPKM data values for RNA-Seq and normalized probe intensity values for 
microarray  data. To keep the fold change values accurate only genes showing RPKM 
values of more than one and probe intensity values of more than 20 at both time 
points were used in the comparison. The fold changes were converted into signal log 
ratios (SLRs) by  converting the fold change into its log2 value and the resulting SLR 
values of RNA-Seq and microarray  data were plotted against each other and the 
coefficient of determination (R2) value was calculated for the two datasets.
2.4.3 Gene ontology analysis
Gene ontology analysis was performed using the Panther classification system (http://
www.pantherdb.org/, genome biology article). The geneIDs were uploaded and the 
enriched human gene ontology terms were extracted.
2.4.4 Hierarchical clustering
To gauge the differentiation to the trophoblast lineage brought about by the treatment, 
the microarray expression levels of the treated samples were compared against a 
compilation of published microarray data of normal tissues and cell lines (Ge, 
Yamamoto et al. 2005; Burleigh, Kendziorski et al. 2007; Bilban, Tauber et al. 2010). 
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All the data were normalized using default parameters using Genespring GX, and 
exported into Genesis (Sturn, Quackenbush et al. 2002). There the data was used to 
perform a Hierarchical Clustering using Pearson correlation.
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2.5 Interpreting UCSC browser views
The main usable dataset  of any RNA-Seq experiment includes the locations of the 
genome where each and every sequenced read map to. In this thesis the UCSC 
genome browser (www.genome.ucsc.edu) (Kent, Sugnet et al. 2002) was used to 
visualize the data. The UCSC genome browser has the capacity to take in the large 
RNA-Seq dataset and display it as peaks, which denote the expression of a particular 
region. The USCS browser is also capable of showing existing annotation data 
(exons, genes, ESTs, microRNAs etc.) together with the above mentioned RNA-Seq 
peaks. 
2.5.1 The organization of  data in the UCSC genome browser
UCSC genome browser displays data and annotation information based on the 
genomic coordinates. Each browser view, which is the image the user sees, is 
composed of 1) a data section, where the user provided data is displayed - in this case 
RNA-Seq peaks and 2) an annotation section which comes built into the browser, 
where the user can select the information to be displayed -  such as RefSeq genes. 
Both data and annotations are organized as tracks which are “strips” of either data or 
annotation whose appearance  and the order can be customized by  the user (see Figure 
2.1).
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Figure 2.1: Organization of data and annotation in the UCSC genome browser. 
UCSC genome browser displays data based on the genomic co-ordinates. Annotations 
(shown in blue) for a particular genomic region and the RNA-Seq peaks (shown in 
red) corresponding to the region are overlaid on-top of each other as “tracks”. The 
user has the ability to upload custom data (in this case the RNA-Seq data) and also to 
select which annotation types are selected.
2.5.2 A typical view of the UCSC browser
The RNA-Seq data on the trophoblast differentiation (mRNA and small RNA) is 
strand specific which means that by looking at  the alignment of a particular read the 
location as well as the strand which it originates from can be identified. During 
visualization of RNA-Seq data using the UCSC genome browser the strand specificity 
is represented by two tracks (one for each strand) per sample.












A typical UCSC browser view contains 
two major sections.
1) A data track section for user’s data  - 
in this case showing RNA-Seq read data
2) Annotation data from UCSC and 
other databases
The data and annotation section can be 
overlaid with different datasets known 
as tracks. In this case the view includes 
all time points. 
In the case of RNA-Seq, due to the 
strand specific nature of the data, each 
sample track is subdivided into positive 
strand and negative strand.
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The summary of peaks aligned to the region. The 
peak height for each base shows the number of 
reads mapping to  that particular location. Higher 
the peak height more the expression.
Since this particular gene is expressed in the 
negative strand (see below) there are no reads 
mapping to the positive strands, and the peaks are 
only found in the negative strand.
In this case data relating to only one sample is 
shown. When a comparison of peaks / expression 
levels between samples is required , multiple data 
tracks can be stacked on top of each other.
Standard UCSC annotation notation. The thick blue 
box shows the presence of an exon and the thin line 
joining them shows an intron.
If a particular gene has multiple different transcripts 
they are shown in a separate line. In this case based 
on RefSeq annotation this gene has 9 different 
transcripts.
If the intronic lines show arrows pointing from left 
to right then the gene is present in the positive 
strand and vice versa.
In intergenic regions this annotation is empty. 
RNA-Seq data tracks
Here the reads 
aligning to both 
positive and negative 




Here only two 
tracks are shown. 
First is the UCSC 
gene annotation 
track and the second 
is the RefSeq 
annotation track.




Figure 2.2: Visualizing RNA-Seq data using UCSC genome browser
UCSC browser provides co-ordinate specific information of the genome onto which 
user data (in this case data from RNA-Seq ) can be overlaid. The panel on the left 
shows the read data of the entire chromosome 10, while the panel on the right shows a 
small enlarged view marked by  the black rectangle. For clarity  positive and negative 
stand tracks from only one sample are shown.




Reads aligned to the 
positive strand




Programatic workflows designed for the 
analysis of RNA-Seq data
The function of Bioscope software from ABI, which is provided together with the 
sequencing platform, is primarily to align sequence reads to the reference genome. 
Thus to perform analysis of the RNA-Seq dataset beyond expression levels, I 
developed a set of programmatic workflows. These workflows, coded using the 
python programming language (www.python.org), were designed to use the data / 
files produced by Bioscope as input and produce results files on various aspects of 
transcriptome dynamics.
Over the course of this thesis project, programmatic workflows were designed for the 
following tasks.
• Identification of genes which show changes in their splicing profile during 
treatment
• Identification of genes with exons which show mutually exclusive expression
• Identification of novel transcribed regions
• Identification of novel transcripts
• Identification of extensions of annotation
All the workflows described here, when combined, make up a suite of software 
utilities which enables the rapid identification of interesting transcriptomics 
phenomena from an RNA-Seq dataset. Since these were developed during the course 
of the thesis and used for the analysis of data presented here, the workflows are 
shown in the results section.
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3.1 Workflow for identifying genes for which the splicing pattern is 
altered during treatment
This workflow identifies genes which undergo alternative splicing events of a RNA-
Seq dataset. Apart from altering the expression level of a gene, a treatment can also 
cause a change in its splicing profile (i.e. induce or suppress the expression of 
different isoforms of the same gene). In cases where alternative splicing takes place, 
the overall expression of the gene might not change significantly, even though a 
considerable change in function could occur. 
A straightforward approach to identifying alternative splicing events from an RNA-
Seq experiment would be to use junction reads (reads which originate from the exon - 
exon boundary). This approach works well provided that there is a significant amount 
of junction reads available in the dataset. Unfortunately in the case of most RNA-Seq 
datasets this is not so, as the commonly used fragment library  protocol produces 
fragments of 50bp and this short  sequencing length reduces the likelihood of a 
junction read being mapped to the genome. This reduces the number of junction reads 
discovered.
In order to compensate for the lack of junction reads, this workflow was designed to 
identify splicing events purely  based on individual exon counts and not on junction 
reads. Despite not using split reads, with the correct settings, this workflow produces 
good quality predictions with a minimum number of false positives.
A change in the number of reads mapping to a particular exon during a time course, 
can be due to either a change in the expression level of the gene or due to a splicing 
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event or both. Thus when trying to identify  genes which show an altered splicing 
profile it  is vital to negate the effects of changes in expression levels. In the workflow 
this is done by comparing the expression level of an exon relative to its neighbors. 
The assumption here is that while expression level of the gene is proportional to the 
read counts of its individual exon, a change in gene expression should not change the 
proportion of contribution made by individual exons to the gene expression level if no 
splicing event takes place. For example, in the case of the three exons shown in 
Figure 3.1 - left panel, when the splicing profile remains unchanged, each has a read 
count of 100 which goes down to 50 during treatment. Even though their expression 
levels change, the ratio of expression levels remains constant (100:100:100 = 1:1:1 = 
50:50:50) because the splicing profile remains the same. However when there is a 
change in splicing the ratio cannot be maintained, as splicing selectively  increases or 
decreases the read counts of a exon (100:100:100 vs 50:25:50). By detecting this 
phenomenon the workflow can predict the alteration of the splicing profile of a gene.
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Figure 3.1: The workflow for identifying genes whose splicing profile is altered 
during treatment.
If there is a change in the splice profile it would be seen as a marked increase or 
decrease in read counts of a particular exon with respect to its neighboring exons. 
This method of normalization negates the effect of changes in read count due to up  or 
down-regulation of the gene.
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3.2 Workflow for identifying genes which show mutually exclusive 
exon patterns
This workflow is an extension of the (above mentioned) method for detecting genes 
which show changes in their splicing profile during a treatment. Here the expression 
pattern (up-regulation or down-regulation) of individual exons belonging to a 
particular gene is monitored during treatment to identify a pair or more of exons 
which show an opposite regulation pattern. For example in the case of Figure 3.2, 
genes with the expression pattern on the left will be discarded as all of them show a 
similar type of regulation. However genes showing an expression pattern on the right 
will be identified as having mutual exclusively expressed exons as it  has one down-
regulated and one up-regulated exon.
Figure 3.2: Workflow for the identification of genes with mutually exclusive 
exons. 
The workflow looks for a pair or more exons which are regulated in an opposing 
manner in two time points.
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3.3 Workflow for the Detection of novel transcribed regions (NTRs)
Novel transcribed regions (NTRs) are defined as unannotated regions which are 
transcribed, as shown by RNA-Seq data.  Throughout this study, RefSeq annotations 
were used to identify NTRs, although it should be mentioned that the NTR detection 
workflow was designed to take in any annotation. The identified NTRs could be new 
exons of known transcripts, extensions of known genes or totally new transcripts.
The first step of the NTR detection process involves identifying unannotated regions 
(i.e gaps between annotated regions) of the genome. In the case of RefSeq annotation 
these gaps include introns as well as regions between gene footprints. In the next 
stage, regions identified as unannotated are probed, to find locations which are shown 
to be expressed by having reads mapping to it. These regions are identified as NTRs 
provided that they satisfy  user provided expression criteria which includes the 
minimum height of the peak and the read count of the NTR peak.
Figure 3.3: Novel transcribed regions (NTRs) identification workflow.
NTRs are identified by finding expressed regions in un annotated regions. 
56
3.4 Workflow for the detection of novel transcripts using NTR data
Identification of novel transcripts is done by clustering the novel transcribed regions 
based on the distance between them. The premise is that if there is a series of novel 
transcribed regions with close proximity  to each other then there is a very good 
likelihood that they belong to the same transcript (NTRs acting as exons of the new 
transcript). While NTRs are dispersed throughout the genome and can be found in 
intronic regions, close to known genes and far away from genes, the NTRs which are 
important in identifying novel genes should ideally exist as a cluster of peaks located 
a considerable distance away from known genes. 
Thus the transcript identification workflow first  filters out NTR regions which lie 
close to known exon and gene footprints. In the first pass it  filters out NTRs which 
fall within 25 nucleotides before and after an exon boundary. NTRs filtered at this 
step are used to redefine the known exon boundary based on expression data. Then in 
the second pass it  removes NTRs which fall within 10,000 nucleotides before and 
after a known gene boundary. The NTRs removed here could potentially be novel 
exons of known genes. Resulting NTRs are used for novel transcript identification. A 
set of NTRs are recognized as part of a novel transcript if they are within 10,000 
nucleotides of each other. Once the potentially novel genes are identified they are 
grouped based on whether they are expressed at all time points, a few or at only one.
57
3.5 Workflow for the identification of Extended exon footprints
RNA-Seq data, when aligned to the entire genome, is not dependent on existing 
annotation. While in most  cases the existing RefSeq annotation matches with the 
footprints of the expressed regions as obtained by  RNA-Seq, there are some striking 
examples where expression occurred beyond the existing annotation. These 
‘extensions’ of expression beyond RefSeq annotation, were seen in exons, 3’ UTR and 
5 ‘UTR regions. A workflow was designed to identify  regions where there is a 
significant difference between RNA-Seq data and existing annotation.
To identify  extensions in ordinary  exons (non UTR exons), the workflow first 
identifies exon boundaries from RefSeq and extends the exon footprint until it covers 
all the expressed bases on either side of it. This process essentially  corrects the exon 
annotation, based on the RNA-Seq data.
To identify extensions of the 3’ and 5’ UTR, the workflow starts at the end of the UTR 
and tries to extend the footprint using the expressed regions. Since most UTRs 
contain regions where mapping  efficiency  is low, the workflow allows the extended 
region to have gaps of less than 100 base pairs.
Figure 3.4: The workflow for the identification of exon extensions.
The extensions are identified by comparing RNA-Seq data and RefSeq data.
58
3.6 Workflow for the discovery of expressed repeat regions
Repeat regions usually consist  of long interspersed nuclear elements (LINEs), short 
interspersed nuclear elements (SINEs), long terminal repeat elements (LTRs), DNA 
repeat elements, satellite repeats and RNA repeats.
Bioscope software automatically  does basic filtering of some repeat regions during 
alignment. However the filter process is not extensive and, based on the unique 
alignment, it seems that a significant proportion of repeat regions do show expression. 
Here the main interest was to identify expressed repeat regions which did not have 
any overlap  with RefSeq annotations. Thus during this workflow the repeat regions 
(which were downloaded from UCSC repeat masker track) that  did not have an 
overlap with RefSeq genes were first identified. Subsequently the reads which map to 
these individual regions were counted.
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3.7 Workflow for the identification of novel splice sites
As mentioned earlier, the efficiency of junction reads mapping is low in the case of 
50bp fragment RNA-Seq. While this reduces its effectivity in identifying alternative 
splicing events, these can be used to identify un-annotated exon - exon junctions (i.e.. 
novel splicing between known RefSeq exons). The inherent flaw in this method is that 
it only  picks up novel exon junctions of highly expressed transcripts as they  have the 
highest chance of generating a significant number of junction reads.
To identify novel junctions, the novel junction reads identified during alignment are 
filtered to obtain only the reads which are of best quality and align perfectly to the 
junction. These reads are then grouped based on the gene they belong to.
Figure 3.5 : Novel junction identification workflow 
The workflow for identifying novel splice sites uses the Bioscope junction reads 
which are conveniently labelled to be either known (from a known splice site) or 
putative (unknown splice site). To identify reliable splice sites the junction reads are 
first filtered to remove any potentially mis - aligned reads. Then the filtered putative 
junction reads are used to identify the corresponding exons connected by  the junction, 
thereby defining novel splice sites.
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3.8 Workflow for the identification of novel microRNA from 
smallRNA RNA-Seq
From a theoretical point of view, the smallRNA-Seq experiment should be able to 
capture all the smallRNA expression events that takes place during the experiment. 
By using the novel transcribed region (NTR) detection workflow described above, all 
the potentially novel small RNA in the transcriptome can be identified. Looking at the 
data, as shown in the second results section, most of the novel smallRNA turn out to 
be within the size range of mature microRNAs. Therefore a workflow was developed 
to identify novel microRNA from small RNA-Seq data.
In this workflow (Figure 3.6), the unique properties of the microRNA stem loop 
structure was used to confirm whether an NTR was a microRNA. In this workflow, an 
NTR discovery was done using the smallRNA sample, and then the footprint  of the 
NTR was expanded to encompass the sequence of the stem loop  structure. This DNA 
sequence was then programmatically  folded using RNAfold (Hofacker 2003) using 
minimum free energy to see if it was capable of producing a stable stem loop.
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Figure 3.6: Workflow for the identification of novel microRNA.





The differentiation protocol using SU5402 and BMP4, which pushes a human 
embryonic stem cell to the trophoblast lineage, gives access to a unique and scarcely 
studied cell type. The unbiased nature of RNA-Sequencing is ideally suited to study 
the transcriptome of such a product. This is because RNA-Seq provides much more 
information than the expression levels provided by traditional technologies such as 
microarrays and quantitative PCR.
4.2 hESC derived trophoblast gene expression strongly correlates 
with that of placental derived tissue
Though we were confident that SU5402+BMP4 treatment directs human embryonic 
stem cells to the trophoblast lineage (as described in Dr. Wenlong Luo’s thesis 
(Wenlong 2008)), a recent report suggested that hESC-based protocols did not form 
true trophoblast (Hemberger, Udayashankar et al. 2010), particularly because there 
was a lack of expression of ELF5, a key gene in the trophoblast that is repressed in 
embryonic stem cells through promoter DNA methylation. Thus I aimed to 
comprehensively compare the outcome of our novel differentiation protocol (which 
was not taken into account in Hemberger et. al.) to that of its natural counterpart. 
Trophoblasts are the major zygotically-derived cell type which contributes to the 
placenta from the fetus. In order to find out the cell lines / tissues(s) that show a 
similar expression pattern to that brought about by the differentiation, unsupervised 
hierarchal clustering was used to compare a dataset  containing microarray expression 
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levels of published tissues / cell types and the SU5402 + BMP4 differentiation 
microarray  data. Importantly, besides a broad array of human tissues including the 
placenta (Ge, Yamamoto et al. 2005) this comparison also include sorted extravillous 
trophoblast and cytotrophoblast  cells from first trimester human placentae (Bilban, 
Haslinger et al. 2009), the earliest possible placental cells from post-implantation 
human development. Hierarchal clustering is designed to cluster together similar 
datasets. Therefore, tissues / samples / cell lines which are clustered together can be 
considered as having closely matching global expression profiles. 
Reassuringly, the closest  tissue type to day 6 and day 8 of treatment was the placenta, 
and the closest cell types were the extravillous trophoblast and cytotrophoblast cells. 
In addition, our microarray data indicated that ELF5 was indeed expressed during the 
differentiation. These evidence support that the products of our trophoblast 







Figure 4.1: Trophoblast differentiation products cluster closely with placenta and 
related cell types.
This shows the hierarchical clustering result of the five time-points of the 
differentiation protocol with a list of tissue / organ expression profiles. Day 6 and Day 
8 time-points cluster with Placenta, EVT - Extravillous trophoblast and CTB - 
Cytotrophoblast samples.
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4.3 Poly A extraction of total RNA effectively removes ribosomal 
RNA to increase the dynamic range of the transcriptomic data
RNA-Seq involves extraction of RNA from a particular sample and converting it to a 
library which can be sequenced so that the transcripts can be later reconstructed, and 
their expression levels measured. Ribosomal RNA (rRNA) is the single most 
abundant species (>90%) in any total RNA sample extracted using conventional 
methods. If a sample contains a significant amount of rRNA, it reduces the 
sequencing depth of messenger RNA (mRNA). This hinders the study  of the 
dynamics of the transcriptome as rRNA levels are mostly static. Therefore, for the 
trophoblast differentiation experiments, an mRNA extraction step (based on the 
polyA tail) was performed to remove rRNA from the sample. The Agilent bioanalyzer, 
which measures the length distribution with concentration of RNA, was used to asses 
the reduction of rRNA for each sample.
Figure 4.2: Removal of rRNAs from polyA RNA. 
Overlapped Agilent Bioanalyzer trace of total RNA (blue) and one time - poly  A 






Above observation was confirmed after sequencing, where the reads which mapped to 
known rRNA sequences (and some other filter sequences) were less than 10% of the 
total sequenced reads (Table 1).
Sample Name Percentage of reads mapping to rRNA
SB - Day 0 9%
SB - Day 2 6.5%
SB - Day 4 6.8%
SB - Day 6 7.9%
SB - Day 8 6.2%
Mm - E 3.5 BL 4.2%
Mm - E 4.5 BL 4.2%
Mm - E 4.5 ICM 2.7%
Mm - 8 cell 2.1%
Table 1: Percentage of reads which map to rRNA.
If a sequencing run has a high percentage of reads mapping to rRNA regions of the 
genome, it reduces the number of reads representing mRNAs. All the RNA-Seq 
samples presented in this thesis show a low percentage of reads mapping to rRNA. SB 
- SU5402 +BMP4 treatment, Mm - mouse embryo samples, showing that  the rRNA 
removal was successful.
4.4 Expression levels obtained by RNA-Seq for known genes show a 
good correlation with microarray data
Parallel to the RNA-Seq experiment, a microarray run was performed using the same 
samples (These samples were also used for the hierarchical clustering mentioned 
above). Microarray run was carried out by Ms. Woon Chow Thai from our group. The 
intention of running the microarrays was to observe how expression levels of all 
genes compared between RNA-Seq and the more conventional microarray 
technologies. The comparison was done on differential expression values of RNA-Seq 
and microrray data. To do the comparison en masse the Signal Log Ratio values 
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(SLR = log2 of fold change) of the two datasets were plotted with each other. To 
obtain reliable fold change / signal log ratio values from the microarray data, only 
genes which had a raw signal value of more than 10 in both day 0 and day 8 time-
points were used for the comparison. No filtering was done based on RNA-Seq 
RPKM values. The value of coefficient of determination (R2) between the two 
datasets was 0.8055. Expected R2 value for the two identical datasets is 1 (on a range 
of 0 - 1), thus the two expression datasets with a R2 value of 0.8 can be considered to 
be significantly  comparable with each other. This is further confirmed by the fact that 
94% of the genes had a difference of less than 1 SLR (signal log ratio) value between 
the two datasets and only  5 of the genes showed contradictory expression pattern (i.e 
up-regulated according to one dataset and down-regulated in the other) (Figure 4.3).
Figure 4.3 : Comparison of signal log ratio values of microarray and RNA-Seq 
dataset. 
The fold change values of day 0 vs day  8 were converted to Signal Low Ratios 
(SLRs) by converting them to log2 form. The RNA-Seq and microarray expression 
values showed a good correlation with each other. 
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There were only 5 genes which showed opposite expression patterns (i.e. up-
regulation in one dataset and a down-regulation on the other). Upon closer 
examination these were found to be due to issues with the placement of the Illumina 
microarray  probe. For example in the case of BAX, microarray data indicated the gene 
is up-regulated during differentiation while RNA-Seq data showed otherwise. 
Looking at the RNA-Seq peak profile of BAX, clearly a short and a long isoform of 
the gene is being expressed, and the longer one is down-regulated while the shorter 
one is up-regulated (Figure 4.4). However the Illumina microarray probe in this case, 
only picked up the shorter isoform, marking the gene as being up-regulated. This 
clearly  shows the advantage of looking at the expression of the entire transcript(s) of 
any gene (as in the case of RNA-seq), instead of merely  considering a small portion to 
represent the expression of the entire gene as done by microarray technology.
Figure 4.4: Differences in methods used in RNA-Seq and microarrays for 
measuring gene expression. 
Figure shows the BAX RNA-Seq UCSC view. There is a conflict between RNA-Seq 
and microarray  expression patterns for this gene. The 3’ portion of the gene has been 
enlarged for clarity on the panel on the right, and the red bar marks the position where 
the Illumina microarray probe binds. RNA-Seq data shows that  in the case of BAX, 
the longer isoform is being up-regulated while the shorter isoform is down-regulated. 
Since the microarray probe only detects the shorter isoform, it marks the gene as 
being down-regulated.
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4.5 The trophoblast differentiation protocol brings about drastic 
changes in the hES cell transcriptome as identified by RNA-Seq 
One of the advantages of RNA-seq is its ability to provide a digital count of 
expression levels through the RPKM  value. As described in the methods section, 
RPKM value represents the number of reads mapping to a particular gene normalized 
to it  is length and the total sequencing depth. A gene was defined as significantly 
expressed when it had an RPKM value higher than a set number.  Based on the 
numbers presented in Table 2, it is evident that there is an increase in expressed genes 
upon treatment, which is maintained up to day 6. In other words the treatment seems 
to be inducing a number of genes which are not expressed in human embryonic stem 
cells under normal conditions. The decrease of expressed transcripts between day  6 
and 8, could be due to the clearance of pluripotent genes. Indeed, this differentiation 
protocol had been characterized to co-express both pluripotent and trophoblast  genes 
over the first  couple of days of differentiation and become committed to the 




















Day 0 17005 11094 8688 6452
Day 2 16965 11138 8896 6583
Day 4 17127 11306 9084 6728
Day 6 17132 11359 9155 6729
Day 8 17238 11279 8967 6575
Table 2: RefSeq genes expressed during the trophoblast differentiation time-
course from a total of 21296 RefSeq genes.
Day 0 represents undifferentiated H1 human ES cells. The number of total expressed 
genes increases during differentiation and peaks at day 6.
Figure 4.5: Genes expressed at very high level (RPKM > 10) at each time point. 
There is a clear increase in expressed genes in all time points compared to day 0. 
Please note that  the baseline of the graph has been raised to 6400 to highlight the 
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Figure 4.6: Differentially expressed genes during trophoblast differentiation.
This shows the extent of differential expression between day 0 and day 8, during the 
transition from human ES cells to the trophoblast lineage. Each horizontal bar in the 
main graph depicts the signal log ratio (SLR) of each of the total 21,296 genes. The 
top 10 up and down-regulated genes have been magnified and are shown in the two 
sub charts. The extent of up and down-regulation suggest that the differentiation 
protocol leads to a profound change in the transcriptome. SLR is defined as the log 2 
of the fold change.
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4.6 A number of genes which are not expressed in undifferentiated 
human ES cells gets induced during trophoblast differentiation
Apart from differentially  regulated genes, induced genes during the trophoblast 
differentiation is of particular interest. Here an induced gene is defined as a gene 
which is not expressed in human embryonic stem cells, but  is significantly expressed 
during the differentiation treatment. There is an increase in the number of induced 
genes during treatment, and the induction of new genes seems to be correlated with 
the length of treatment. Even considering a cut off of RPKM > 2, there are 51 genes 
(shown in table 3) which are induced in day 8.
Treatment Total induced 
number of genes 
(RPKM > 0 )
Total induced 
number of genes 
(RPKM > 1)
Total induced 
number of genes 
(RPKM > 2)
Day 2 679 11 4
Day 4 845 32 16
Day 6 912 59 28
Day 8 1018 78 51
Table 3: Trophoblast differentiation induces a number of genes during the time-






















































Table 4: The 51 genes induced during 8 days of treatment which show expression 
level of more than 2 RPKM units.
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In order to identify the functions of the 51 induced genes as a group, a gene ontology 
study was carried out using panther gene ontology database (www.pantherdb.org).























Figure 4.7: Gene ontology results of the 51 highly induced genes during 
trophoblast differentiation. The ontology terms marked with a red * represents 
terms significantly  enriched by DAVID (http://david.abcc.ncifcrf.gov/) functional 
gene analysis. 
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Based on panther gene-ontology analysis, the 51 induced genes at 8 days of treatment 
seems to be biologically  active proteins. The majority of them seems to be involved in 
regulatory roles which suggests that these might be important effectors of the 
differentiation process.
4.7 Study of fold change distribution of genes during trophoblast 
differentiation
Looking at the genes which are up  and down regulated during the differentiation 
protocol, clearly the number of differentially expressed genes gets increased with 
time.
comparison Up-regulated
 (SLR ! 2 )
Down-regulated 
(SLR " 2)
day 4 vs day 0 1440 1354
day 6 vs day 0 1642 1498
day 8 vs day 0 1789 1684
Table 5: The total number of up-regulated and down-regulated genes increase 
with treatment duration.
To broadly  evaluate the function of up-regulated genes during the differentiation, a 
gene ontology analysis similar to the one above was carried out.
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4.8 Gene ontology analysis of up regulated genes during trophoblast 
differentiation
Summary of protein class
Figure 4.8: Panther protein classes of the up-regulated genes.
Y axis shows the significantly  expressed protein class and the x axis shows the 
number of genes belonging to each class. 
Just as induced genes, the up-regulated genes during 8 days of treatment are enriched 
with transcription factors and signaling proteins. Apart  from these two main groups, 
most other groups of proteins are also represented in the up-regulated genes. These 
results imply that while transcription factors and signaling molecules are the major 
effectors of the observed differentiation outcomes, the treatment brings about a 
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The pathways affected by genes which are up-regulated during trophoblast 
differentiation.
Figure 4.9: Significantly affected pathways from up-regulated genes during 
trophoblast differentiation.
Pathways with the highest number of up-regulated genes, namely Wnt signaling, 
Cadhering signaling and TGF-beta signaling are all reported to be involved in 
mesenchymal to epithelial transition. In addition, Wnt signaling has been implicated 
in embryo implantation (Mohamed, Jonnaert et al. 2005) .
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Table 6: Top 50 up and down regulated genes during trophoblast differentiation.
79
4.9 Comparison of RNA-Seq gene expression levels with published 
human preimplantation data shows a considerable overlap
There is a paucity of gene expression data available for human pre-implantation 
development, a result of the scarcity of such tissues combined with the very limiting 
amount of RNA available in each individual sample. Thus when Zhang et al (Zhang, 
Zucchelli et al. 2009) reported a microarray study of human pre-implantation 
development - the first available data set providing global gene expression of 
significant quality  from the human blastocyst - I eagerly compared it with our hESC-
derived data. The Zhang dataset enabled the identification of differentially expressed 
genes during the transition from the 4 - cell stage to the blastocyst. Using the data 
presented in the paper, it is possible to identify  genes up and down-regulated during 
blastocyst formation, but it is not possible to separate out trophectoderm / ICM 
specific / enriched genes as the paper does not report  the gene expression of ICM  or 
the trophectoderm separately. Nonetheless, the majority  of cells in the blastocyst 
(>70%) would be trophectoderm and the 4-cell embryo would represent a stage at 
which the trophectoderm has yet to form. Thus a comparison of 4-cell stage to 
blastocyst should identify genes up-regulated in the human trophoblast lineage. 
Though many pluripotent genes are thought to be expressed in the 4-cell stage embryo 
there are likely other genes specifically expressed in the ICM of the human 
blastocysts that are up-regulated from the 4-cell to the blastocyst stage. My RNA-Seq 
data of the SU5402+BMP4 hESC differentaitiotn protocol provides a set  of genes up  / 
down-regulated during human trophoblast differentiation. Therefore by overlapping 
the human embryo dataset with the SU5402+BMP4 differentiation, the genes shown 
to be responsible for trophoblast development by the differentiation protocol can be 
validated. 
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However, it should be noted that while the dataset presented by  Zhang et al. is 
impressive, due to the nature of the sample they  only use duplicates for microarray 
runs and that the variability  within the samples is high. As a result 1,501 genes 
identified as significantly up-regulated 2-fold or more is likely  an underestimate of 
the genes truly  differentially regulated. When these 1,501 genes are overlapped with 
the hESC-derived trophoblast differentiation data 542 genes are significantly up-
regulated in both datasets. On average the 542 commonly  up-regulated genes show an 
average fold change of 8 fold ( maximum = 16,348 fold and minimum 2 fold). In 
addition, a hierarchical clustering done between the RNA-Seq and preimplantation 
microarray  data showed that  the 4 cell microarray sample clustered with the hESc 
sample of RNA-Seq and the blastocyst sample of microarray clustered with day 8 
time point of RNA-Seq. This clearly  shows that there is a good correlation between 
the SU5402+BMP4 differentiation RNA-Seq data and human preimplantation data 
(Figure 4.10), and more importantly this correlation suggests that the identified 542 
genes identified may play a vital role in human trophoblast formation and 
development highlighting the utility of my RNA-seq data in identifying the 
transcriptome of early  human trophoblast development. These 542 genes were 
analyzed further.
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Figure 4.10: Hierarchical clustering of RNA-Seq data with published human 
preimplantation data. 
Human blastocyst sample gets clustered with 8 days differentiation time-point while 
four cell human embryo sample gets clustered with human ES sample.
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CGA 0.11 0.26 8.09 544.43 2239.42 14.37 21173.91 126.19
S100P 0 0.28 0.51 31.14 83.46  - - 109.48
GCM1 0.03 0.07 1.23 16.24 33.01 10.26 1226.22 88.05
MUC15 0.03 7.43 25.34 39.22 62.84 10.87 1871.53 80.58
ABCG2 1.55 13.3 94.63 118.81 95.97 5.95 61.82 76.64
ANXA1 11.11 24.35 113.18 481.26 751.31 6.08 67.65 74.84
H19 0.18 15.78 81.45 598.54 808.91 12.16 4576.41 58.78
LRP2 0.15 2.92 23.12 39.26 43.24 8.13 280.14 54.18
KRT19 100 368.9 582.93 630.19 606.56 2.6 6.06 51.01
RCN1 19.12 18.4 26.8 38.87 43.59 1.19 2.28 49.97
CCR7 0.02 0.95 3.35 42.51 122.07 12.8 7131.55 46.9
ZNF750 0.06 27.41 31.55 12.68 15.58 8.07 268.73 41.31
CBLB 10.46 15.66 20.21 34.68 51.22 2.29 4.89 41.1
LYN 12.37 12.57 25.91 54.9 91.76 2.89 7.41 39.84
ENPEP 0.34 18.29 34.39 57.63 54 7.33 160.90 37.57
SGMS1 7.74 12.16 12.98 16.42 16.75 1.11 2.16 36.46
GADD45G 11.56 14 6.93 33.33 82.97 2.84 7.16 35.36
SERPINB9 31.42 233.14 82.11 45.03 73.85 1.23 2.35 34.81
SLC38A1 29.15 47.37 101.27 134.29 128.59 2.14 4.41 33.98
KRT23 0.03 0.49 19.3 96.09 182.97 12.36 5256.91 33.55
SMAD7 5.32 17.88 21.43 21.09 30.92 2.54 5.82 33.21
CCKBR 0.54 1.11 5.27 27.9 32.85 5.92 60.55 32.39
HERV-FRD 0 0 0.14 6.67 32.13  - - 31.54
RAB31 10.26 30.39 26.51 37.7 34.48 1.75 3.36 29.34
RHOU 1.87 20.23 33.93 68.54 71.29 5.25 38.05 29
KANK4 0.18 0.18 3.12 23.74 29.38 7.33 160.90 27.86
GATA2 0.52 31.45 31.26 45.02 77.57 7.23 150.12 27.52
SLC1A3 2.41 4.07 9.87 38.02 54.55 4.5 22.63 27.19
CEBPA 2.25 11.21 33.38 39.25 47.26 4.39 20.97 26.59
REEP1 0.31 0.45 0.94 5.88 6.61 4.42 21.41 26.53
SLC40A1 0.09 0.65 4.16 82.5 152.16 10.74 1710.26 26.03
ANXA3 14.61 68.63 150.09 322.63 290.26 4.31 19.84 25.74
SDC1 21.99 5.05 5.24 29.7 54.74 1.32 2.50 25.29
KRT18 69.59 230.83 322.61 458.84 410.36 2.56 5.90 23.94
COL21A1 1.19 0.6 1.43 10.82 9.26 2.96 7.78 23.36
TACSTD2 0.9 45.09 48.68 32.7 30.38 5.08 33.82 23.31
AMOTL2 14.86 40.87 53.73 77.06 90.51 2.61 6.11 22.28
GPRC5A 0.57 7.43 10 19.25 31.05 5.76 54.19 21.35
S100A14 1.32 25.65 121.89 72.48 57.72 5.45 43.71 21.16
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TNS3 10.54 55.64 28.83 19.3 26.34 1.32 2.50 21.1
IL1R1 0.12 1.35 2.71 8.16 10.7 6.46 88.03 20.87
TGFBR2 2.02 0.9 2.43 10.67 27.39 3.76 13.55 20.73
FHDC1 6.81 18.21 17.82 24.05 39.22 2.53 5.78 20.32
HOPX 0 0.44 0.16 42.53 98.19  - - 20.14
SLC7A11 1.37 1.98 4.29 3.07 2.88 1.07 2.10 19.35
CDKN1C 15.65 41.64 46.75 162.39 252.66 4.01 16.11 19.3
C10orf10 3.21 9.83 12.33 28.87 56.97 4.15 17.75 19.28
TPD52L1 5.86 9.31 21.58 35.53 36.09 2.62 6.15 19.13
HSPB8 3.49 17.14 43.68 150.95 388.24 6.8 111.43 19.03
Table 7: The top 50 up-regulated genes (based on human embryo 4-cell to 
blastocyst fold enrichment) which are also up-regulated in the hESC-based 
trophoblast differentiation protocol.
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4.10 Genes induced / up-regulated during trophoblast differentiation
Table 7 highlights genes that are best induced / up-regulated in human trophectoderm 
formation (based on preimplantation data) that are also up-regulated in the hESC-
based trophoblast system. The RNA-Seq profile of a few of these genes will be 
described hereafter.
4.10.1 CGA (Chorionic gonadotrophin alpha)
CGA codes for the alpha subunit of the human chorionic gonadotropin, the signature 
hormone of the trophoblast. CGA expression is initiated at day 4 and is greatly  up-
regulated as differentiation progresses.
Figure 4.11: RNA-Seq peak profile of CGA on the UCSC browser. 
The CGA expression gets up-regulated from a very  low value of 0.11 RPKM at day  0 
to 2239.4 at day 8, showing a fold change of 21173.9. Only the negative strand for 
each of the time point is shown here for clarity.
Day 0 negative strand
Day 2 negative strand
Day 4 negative strand
Day 6 negative strand
Day 8 negative strand
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4.10.2 CGB (Chorionic gonadotropin beta)
CGB, which together with CGA produces hCG hormone, has six genes in the human 
genome with virtually  the same sequence. These are a result of extensive gene 
duplication of the original LHB gene with some of these gene duplication occurring 
since the divergence from the chimpanzee (Hallast, Saarela et al. 2008). The extent of 
sequence similarity can be seen in the multiple alignment diagram in Figure 4.12. 
This presents a major issue when it comes to aligning the reads from these regions 
into the genome. During the counting phase of RNA-Seq, reads which map to two 
places or more with the same score are discarded and therefore a considerable number 
of reads originating from CGB genes are not taken into account during calculation of 
expression values. This leads to an underestimation of the level of expression from 
this locus. This is in contrast to the microarray data which indicates rather robust up-
regulation (CGB5 max. probe intensity  of 267, CGB8 max. probe intensity  of 281) as 
the hybridization signal is not lost. This multi-mapping issue is a weakness of RNA-
seq but the sequence data can also be used to an advantage here. By  focusing on 
specific bases that vary between the genes, and identifying whether any unique reads 
are mapped in these regions, it is possible to identify which of the 6 CGB genes are 
being expressed, something that would be challenging with an array based method of 
expression detection. From this analysis, RNA-seq  clearly identifies expression from 
CGB8, CGB5 and CGB7 as showing significant up-regulation during the 
differentiation. Such information is valuable particularly if one is interested in the 
transcriptional control of specific CGB genes.
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Figure 4.12: Multiple alignment of CGB8, CGB5, CGB, CGB7, CGB2 and CGB1. 
The analysis was performed using CLC Main workbench. The lines next to the gene 
names show consensus sequences and the bar graph shows the conservation %. Note 
that in most cases the conservation is 100% and that it rarely  goes below 50% 
suggesting extreme sequence similarity. 
Figure 4.13: The UCSC view for CGB5. 
Tracks from the top are, (1) Day 0 unique reads - which there are none, (2)  Day 8 
unique reads - to a maximum height of 37 suggesting that there is robust expression, 
and (3) Day 8 multi-map  reads - which up  to a certain extent recovers some of the lost 
reads due to the high homology of the CGB group of genes. The multimap track 

























4.10.3 CCR7 (CC chemokine receptor type 7)
CCR7 is best known for its involvement in the maturation of dendritic cells and thus 
in adaptive immune response (Sanchez-Sanchez, Riol-Blanco et al. 2006). CCR7 
expression goes from an RPKM value of 0.02 at 0 days to 122 at 8 days and ranks as 
the eleventh most  abundant transcript in the 8 day trophoblast. There are no previous 
reports of its expression in the trophoblast  but an analysis of the Zhang et al data 
clearly  indicates its expression in the human blastocyst. Potential functions for CCR7 
could either be a measure to protect the fetus from future infections, or a way  to 
modulate inflammatory reactions between the fetal - maternal interface, through the 
communication between the trophoblasts and dendritic/Treg/NK cells in the 
endometrium which are known to play a positive role during implantation. 
Considering the up-regulation of the retroviral elements (discussed later) it  is likely 
that CCR7 and expressed retroviral elements misdirects the maternal immune system 
providing an immunosuppressive function.
4.10.4 KRT23 (Keratin type I cytoskeletal 23)
Keratins are classical markers of epithelial cells. In the mouse blastocyst, Krt8 and 
Krt18 (and Krt7 and 19) are used to mark the early trophoblast lineage, while in the 
human blastocyst it is KRT7 that is the classical marker of these cells. I see abundant 
expression and up-regulation of KRT7 (7.8 fold), KRT8 (6.8 fold), KRT18 (5.8 fold), 
and KRT19 (6.0 fold). In addition, I also see KRT23, a keratin not previously defined 
as a trophoblast keratin but is highly expressed in the placenta (KRT23 entry of biogps 
expression database at http://biogps.gnf.org) and the trophoblast differentiation 
(5272.3 fold). KRT23 is required for epithelial cells and its up-regulation can be used 
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as an additional confirmation that the differentiation has produced cells of the 
epithelial lineage. Since Krt23 expression is not seen in mouse early development, 
KRT23 can be considered as a potential human trophoblast specific gene.
Comparing the RefSeq annotation of KRT23 gene and the RNA-Seq peak profile, it is 
clear that the KRT23 isoform expressed during differentiation has a different 
transcription start site to that shown in RefSeq. The transcript seems to skip the first 
exon in the 5’ UTR region and start at the next exon which contains the start codon. 
While this does not affect the structure and therefore the function of the protein since 
the coding sequence remains the same, it might be differently regulated post 
transcriptionally, due to the change in UTR (Figure 4.14).
Figure 4.14: The RNA-Seq peak profile of KRT23 gene.
The first exon in the 5’ URT region (shown within the box) is not  transcribed during 
differentiation, giving rise to a new isoform. For clarity only the negative strand is 
shown.
Day 0 negative strand
Day 2 negative strand
Day 4 negative strand
Day 6 negative strand
Day 8 negative strand
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4.10.5 H19
H19 is a long non-coding RNA, which is well known to be highly expressed in the 
placenta. H19 is reported to be modulated by  steroid hormones including 17-ß-
estradiol which is the dominant form of estrogen, in mammary glands and the uterus 
(Adriaenssens, Lottin et al. 1999).
Considering RNA-Seq data, H19 expression is induced immediately  after treatment 
and gets highly up-regulated during trophoblast differentiation. This expression 
pattern clearly shows that H19 expression in early development is not only  limited to 
maternal tissues, but is also expressed in the embryo and that H19 is involved in 
trophoblast differentiation. Furthermore miR-675 which originates from the original 
H19 transcript (Cai and Cullen 2007) is highly  up-regulated based on the microRNA 
RNA-Seq data presented in the latter part of this thesis suggesting a regulatory role 
for H19.
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Day 0 positive strand
Day 2 positive strand
Day 4 positive strand
Day 6 positive strand
Day 8 positive strand
Figure 4.15: RNA-Seq peak profile of H19.
H19 gets up-regulated from day 2 onwards. For clarity  only the positive strand is 
shown.
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4.10.6 MUC15 (Mucin 15)
Mucins are high molecular weight substances secreted by epithelial cells to form a 
sticky  mass. Mucins are secreted by the uterus and is reported to aid implantation 
(Carson, DeSouza et al. 1998). The function of mucins is not limited to implantation. 
They  are also reported to be expressed in the human placenta and suppress the 
invasion of trophoblast-like cells in vivo (Shyu, Lin et al. 2007). This suggest that 
mucins directly  or indirectly regulate the migratory  properties, first by  facilitating 
implantation and then by regulating invasion and plays an important part  during early 
trophoblast development.
RNA-Seq data shows that MUC15 expression is induced during trophoblast 
differentiation and is highly  up-regulated (1867.4 fold) at day 8 of differentiation. 
This suggests that mucins are secreted by the blastocyst and it is confirmed by the fact 
that MUC15 is one of the greatest up-regulated genes in the Zhang et. al. data during 
the transition from the 8-cell to the blastocyst stage. In addition to this mucin 
secretion also indicates the epithelial phenotype is acquired by the differentiated cells. 
RNA-Seq junction reads show that two out of the three known MUC15 isoforms are 
expressed.
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Day 0 negative strand
Day 2 negative strand
Day 4 negative strand
Day 6 negative strand
Day 8 negative strand
Figure 4.16: RNA-Seq peak profile of MUC15.
MUC15 shares its gene footprint with TMEM16C which is coded by  the opposite 
(positive strand) strand. 
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4.10.7 SLC40A1 (Solute carrier family 40 (iron-regulated transporter), member 
1)
The product for this gene, Ferroportin 1, is essential for iron efflux. It has been 
identified as expressed in the human placenta, found on the basal surface of the 
syncytiotrophoblasts (Donovan, Brownlie et al. 2000). In my data, SLC40A1 is highly 
up-regulated during 4 days of trophoblast differentiation and by 8 days reaches an 
RPKM value of 152 (1715.9 fold change). This is one of many  examples in my 
expression data, where up-regulation is seen in a key molecule involved in nutrient 
supply between mother and the fetus through the trophoblast. 
Located on the basal surface (Donovan, Brownlie et al. 2000), SLC40A1 is in a 
position to secrete iron, out from the trophoblast cytoplasm towards the developing 
embryo. With respect to iron uptake by the trophoblast from the maternal side, it is 
interesting to note that TFRC, encoding transferrin receptor-1 and functioning in iron 
uptake, is abundantly  expressed (86 RPKM) in the 8 day trophoblast. Thus 
presumably, both apically positioned transferrin receptor-1 and basally positioned 
SLC40A1 are able to supply iron to the fetus from the mother. This along with folate, 
of which the transporter is also expressed (FOLR1 25 RPKM at 8 days), adds to the 
mounting evidence that iron supplementation at  preconception and early pregnancy  is 
important for improved pregnancy  outcomes (Titaley, Dibley et al. 2010). Relevant to 
this is the recent finding that Slc40a1 is essential for mouse neural tube closure (Mao, 
McKean et al. 2010), which is precisely the role folate supplementation is known to 
play in early human development.
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4.10.8 GCM1 (Glial cells missing homolog 1)
As described in the introduction, GCM1 is a transcription factor essential for mouse 
placental function, though its expression in the mouse trophoblast lineage occurs 
much later than initial trophoblast formation. Based on RNA-Seq data, GCM1 is not 
expressed in human ES cells, but is highly  up-regulated from day 4 of the trophoblast 
differentiation (Figure 4.17) to a final fold change of 1226.1. 
Day 0 negative strand
Day 2 negative strand
Day 4 negative strand
Day 6 negative strand
Day 8 negative strand
Figure 4.17: RNA-Seq peak profile of GCM1 gene expression.
There is negligible expression in day  0 (undifferentiated ES cells). The Expression 
begins at day 4 of differentiation and increases through the time-points. 
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4.10.8.1 Regulation of GCM1
Regulation of GCM1 is carried out by the proteins GSK3B, FBW2 and DUSP23 at 
the post-transcriptional level. GSK3B phosphorilates GCM1, marking it  for 
degradation by FBW2 (Chiang, Liang et al. 2009) while DUSP23 dephosphorilates 
GCM1 (Lin, Chang et al. 2010) preventing the GCM1 degradation. Interestingly 
during SB differentiation GSK3B gets up-regulated and DUSP23 gets down-regulated 
suggesting that even at earlier preimplantation stages the GCM1 regulatory machinery 
is active. 
4.10.9 Placental BDNF (Brain-derived neurotropic factor) / NTRK2 (Neurotropic 
tyrosine kinase 2) system
It has been reported that in mice, BDNF plays an important role in implantation and 
placental development (Mayeur, Silhol et  al. 2010). In the hESC-trophoblast 
differentiation protocol BDNF is not expressed at very significant levels (max 3.31 
RPKM at 8 days) but its receptor - TrkB (NTRK2) - is, being up-regulated from 0 to 
62 RPKM  over the 8 day time course. This would suggest that  the trophoblast  is 
responsive to BDNF, perhaps supplied from the maternal endometrium.
  
TrkB, in mammals has a full length and a truncated isoform (Tapia-Arancibia, Rage et 
al. 2004). The truncated isoform, while lacking intracellular tyrosine kinase activity, is 
active and can trigger transduction signals (Tapia-Arancibia, Rage et al. 2004; Skaper 
2008). The truncated isoform of TrkB (Trkb-T1) is able to regulate Rho A signaling 
(Ohira, Homma et al. 2006) and Rho A is shown to be predominant in cytotrophoblast 
cells and is implicated in trophoblast migration (Shiokawa 2002; Mayeur, Silhol et al. 
2010). 
96
The RNA-Seq peak profile of both NTRK2 (Figures 4.18) shows an interesting 
transcriptomic phenomenon. In the case of NTRK2, which based on RefSeq has five 
different isoforms, only  the shortest  isoform is expressed during trophoblast 
differentiation. Based on peak heights, it  seems a few of the longer isoforms are 
expressed at very low levels but the shortest isoform is clearly  the highest expressed. 
It is this isoform (Trkb - T1) that has shown to be involved in regulating RhoA 
signaling (Ohira, Homma et al. 2006).   
Day 0 positive strand
Day 2 positive strand
Day 4 positive strand
Day 6 positive strand
Day 8 positive strand
Figure 4.18: The RNA-Seq peak profile of NTRK2.
Data on peak distribution proves that shortest isoform, indicated with a red arrow is 
highly expressed.
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4.10.10 ELF5 (E74-like factor 5)
As a transcription factor essential for mouse trophoblast, much attention has been 
drawn to ELF5 in the human trophoblast literature. Indeed, its lack of expression in 
other hESC-derived trophoblast populations has been used to argue against these cells 
being true trophoblast (Hemberger, Udayashankar et al. 2010). Thus it is comforting 
to see from my RNA-Seq data which clearly shows that the SU5402+BMP4 
differentiation protocol used in this thesis does indeed induce ELF5 expression (0 
RPKM at day 0 and 2.96 at day 8) thereby providing a more realistic transcriptomics 
picture of trophoblast differentiation. ELF5 expression is not high, but  since its been 
reported to be methylated in human ES cells, any form of expression indicates that the 
trophoblast differentiation leads to its de-methylation. Furthermore ELF5 is 
considered to be a trophoblast stem cell marker and not a marker for the entire 
trophoblast lineage, which is brought about by the differentiation.
ELF5 has two isoforms, 2a and 2b. It  has been reported that ELF5 - 2b is the major 
variant found in the placenta (Hemberger, Udayashankar et al. 2010). In agreement 
with above, the SU+BMP4 differentiation clearly induces ELF5 - 2b (Figure 4.19). 
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Figure 4.19 : Peak profile of ELF5.
ELF5 expression begins at  round day 4 - day 6 during the differentiation. ELF5 has 
two isoforms 2b and 2a. 2a has its first exon within the first intron of 2b. SU+BMP4 
induces the ELF5 - 2b isoform, just as in the placenta where it is the major variant.
4.10.11 ABCG2 (ATP-binding cassette sub-family G member 2)
ABCG2 is highly expressed in the human placenta, and is believed to protect the fetus 
from xenobiotics transported from the maternal circulation (Kolwankar 2005). It has 
been shown that knocking down of ABCG2 in BeWo cells, causes the down-
regulation of trophoblast markers and reduces cell fusion (Evseenko, Paxton et al. 
2007). ABCG2 is directly  regulated by estrogen and PPARgamma (Szatmari 2006), 
both highly expressed during early  development and during the trophoblast 
differentiation. 
The RNA-Seq peak profile of ABCG2 shows an interesting transcriptomics dynamic. 
ABCG2 gene which is expressed at low levels in human ES cells get highly  up-
Day 0 negative strand
Day 2 negative strand
Day 4 negative strand
Day 6 negative strand
Day 8 negative strand
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regulated during differentiation (61.7 fold). Furthermore, as can be seen in Figure 
4.20 panel A, the ABCG2 changes the starting exon of transcription during 
differentiation. In addition to this the third exon which is not expressed in human ES 
cells starts getting expressed.
AB Panel B enlarged
Day 0 negative strand
Day 2 negative strand
Day 4 negative strand
Day 6 negative strand
Day 8 negative strand
Figure 4.20: The expression and splicing dynamics of ABCG2. 
The entire RNA-Seq profile is shown on the right panel. The box marked A shows the 
first exon which is unused in human ES cells and used during differentiation. The box 
marked B shows the third exon which has a similar expression pattern as the first  - 
see the enlarged view on the right.
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4.11 Comparison with mouse pre-implantation data
While the main focus of this thesis is human trophoblast development, it is important 
to compare the data from the human samples with the mouse model. This comparison 
enables the validation of existing knowledge as most  observations regarding early 
development originate from the mouse system, and enables the identification of 
human specific phenomena during trophoblast differentiation.
The mouse pre implantation RNA-Seq dataset presented in this thesis consists of four 
samples - uncompacted 8-cell, E3.5 blastocyst, E4.5 Blastocyst  and E4.5 ICM. (The 
E4.5 trophoblast cells are difficult to isolate from the embryo without being 
contaminated by cells in the ICM). Dr. Guo Guoji, a former member of the lab, 
carried out the collection of the mouse embryos and performed the immunosurgery 
(Solter and Knowles 1975) to isolate the ICM.
Using the four mouse RNA-Seq samples, trophoblast  related gene expression changes 
can be identified via the comparison of gene expression changes between the E4.5 
blastocyst / 8-cell and E4.5 ICM / E4.5 blastocyst. i.e genes which are involved in 
mouse trophoblast differentiation can be considered as genes which show an up-
regulation in both E4.5 Blastocyst / 8 cell stage comparison and E4.5 Blastocyst / 
E4.5 ICM comparison (i.e. low in 8 cell, low in ICM but high in blastocyst). At the 
uncompacted 8-cell stage, markers and some key regulators of the trophectoderm are 
not yet expressed, morphological epithelialization of the outer cells does not occur 
until the early 32-cell stage. The ICM is clearly  distinguishable from the 
trophectoderm by gene expression as early as the later 32-cell stage (Guo, Huss et al. 
2010). 
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To validate the mouse RNA-Seq data it was compared with the expression levels of 
the 48 genes presented in Guo et al. There was a good qualitative co-relation between 
the two datasets. For example Gata3 and Cdx2 which are expressed at low levels in 
the 8 cell stage and becomes TE specific showed a 4.59 and 4.11 fold up-regulation (8 
cell stage vs outer cells at 32 cell stage) in Guo et al and a 35.1 and 35.7 fold (8 cell 
stage vs E4.5 blastocyst) in mouse RNA-Seq data. Nanog and Sox2 which are specific 
to ICM compared to TE shows a fold enrichment of 17.1 and 354.6 in the ICM (32 
cell stage in vs out cells) based on Guo et al data and mouse RNA-Seq data showed 
an enrichment of 2 and 1.5 fold between E4.5 blastocyst and E4.5 ICM. As can be 
seen from these data the expression of key genes is qualitatively the same in both 
datasets. The values of fold change differs as the sample types used for the 
comparison are different.
When comparing the gene sets related to trophoblast development in both human and 
mouse systems, the most clear observation is the significant difference of both the 
expression level and expression pattern with each other. This point is clearly 
illustrated in Figure 4.21. The figure is a scatterplot of the top 500 up-regulated genes 
in human during trophoblast differentiation. The genes which have a RPKM value of 
less than 1 has been reset to one to make the comparison simpler. As can be clearly 
seen there is no correlation between human and mouse. There are a number of genes 
which are highly expressed in human but are not significantly  expressed in mouse 
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Figure 4.21: Comparison of mouse and human RNA-Seq data during 
trophoblast differentiation.
The RPKM values less than 1 has been reset to 1. Only the top 500 up-regulated 
genes in human are shown. The top 35 genes which are highly up-regulated in human 
and expressed at very low level (less than 1 RPKM) in mouse are highlighted in red. 
It should be highlighted that the comparison done in Figure 4.21 is not exact. In-fact 
considering the lack of clinical samples of human early trophoblast development, a 
one-to-one comparison is not feasible. Therefore for the comparison human ES cells 
differentiated into the trophoblast lineage was used. Given the evidence presented 
here it could be correctly assumed to produce a realistic early trophoblast 
transcriptome. 
Due to the difference in the initially available RNA amounts two different protocols 
(as outlined in the methods section) was used to process the samples. The protocol 
used to process the trophoblast differentiation samples produce reads specific for 
transcripts with a poly  A tail while the single cell protocol used to process mouse 
embryos provides information on all the transcripts - including poly A ones. Therefore 
as far as the poly A genes are concerned the data should be comparable. The usage of 
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fold change as the primary  measure of gene expression also removes sample specific 
biases. 
The purpose of the Figure 4.21 and this entire section, is to emphasize that at the 
transcriptome level, human and mouse systems, during trophoblast differentiation 
show significant difference and cellular heterochrony.
4.11.1 GCM1 expression in SB differentiation, human and mouse early 
development
The gene expression of GCM1 in both human and mouse systems during early 
development is drastically different. Based on the Zhang et. al. paper, raw probe 
intensity value of GCM1 during the human 4 cell stage embryo is 50 and it gets 
increased up to 7117 during the blastocyst  stage. The human trophoblast RNA-Seq 
data has a similar pattern where in human ES cells GCM1 gets only 2 reads and at day 
8 it increases to 2399 reads - a 1226 fold up-regulation based on RPKM  value. 
However in the mouse RNA-Seq system this drastic increase is not seen. In fact the 
up-regulation of Gcm1 from 8 cell stage to E4.5 blastocyst is just 2.73 fold, where the 
E4.5 blastocyst sample gets only 45 reads being aligned to the gene. This drastic up-
regulation of GCM1 during human trophoblast differentiation as compared to the 
mouse system suggests that GCM1 plays a more important role in the human system 
compared with the mouse. This is further confirmed by the observed up-regulation of 
PGF, Syncytins and Aromatase, which are genes regulated by GCM1, suggesting that 
GCM1 protein is highly active during trophoblast formation.
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4.12 Retroviral expression as a possible explanation for the 
transcriptomic difference of early development factors in human and 
mouse
As explained in the Introduction, expression of endogenous retroviral components 
have the to capacity  influence the transcriptome of early development. Existing data 
shows that they can create new genes and form regulatory regions of existing genes 
influencing their expression. Since the endogenous retroviral component of the 
genome changes with evolution, the retroviral elements in mouse and human can be 
considered to be quite different, and this difference has the potential to bring about the 
changes in the gene regulatory mechanisms of early  development in mouse and 
human. 
4.12.1 Expression of genes originated from retroviral elements during 
trophoblast differentiation
The fusogenic Syncytin 1 and Syncytin 2 are primate-specific genes, which originated 
from  retroviral elements inserted into the ancestral genome ~25 and 40 million years 
ago respectively  (Cheynet, Ruggieri et al. 2005; Renard, Varela et al. 2005). They are 
induced during the hESC-to-trophoblast differentiation. The human pre-implantation 
data also shows a similar expression pattern. Their peak profiles are shown in Figures 
4.22 and 4.23. 
Expression of Syncytin 1 and 2 starts at day  6 and gets up-regulated at day 8. 
Considering the distribution of uniquely mapped reads, Syncytin 1 which is the newer 
gene among the two, has a coverage of around 50% while the older Syncytin 2 has a 
100% coverage. Once the multi-mapped reads are used to measure the coverage, 
Syncytin 1 reaches a 100% coverage (Figure 4.24). This highlights an important point 
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when trying to identify new retroviral insertions. When the insertion is relatively  new, 
even if it is highly  expressed, due to sequence similarity, aligning reads becomes 
difficult and the coverage goes down. However when the insertion gets “older” and 
accumulates point mutations, then identification of those regions through RNA-Seq 
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Figure 4.22 : RNA-Seq peak profile of Syncytin 1.
Syncytin 1 is not expressed in day  0 and day  2. It starts to get expressed in day 6 and 
is up-regulated there after. There is only  a partial UCSC annotation. Note the new 
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Figure 4.23: RNA-Seq peak profile of Syncytin 2.
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Figure 4.24 :  Change of coverage of expressed retroviral elements with insertion 
time.
The first track shows the standard unique reads whereas the second track shows multi-
mapped reads which are reads that map to the genome up  to 10 times. Syncytin 2 gene 
which is the older of the two has 100% coverage in both unique and multi-mapped 
tracks, while Syncytin 1 show only around 50% coverage in the unique track.
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4.12.2 Expression of genes with retroviral derived regulatory elements during 
trophoblast differentiation
Trophoblast-specific expression from ERV LTRs has been described for a number of 
genes (Cohen, Lock et al. 2009) . I first investigated my  data set to determine if there 
was expression derived from these ERV LTRs. Of the 9 placenta-specific ERV LTRs 
described in Cohen et al. there was evidence for significant expression from CYP19A1 
(RPKM = 102 at day 8), PTN (RPKM = 244), INSL4 (RPKM = 1.97), PAPPA2 
(RPKM = 25), MID1 (RPKM  = 14) and EDNRB (RPKM = 60) but no expression 
from IL2RB, NOS3 and ENTPD1.
4.12.3 CYP19A1 (Cytochrome P450, family 19, subfamily A, polypeptide 1)
Human trophoblast expression of CYP19A1 is known to be driven by an ERV LTR 
promoter (Conley and Hinshelwood 2001; Cohen, Lock et al. 2009). In my data set 
CYP19A1 is highly up-regulated during SB differentiation (Figure 4.25). Based on 
RNA-Seq data, the placenta-specific isoform is expressed while the others, driven 
from different tissue-specific promoters, are not. Based on the UCSC annotation track 
it seems that another - third isoform is expressed, but its expression is not as nearly  as 
high as the placenta specific one.
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Day 0 negative strand
Day 2 negative strand
Day 4 negative strand
Day 6 negative strand
Day 8 negative strand
Figure 4.25: The RNA-Seq peak profile of CYP19A1.
It is not expressed at day 0 (undifferentiated human ES cells) and gets highly up-
regulated during differentiation.
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Figure 4.26: The RNA-Seq expression profile of CYP19A1 at day 8 time point of 
SB differentiation protocol.
The major expressed isoform incorporates the first exon (enlarged view in the box on 
the right) and is the one reported to be placenta specific. The other RefSeq isoform 
incorporating the second exon (shown by the circle) is not expressed. RNA-Seq data 
also shows the expression of a third isoform (shown enlarged in the box on the right), 
which is unannotated in RefSeq. 
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4.12.4 EDNRB (Endothelin receptor type B)
Based on RNA-Seq data EDNRB is highly  up-regulated during SB differentiation. 
Unlike CYP19A1, it is expressed in undifferentiated human ES cells and this 
expression is further up-regulated throughout the treatment. What has been previously 
described as the placental-specific isoform, driven from an ERV LTR promoter, starts 
to be expressed from day  6 onwards of the differentiation process. Expression from 
this LTR-based promoter only  accounts for 10-15% of total expression at the 8 day 
time-point. Based on RNA-Seq data, a novel third exon is observed between the 
expressed first exon and the non-expressed second exon. This novel isoform seems to 
have an expression pattern similar to the placenta specific one (Figure 4.27).
Day 0 negative strand
Day 2 negative strand
Day 4 negative strand
Day 6 negative strand
Day 8 negative strand
Figure 4.27 : The RNA-Seq peak profile of EDNRB.
The gene gets up-regulated during differentiation. While the gene is expressed (albeit 
at a lower level) in undifferentiated human embryonic stem cells, the placenta specific 
isoform is only expressed from day 6 - 8 onwards.
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Figure 4.28: An enlarged view of the RNA-Seq expression profile of EDNRB gene 
at day 8 timepoint.
The box on the right shows the exon responsible for the placenta specific isoform 
under the regulation of the LTR promoter. In accordance with published data this 
isoform is expressed at around 10 - 15% of the total transcripts (based on peak 
height). The third isoform (which does not have a RefSeq annotation) shows a similar 




PTN gene has an HERV-C family LTR region, which acts as a placenta-specific 
alternative promoter producing a different isoform (Schulte, Lai et  al. 1996) . Based 
on RNA-Seq, PTN is highly up-regulated during differentiation. The placenta-specific 
isoform is highly expressed at day  8, but there also is expression in undifferentiated 
human ES cells albeit at  a much lower level. The RNA-Seq data also indicates the 
presence of another novel exon, which is not annotated in either the RefSeq or UCSC 
tracks. This is absent in day 0 and the early days of differentiation but starts to get 
expressed at day 6 and onwards (Figure 4.29) and, interestingly, the new exon is 
actually an expressed LTR  - ERV1 element.
Day 0 negative strand
Day 2 negative strand
Day 4 negative strand
Day 6 negative strand
Day 8 negative strand
Figure 4.29: The RNA-Seq expression profile of PTN gene.
It gets highly up-regulated during differentiation. Novel exon is highlighted.
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Figure 4.30 : A magnified view of the novel exon, with an LTR footprint of PTN 
gene found by RNA-Seq.
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4.13 Novel transcribed regions (NTRs) active during trophoblast 
differentiation
One of the advantages of RNA-seq over other gene expression detection methods is 
that it provides an unbiased view of the transcriptome and thus has the opportunity to 
identify transcripts not defined previously. This feature is particularly  important in the 
context of the cell type I was analyzing as the early human trophoblast has not been 
fully  transcriptionally explored before.  For this reason I spent some effort in trying to 
identify and characterize novel transcribed regions (NTRs). NTRs are defined as 
expressed regions in the genome that do not have any valid RefSeq annotations (see 
Methods for details). NTR detection was done for all five samples.
Time point Total NTRs
Total mapped 
reads to the 
genome.
NTRs per million 
mapped reads
Day 0 556,207 42,845,342 12,981.74
Day 2 1,074,476 42,203,140 25,459.62
Day 4 1,144,784 40,421,804 28,320.95
Day 6 1,007,134 40,218,029 25,041.85
Day 8 975,546 40,174,214 24,282.89
Table 8: Total Novel Transcribed Regions (NTRs) identified from each sample.
Showing NTRs per million mapped reads normalizes the total NTRs to the 
sequencing depth.
Table 8 shows the total NTR counts for each sample, and the total NTRs per million 
mapped reads to normalize for sequencing depth.  The main pattern which stands out 
from the above dataset is the increase of total NTRs from day 0 to day  2. This 
increase is maintained throughout the time-course. The increase of total NTRs from 
day 0 to day 2 is 196% while the increase from day 0 to day 8 is 187%. Almost 
doubled increase in NTRs in the differentiated cells fits with my hypothesis that 
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unbiased transcriptomic analysis of the trophoblast lineage would uncover greater 
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Figure 4.31: Distribution of NTRs per million reads during treatment.
There is a marked increase in NTRs during the initial stages of treatment (day 0 to 
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Figure 4.32: Distribution of the size of known exon from RefSeq.
The distribution is skewed to the left  but the exon counts are maintained even beyond 
1000 nucleotides. Note that the logarithmic scale is used for the Y axis and only exons 








50 200 350 500 650 800 950 1100 1250 1400 1550 1700 1850 2000




Upperlimit of bin in nucleotides
Figure 4.33: Distribution of size in novel transcribed regions in day 0.
The size distribution follows a logarithmic decrease as the size of the NTR increases. 
Note that the logarithmic scale is used for the Y axis. Clearly  the NTR distribution 
differs from that of RefSeq exons.
Since NTRs could be assumed to be potential unannotated exons, one would assume 
that the NTR distribution would follow the same distribution as that of RefSeq exons. 
Therefore I first studied  the distribution of RefSeq exon size (Figure 4.32), which 
peaks at around 150 - 250 nucleotide. While the RefSeq distribution is skewed to the 
left, there are a significant number of exons which are larger than 1000 nucleotides. 
This is significantly different from the length distribution of NTRs which peaks at the 
smallest size bin (Figure 4.33). The highest number of NTRs belong to the very  short 
0 to 50 nucleotide range and counts gets exponentially reduced as the NTR length 
increases. In contrast to the RefSeq known exon distribution which contains a 
considerable number of exons more than 1000 nucleotides long, there seem to be very 
few NTRs of that size. And there seems to be quite a high number of NTRs which are 
of smaller size (100 nucleotides or less).
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Distribution pattern of NTR length remains unchanged during treatment, all time 
points share the same histogram shape. However, the rapid increase in NTRs due to 
treatment is reflected in the read counts, where all size bins show a considerable 
increase between day 0 and day 2.
Range day 0 day 8 Fold Change (8D / 0D) Increase %
0 - 50 419367 709193 1.69 169
50 - 100 102981 202784 1.97 197
100 - 150 20424 39536 1.94 194
150 - 200 6562 12033 1.83 183
200 - 250 2761 5109 1.85 185
250 - 300 1456 2498 1.72 172
300 - 350 827 1415 1.71 171
350 - 400 502 841 1.68 168
400 - 450 368 577 1.57 157
450 - 500 215 384 1.79 179
500 - 550 164 263 1.60 160
550 - 600 130 198 1.52 152
600 - 650 95 149 1.57 157
650 - 700 64 114 1.78 178
700 - 750 54 77 1.43 143
750 - 800 40 69 1.73 173
800 - 850 24 53 2.21 221
850 - 900 31 39 1.26 126
900 - 950 24 27 1.13 113
950 - 1000 14 22 1.57 157
Table 9: Comparison of NTRs of difference sizes between day 0 and day 8.
There is a clear up-regulation of NTRs on all size bands. Note that only NTRs of less 
than 1000 nucleotides are shown for clarity.
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NTR Range day 0 day 2 day 4 day 6 day 8
0 - 50 419367 777948 820404 720453 709193
50 - 100 102981 225709 243633 218154 202784
100 - 150 20424 44070 49552 42624 39536
150 - 200 6562 13412 15516 13019 12033
200 - 250 2761 5633 6427 5464 5109
250 - 300 1456 2799 3372 2756 2498
300 - 350 827 1561 1917 1537 1415
350 - 400 502 984 1156 921 841
400 - 450 368 602 739 602 577
450 - 500 215 418 507 388 384
500 - 550 164 318 350 266 263
550 - 600 130 231 264 221 198
600 - 650 95 166 200 153 149
650 - 700 64 115 152 107 114
700 - 750 54 89 100 92 77
750 - 800 40 84 98 58 69
800 - 850 24 56 71 61 53
850 - 900 31 44 51 41 39
900 - 950 24 38 36 38 27
950 - 1000 14 33 38 22 22
1000 - 1050 9 21 31 27 22
1050 - 1100 23 25 21 24 25
1100 - 1150 9 13 22 18 16
1150 - 1200 9 11 26 15 20
1200 - 1250 10 12 13 9 12
1250 - 1300 13 10 14 11 10
1300 - 1350 6 12 8 9 13
1350 - 1400 3 6 6 8 11
1400 - 1450 4 4 5 7 11
1450 - 1500 2 11 11 1 5
1500 - 1550 2 5 8 5 4
1550 - 1600 0 3 4 4 0
1600 - 1650 3 7 5 1 1
1650 - 1700 0 2 2 1 0
1700 - 1750 1 3 3 0 2
1750 - 1800 2 3 1 2 2
1800 - 1850 1 0 2 1 1
1850 - 1900 0 2 3 1 2
1900 - 1950 1 1 0 0 0
1950 - 2000 2 3 0 2 2
Table 10: NTR counts of all the treatments divided into size bands of 50 
nucleotides. 
For clarity only NTRs less than 2000 nucleotides are shown. As observed in the total 
NTR counts, there is a marked increase in NTR in day 2 compared to day 0.
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During the discovery  of novel transcribed regions, it was believed that most NTRs 
would be either new exons of known genes, or exons from totally  novel genes. While 
NTR counts and the distribution of length of NTRs support the potential existence of 
new transcripts and new exons, the presence of large numbers of very small NTRs 
appeared to be a mystery.
4.14 Identification of Novel transcripts
The potential for identification of novel transcripts, presumably found in a subset of 
the NTRs, was one of the reasons RNA-Seq was applied in this study. The novel 
nature of the cell type caused by the SU5402+BMP4 differentiation creates the 
possibility of identifying new genes / exons which have not been described 
previously.
The strategy  I used to identify novel transcripts from NTR data is fully  described in 
the materials and methods section. Briefly, to be identified as a cluster of exons 
contributing to a new gene, the NTRs had to be significantly  expressed (on average 5 
reads per base) and exist away from any know exon / gene footprint but significantly 
close with each other (less than 10,000 nucleotides). Samples from Day 0 
representing human embryonic stem cells and Day 8 representing the most 
differentiated time-point were used for the novel transcript discovery.
The novel transcript discovery pipeline identified 741 potential novel transcripts in 
Day 0 and 701 potential novel transcripts in Day  8. Out of these 367 were present in 
both the undifferentiated hESC and the 8 day differentiated trophoblast.
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To further study theses novel transcripts their distribution of average exon length was 
observed. It became evident that the majority  of potentially novel transcripts had an 
average exon length less than the 110 - 120 nucleotides found to be the average size 
RefSeq exons. This potential novel transcript exon size distribution was similar to the 
length distribution in the total NTR set where the majority of NTRs were less than 
100 nucleotides. 
Figure 4.34: The distribution of the average exon length of the potential novel 
transcripts.
The distribution is skewed showing a bias towards exon lengths less than 100.
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4.14.1 Interference of the novel transcript discovery by processed pseudogenes
While looking at the footprints of the potentially novel transcripts, it  was observed 
that a considerable number of them had overlaps with footprints with processed 
pseudogenes. Though one hypothesis could be that these represented expressed 
processed pseudogenes, this should not be the case as the definition of a processed 
pseudogene is that it contains no introns. Thus there should not be multiple peaks but 
only a single peak detected from a processed pseudogene; I detected multiple, small 
(50-60 base window) peaks. A sequence search indicated that  the footprint of these 
peaks were the same as the exon - exon junctions of the parental gene from where the 
pseudogene originates. This implies that these reads are actually  from the parental 
gene transcript but they get  mapped to the processed pseudogene than the actual exon 
- exon junction as the aligner favors alignment without gaps like in the intron between 
the exons. This leads to the creation of small peaks outside the footprints of known 
genes and located in pseudogene regions, which are then (incorrectly) identified as 
NTRs. This explains the unexpected high number of short NTRs observed. Since the 
processed pseudogene contains sequences to all the exon - exon junctions, these small 
RNAs exists as groups representing all the exon - exon junctions of the active 
transcript, thereby falsely showing as a new transcript. For an example please see the 
explanation below.
1. Observation: Presence of short peaks (less than ~100 nucleotides), often in groups 
(mostly  two but can be more). In most cases (such as in this) they are on an annotated 
processed pseudogene footprint shown in blue. 
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2. When a sequence search of the annotated processed pseudogene (in blue) is done 
using a UCSC blat search, the second hit is the gene  AHCY, which is the active 
counterpart of the pseudogene. (The first hit  is the processed gene itself). 
Visualization of the blat result is shown below. The first track is the RefSeq 
annotation and the blat alignment of the processed pseudogene is shown as the second 
track. Note the alignment with only  the exons - a characteristic of a processed 
pseudogene.
3. When the sequence of the footprint of the first peak is used to search the human 
genome (same as above) it results in the following location. The sequence match is 
shown in black. Note that the sequence of the small peak footprint is identical to a 
junction region of the AHCY gene. Therefore the conclusion is that the small peaks 
in clusters originate from the junction reads of active genes.
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This observation clearly explains the high number of short NTRs which were then 
removed from the dataset and the novel transcript identification was repeated.
It has been reported that  LINE-1 repeat elements have the ability to create 
pseudogenes (Esnault, Maestre et al. 2000) and that they are active in human ES cells 
(Garcia-Perez, Marchetto et al. 2007). Therefore the ‘noise’ created by pseudogenes in 
RNA-Seq experiments should be monitored and removed. This observation would be 
quite useful for the RNA-Seq community as it introduces a source of false positives in 
an RNA-Seq experiment and because it  leads to an under estimation of read counts of 
genes which have pseudogenes, by taking away their junction reads. 
Even after removing the small NTRs, all the patterns of NTR such as the marked up-
regulation of NTRs during the start of the differentiation remains the same.
4.14.2 Novel transcripts discovered from RNA-Seq data after removing 
interferences by pseudogenes
Identification of the above mentioned phenomenon which created false positive peaks 
due to exon - exon junctions was a disappointment as it brought down the total 
number of novel transcribed regions and thereby novel transcripts in each sample. 
Despite this, after removing NTRs which are less than 120 nucleotides in length (the 
ones which are most likely  be mapped to exon-exon junctions of pseudogenes) and re-
running the novel transcript discovery pipeline, 260 potentially novel transcripts from 
day 0 and 272 transcripts from Day 8 were identified. A subset of these were validated 
by PCR, cloned and sequenced. Some of the examples are described below.
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4.15 Examples of identified and validated novel transcripts
The sequences of the novel transcripts 1 - 8, which were obtained by PCR and cloning 
are given in appendix II.
4.15.1 Novel transcript 1 (chr1:63,559,143 - 63, 560, 695)
As can be seen in Figure 4.35, there is a novel multi-exonic gene which overlaps 
FOXD3 gene, and is coded by the opposite strand. There are no RefSeq or UCSC 
annotations describing it. However to support the above observation there are valid 
split ESTs (one originating from ES cells) with a shared footprint. FOXD3, being a 
major pluripotency  factor, is inhibited immediately  upon treatment, and interestingly 
the novel gene has exactly the same expression pattern, suggesting that there may be a 
functional relationship  and co-regulation, between the two, potentially through a 
bidirectional promoter.
This novel transcript does not have a valid open reading frame starting form AUG 
( but does have a 405 nucleotide coding sequence beginning from UUG). Therefore it 
is most likely a non-coding transcript. Novel transcript 1 was validated by PCR, 
cloning and sequencing.
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Figure 4.35: The novel gene next to FOXD3.
The peaks belonging to FOXD3 is shown highlighted in red while the peaks of the 
novel gene is shown in blue.
FOXD3 peaks
Novel gene
Day 0 positive strand
Day 0 negative strand
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4.15.2 Novel transcript 2 (chr7:100,729,591-100,731,304)
This new transcript was identified in the undifferentiated hESC sample. It is down-
regulated immediately upon differentiation (maximum peak height of 105 in day 0 
goes down to 2 in day 2). There is a LINE element which has an overlap  with this 
transcript thus suggesting that this transcript originated from a LINE insertion. This 
has an open reading frame of 447 nucleotides. Novel transcript 2 was validated using 
PCR, cloning and sequencing.
Figure 4.36: RNA-Seq peak profile of the novel transcript 2. 
Only the positive strand of Day 0 is shown for clarity.
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4.15.3 Novel transcript 3 (chr7:100,738,332-100,740,838)
This novel transcript  shows a down-regulation during the trophoblast differentiation 
but does not show a rapid suppression upon treatment compared to novel transcript 2. 
It has a maximum peak height of 213 in day  0, which goes down to 14 in day 8. This 
does not have a RefSeq annotation, and UCSC only has a putative annotation, and 
reports that it is from an IMAGE clone. It should be noted that based on RNA-Seq 
data there appears to be an additional exon on the 3’ side of the transcript. The 
transcript does have an open reading frame and appears to be originating from a LINE 
insertion based on the LINE sequences found on the base of both exons. This novel 
transcript has been validated by PCR, cloning and sequencing.
Day 0 positive strand
Day 0 negative strand
split EST track
Figure 4.37: RNA-Seq profile of the novel transcript 3.
The three potential exons are shown in boxes. There is no RefSeq transcript for this, 
but there is an incomplete UCSC annotation which excludes the last exon on the 3’ 
end.
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4.15.4 Novel transcript 4 (chr17:34,456,005-34,462,831)
This novel transcript is human ES specific. It does not have a RefSeq annotation, and 
has only  an incorrect  UCSC annotation. The footprint of this transcript is supported 
by split ESTs. The 5’ exon appears to be originating from an LTR region.
Day 0 positive strand
Day 0 negative strand
split EST track
Figure 4.38: RNA-Seq peak profile of the novel transcript 4.
The two exons are enclosed in black boxes and the LTR region which overlaps the 
first exon is shown within the red box.
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4.15.5 Novel transcript 5 (chr19:44,838,393-44,843,124)
This transcript originally did not have a RefSeq annotation or a UCSC annotation. Its 
existence is supported by  split - human ESTs  with placental origins. This transcript is 
expressed only  at later time points (day 6 and day 8) during differentiation implying 
that it might be important in trophoblast differentiation. PCR validation and 
sequencing proved the existence of the four exons. The latest version of UCSC 
browser shows this gene as LGALS16 supported by  a publication (Than, Romero et 
al. 2009) which reports that its placenta specific. While this takes away the novelty  of 
this transcript, this proves the effectivity of the differentiation protocol for inducing 
this transcript and the transcript detection pipeline for identifying it.
Day 0 positive strand
split EST track
Day 2 positive strand
Day 4 positive strand
Day 6 positive strand
Day 8 positive strand
Figure 4.39:  The UCSC view of the novel transcript 5.
The expression begins late at day 6. There are split ESTs supporting it.
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4.15.6 Novel transcript 6 ( chr13:99,536,264-99,539,117)
This transcript is expressed during the entire differentiation but shows a significant 
down-regulation through the course of differentiation. It does not have RefSeq or 
UCSC annotations, but is supported by split ESTs. 
The gene PCCA (Propionyl CoA carboxylase, alpha polypeptide) is just next to this 
transcript and is coded by the opposite strand, thereby suggesting that both transcripts 
could be regulated by a bi-directional promoter. PCCA has a similar expression 
pattern to this novel transcript. Novel transcript 6 was validated using PCR, cloning 
and sequencing.
Day 0 positive strand
Day 0 negative strand
split ESTs
Figure 4.40: UCSC view of the novel transcript 6.
Note that the novel transcript  is expressed from the negative strand (right to left), 
while the PCCA gene is expressed from the positive strand (left to right). The 
proximity of these two transcripts, common expression pattern and their orientation 
suggests the regulation through a bi-directional promoter.
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4.15.7 Novel transcript 7 (chr13:90,577,939-90,644,334)
This transcript is specific for the day 8 time-point of trophoblast development. Its 
footprint is quite long, and does not have RefSeq or UCSC annotations. However it is 
supported by EST data including one originating from embryonic trophoblast. 
Expression of this transcript begins at day 4 at  a maximum peak height of 34 and 
increase up to 140 in day 8. Novel transcript  7 was validated using PCR, cloning and 
sequencing.
Day 0 negative strand
split EST track
Day 2 negative strand
Day 4 negative strand
Day 6 negative strand
Day 8 negative strand
Figure 4.41: RNA-Seq peak profile of the novel transcript 8.
This transcript gets up-regulated during trophoblast  differentiation. Three exons 
which make up the transcript as identified by PCR and sequencing is shown within 
the boxes. Additional peaks in the surrounding suggest that  there could be additional 
transcripts originating from this locus.
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4.15.8 Novel transcript 8 (chr10:54,432,626-54,459,840)
This transcript is composed of three exons and has no RefSeq or UCSC annotations. 
Based on the RNA-Seq data it is up-regulated throughout the differentiation. Its 
existence is supported by a human EST which has a fetal origin. Expression of this 
transcript starts at day 2 and gets up-regulated during the course of the differentiation. 
There is no clear open reading frame. Novel transcript 8 was validated using PCR, 
cloning and sequencing.
Day 0 negative strand
split EST track
Day 2 negative strand
Day 4 negative strand
Day 6 negative strand
Day 8 negative strand
Figure 4.42: RNA-Seq peak profile of novel transcript 8. 
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4.15.9 A cluster of new transcripts (chr7:100,728,243 - 100,742,923)
Day 0 positive strand
Figure 4.43: A cluster of novel transcripts identified by RNA-Seq.
A cluster of three novel transcripts expressed at day 0. They do not have RefSeq 
annotations, and only the transcript on the extreme left has a partial UCSC annotation. 
This cluster was validated using PCR, cloning and sequencing. 
134
4. 16 Expression of retroviral related elements in the genome during 
trophoblast differentiation
Even after the removal of small NTRs formed by  junction reads of active genes (i.e. 
exon exon junctions of processed pseudogenes), the number of NTRs present in the 
sample were still considerable. When NTRs longer than 150 nucleotides are 
considered, there are 6,562 NTRs in day 0 and 12,033 NTRs in day 8. Among these, 
3,151 NTRs in day  0 and 2,976 NTRs in day  8 contribute to potential novel 
transcripts. This leaves 3,411 NTRs in day 0 and 9,057 in day 8 unaccounted for. The 
significant increase (almost threefold) of NTRs from day 0 to day 8 suggest  that these 
NTRs might serve a biological purpose. To study this, the locations of these NTRs 
were analyzed. From an initial manual analysis of some of these NTRs it became 
apparent that many of  these were derived from short interspersed nuclear elements 
(SINEs), long interspersed nuclear elements (LINEs), and long terminal repeat (LTR) 
elements of the genome, in other words, the “dark matter” of the genome. Indeed, it 
turns out that a majority  (Table 11) of these NTRs were derived from these repetitive 
elements. 
To study the expression of these elements during differentiation, all SINE, LINE and 
LTR elements which do not fall within any known RefSeq footprint was identified 
and their expression based on RNA-Seq read counts were analyzed. The following 
table shows the summary  of the counts. Based on the read counts it  is clear that both 
SINE and LINE elements show an increase during differentiation.
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315 674(684) 734(777) 656(701) 557(593)
269 269(284) 261(276) 247(263) 237(252)
241 459(465) 558(590) 449(478) 417(444)
Table 11: The number of SINE / LINE / LTR elements which show expression 
during day 0 - day 8 based on uniquely mapping reads. 
An element is considered expressed only if on average it has a read count of 4 per 
base. The number enclosed in brackets are values normalized for the sequencing 
depth.
Since SINE, LINE and LTR elements all have different subcategories, their 
expression dynamics  were further analyzed to see if there was any sub-type specific 
expression. The tables containing the number of expressed elements belonging to a 
particular category and graphs showing their expression pattern are shown in Figures 
4.44, 4.45 and 4.46. Overall, this shows that the trophoblast differentiation causes a 
clear increase in all sub categories of SINE and LINE elements and the highest 
increase is between day 0 and day  2 - the start of the treatment. As far as the LTR 
elements are concerned, despite the reduction in total expressed elements, three out of 
four subcategories - namely ERVL, ERVK and MaLR show a distinct increase in 
expressed elements at the start of differentiation, and the increase is maintained 
throughout the differentiation.
4.16.1 Specificity of reads mapping to the repeat elements
The notion that all the repeat regions in the genome have similar sequences and 
therefore are unable to provide unique read mapping surfaces is untrue. Detection by 
hybridization is problematic but sequence-based detection is possible. While the 
repeat regions originally inherits a particular primary structure based on it's type and 
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class, it gets rapidly altered due to point mutations. And since different repeat regions 
acquire different mutations their sequences become unique. however it should be kept 
in mind that this process requires time and that the most recently integrated repeats 
would not show a sequence diversity as shown by the more mature ones.
RNA-Seq has been designed from ground up to identify  all expressed regions 
including ones that arise from repeat regions while preventing non-specific binding. 
Firstly the reads which map to more than one location with the same score are 
discarded and not used in counting. These discarded reads could come from expressed 
repeat regions which have not yet accumulated enough point mutations to become 
truly  unique. Secondly a read is considered to be uniquely aligned only if the 
difference between it's best alignment score and the second best is more than four. 
This too prevents non specific binding.
All the data on the expressed repeat  regions reported in this thesis have been obtained 
by the same alignment criteria used for the rest of the genome (as described in the 
methods section and as highlighted above). This results in the rejection of large 
number of reads arising from expressed regions as seen by the huge increase of reads 
in the multi mapped track compared to that of the uniquely mapped. Therefore the 
extensive expression of repeat regions reported in this thesis is not a result of mis 
aligned reads and in fact the reported repeat expression is an underestimate of what 
actually is due to the large number of reads lost  due to the stringent alignment 
process.
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To quantitatively  show the above mentioned point the reads mapping to introns and 
coding sequences were compared with the reads mapping to repeat regions. The data 
is summarizes in table 12.   
Description # of regions Average reads 
per base
Introns of genes with one known isoform 118432 0.07
SINE , LINE , LTR elements with at least 4 reads per base 1211 10.4
All RefSeq exons with at least 4 reads per base 4079 10.1
NTRs with 5 reads per base with 60 bases or more overlap 1530 16.0
Table 12: Statistics of reads mapping to repeat elements, introns and exons of 
day 8 sample.
As can be seen in the table the average reads mapping per base in known eons and the 
repeat regions are almost the same while the reads mapping to the introns is 
negligible. Looking at the novel transcribed regions which arise from a repeat region 
and go beyond it's footprint, the average reads per base number goes higher even than 
that of known exons to 16. 
This clearly  demonstrates that  the reported expressed regions are indeed real and that 
the cutoff used to identify the expressed ones is comparable with that of known exons.
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Expression of SINE elements during trophoblast differentiation
Repeat TypeDay 0Day 2Day 4Day 6Day 8
MIR 265 586 647 572 12


































Figure 4.44: Number of expressed SINE elements during trophoblast 
differentiation. 
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Repeat TypeDay 0 Day 2 Day 4 Day 6 Day 8
L2 128 250 317 230 225
L1 85 151 187 158 134
CR1 21 41 37 45 44

























Figure 4.45: Number of LINE elements expressed during trophoblast 
differentiation.
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Expression of LTR elements during trophoblast differentiation
Figure 4.46: Number of LTR regions expressed during trophoblast 
differentiation.
*+,-! *+,-" *+,-# *+,-$ *+,-%
Repeat TypeDay 0 Day 2 Day 4 Day 6 Day 8
ERV1 171 100 95 104 107
MaLR 66 103 98 84 69
ERVL 29 48 47 37 43
ERVK 3 17 20 21 17
































4.17 Distribution of expressed repeat regions in the genome
Once it was observed that the SINE, LINE and LTR elements are expressed 
throughout differentiation the location of these expressed elements were studied to see 
if they are spread throughout the genome or localized to a particular area. A Circos 
diagram (http://mkweb.bcgsc.ca/circos/) (Krzywinski, Schein et al. 2009) (Figure 
4.47) shows that the expressed SINE, LINE and LTR elements are found everywhere 
in the genome and that they show considerable differential expression.
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Figure 4.47: A circular chromosomal image (generated by circos software) 
showing the expression of LINE, SINE and LTR elements. 
The chromosomes of the genome is shown in each of the segments of the outermost 
circle. Each concentric circle is a scatterplot showing the expression level of the 
particular element in the y axis. The two outer most rings / charts show the expression 
based on the multi map read counts, while the next two tracks show the expression 
based on the unique read counts. The innermost track shows the differential 
expression based on the unique counts (Red - Up-regulated, Green - Down-regulated). 
The objective of this diagram is to show that the expression of SINE, LINE and LTR 
elements are widespread throughout the genome.
143
Figure 4.48: The track showing differential expression of the repeat elements 
(day 0 vs day 8). 
This is the SLR (Signal log ratio, which is the log2 of fold change) track from the 
previous figure. The red markers showing up-regulation and green showing down-
regulation shows clearly that the repeat elements are differentially  expressed during 
differentiation.
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4.18 Retroviral elements acting as new exons of known transcripts 
during trophoblast differentiation
To gauge the influence of retroviral elements in gene expression, a proximity study of 
the expressed retroviral elements to known genes was carried out. A retroviral element 
was considered as a potential new exon of a gene if it was found to be within 10, 000 
bases of a gene footprint. There were 86 such cases in day 0 and 259 cases in day 8. 
This threefold increase from day 0 to day 8 further suggests that LTR elements do 
have a significant biological role in trophoblast differentiation. 
4.18.1 CLDN4 (Claudin 4)
CLDN4 shows a novel exon on its 5’ side which has an annotated LTR footprint from 
the ERV1 subfamily. The new exon is shown in panel 1 of Figure 4.49 and is enlarged 
in panel 2 to show its LTR footprint. The additional exon is not expressed in day 0, 
even though the CLDN4 gene itself is expressed. The new exon is induced by  the 
differentiation, reaching its maxima in day 8. Another novel exon just next  to the 
CLDN4 extension can also be seen. The novel exon and the extension has been 
validated by PCR, cloning and sequencing.
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Figure 4.49: RNA-Seq peak profile of CLDN4 and its novel exons as identified by 
RNA-Seq.
Panel 1 shows the first novel exon and panel 2 shows an enlarged view of that peak 











Figure 4.50: Enlarged view of the novel exons of CLDN4 identified using RNA-
Seq.
The extension to the original CLDN4 can also be seen. Here only the peaks of day 8 
time point are shown.




4.18.2 DHX32 (DEAH (Asp-Glu-Ala-His) box polypeptide 32)
The gene DHX32 gets up-regulated during trophoblast differentiation. Apart  from the 
known exons, the gene seems to have an additional one in the 5’ side and this novel 









Figure 4.51: The gene DHX32 has a novel exon on its 5’ end (exon 1).
The panel on the right (exon 1 magnified) shows an enlarged view of the same exon 
with the LTR annotations. The peak falls fully on an LTR element which is flanked by 
two LINE elements.
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4.18.3 MYCT1 (MYC target 1)
Based on RefSeq annotation the gene MYCT1 has two exons. Its expression begins at 
day 2 and continues throughout the differentiation. RNA-Seq data indicates that the 
first exon of MYCT1 is not expressed, however there are two novel transcribed 
regions which are on the 5’ side of the transcript, and they share footprints with LTRs. 
The similar expression pattern between MYCT1 and the two NTRs suggests that they 
could be two new exons of MYCT1.
!









Figure 4.52: RNA-Seq profile of MYCT1 and its two novel exons identified by 
RNA-Seq.
There are two new ‘exons’  on the 5’ end of the MYCT1 gene. Both peaks have 
overlaps with LTRs (shown on the left portion of the Figure).
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4.18.4 ZBTB3 (Zinc finger and BTB domain containing 3)
The gene ZBTB3 is down-regulated during trophoblast differentiation. Looking at the 
RNA-Seq data (Figure 4.53) it is clear that  there is an additional exon on the 5’ side of 
the transcript. This transcript is only present in day  0 and therefore can be considered 
as stem cell specific. The footprint of the new exon is derived from an LTR element. 
This has been validated using PCR. 
Interestingly  this LTR has been reported to recruit NANOG in ES cells (Kunarso, 
Chia et al. 2010) which hints at a co-regulation mechanism between the expressions 









Figure 4.53 : RNA-Seq peak profile of ZBTB3 and its ES specific novel exon.
The gene ZBTB3 has a novel exon on its 5’ end which has a complete overlap with an 
LTR element (ERV1 subfamily)
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4.18.5 SCGB3A2 (Secretoglobin, family 3A, member 2)
SCGB3A2 is down-regulated during trophoblast differentiation. RNA-Seq indicates 
that the first exon of the transcript is hardly  transcribed (has low number of reads 
aligned to it) and that there is a novel exon, which has originated from an LTR region 
and expressed at  a similar level to the gene.  Expression of the novel exon and the 
skipping of the RefSeq 1st exon which contains the original start codon, suggest that 
the SCGB3A2 protein structure could be affected.  PCR results showed that the NTR 
is indeed a novel exon of SCGB3A2.






Figure 4.54 :RNA-Seq peak profile of SCGB3A2 and its novel exon identified by 
RNA-Seq.
SCGB3A2 gene has one new exon on its 5’ side which has an LTR footprint.
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4.19 Genes which show a change in their splicing profile during 
trophoblast differentiation
Transcriptomic dynamics of any system cannot be exclusively described based on the 
expression level of genes. To sufficiently study a transcriptome, the alternate splicing 
events needs to be described together with gene expression. Alternative splicing 
events are quite common in the transcriptome (Wang, Sandberg et al. 2008) and they 
are reported to be important in regulating developmental processes (Kanadia and 
Cepko 2010).
If the splicing occurs in a protein coding region then it could influence the biological 
function of the protein. On the other hand, if the splicing is restricted to an 
untranslated region then the postranscriptional regulation of the transcript could 
potentially be affected. 
A comprehensive study  on the alternative splicing events during early  development 
has not been done before, mainly due to the limitations of microarray technology. 
Therefore the alternative splicing detection workflow (as described in Results 1 
section) was written to identify  alternative splicing events leveraging on RNA-Seq 
data which provides expression information of the entire gene.
Based on the alternative splicing detection workflow, 385 genes which show a change 
in their alternative splicing profiles were identified. The criteria used were that both 
exons showing the splicing should have a read count of more than 10 and that they 
should show a three fold or more differential change in the two exons (i.e. fairly 
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stringent criteria). Based on results, the workflow identified standard alternative 
splicing events, mutual exon splicing events and also alternative start  / stop sites.
 
4.19.1 Mutual exclusive splicing of Fibroblast growth factor receptor 2 (FGFR2)
One of the most striking examples of alternative splicing was found in the fibroblast 
growth factor receptor 2 (FGFR2) which happens to be mutually exclusive. Data 
shows that there is a shift  of expression from the 8th exon of FGFR2 transcript variant 
1 (NM000141.4) to the 8th exon of FGFR2 transcript variant 2 (NM022970.3), when 
comparing day 0 and day 8 samples (i.e. a shift from exon IIIc to IIIb). It  has been 
reported that the FGFR2 - IIIb isoform is specific to epithelial cells and the IIIc 
isoform is specific to mesenchymal lineage (Orr-Urtreger, Bedford et al. 1993). 
Therefore this observation clearly shows the transformation of stem cells into an 
epithelial lineage. Furthermore, ESRP1 and ESRP2, which are epithelial cell type-
specific splicing regulators of FGFR2 (Warzecha, Sato et al. 2009), are up-regulated 
during the early stages of differentiation (day 2 and day 4), which are the time points 
where the flip in the mutual exclusive isoforms takes place. 
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Figure 4.55: Mutual exclusion of FGFR2 exons.
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4.19.2 Mutual exclusion splicing of dynamin 2 (DNM2)
Similar to that of FGFR2, Dynamin 2, also shows a mutual alternative splicing 
between its  10th exon of isoform NM_001005361.1 and the 10th exon of isoform 
NM_004945.2.
Figure 4.56: RNA-Seq peak profile of DNM2.
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4.19.3 Alternative start exon in guanine nucleotide binding protein (G protein), 
alpha stimulating activity polypeptide (GNAS)
The alternative splicing detection workflow also picks up genes which change their 
transcription start sites by ‘dropping’ exons. GNAS shows such a change in expression 
where it shifts the expression from transcript variant 4 (NM_080425.2) to transcript 
variant 2 (NM_016592.2). It should be noted that based on RNA-Seq data, the 
opposite strand also show some expression at day-0.
Figure 4.57: RNA-Seq peak profile of GNAS.
Panel A shows the profile of the full gene and Panel B shows the enlarged footprints 
of the two start exons. While the expression of one start exon goes down, the other 
start exon’s expression level goes up suggesting a change in isoforms and start exon 
usage.
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4.19.4 GATA binding protein 2 (GATA2)
GATA2 is reported as an important regulator of trophoblast  specific gene expression 
and placental function (Ma, Roth et al. 1997). GATA2 is one of the highest up-
regulated genes in both the RNA-Seq trophoblast differentiation (150 fold) and in 
human blastocyst development (Zhang, Zucchelli et al. 2009) . Up-regulation of 
GATA2 is immediate upon differentiation by SU5402 + BMP4 as can be seen by the 
RNA-Seq peak profile in Figure 4.58. This immediate up-regulation can, in part, be 
explained by the fact that this gene is a known BMP4 target.
Based on RefSeq annotation, GATA2 has three isoforms that differ from each other by 
use of different transcription start sites leading to three unique first exons. The 
translation start site resides in exon 2. This alternative promoter use has been 
conserved between the chick and human (Nony, Hannon et al. 1998; Pan, Minegishi 
et al. 2000), at least for the most distal and proximal promoters. Analysis of my  RNA-
Seq data indicates that during differentiation, the most proximal promoter (producing 
transcript NM 001145662.1) is expressed first, identifiable in the day 2 data, and at 
around day  6, expression is evident from both the proximal and distal promoter 
(transcript NM  032638.4) (Figure 4.58). There is a Smad responsive element 
immediately adjacent to the proximal promoter of GATA2 (Karaulanov, Knöchel et al. 
2004). This could explain early  activation of the GATA2 isoform corresponding to the 
proximal promoter as Smad7 is expressed and up-regulated throughout the 
differentiation. The presence of a GATA2 binding site at  the distal promoter might 
explain the expression of the alternative isoform.
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This observation suggests of an instance where a gene is regulated by two promoters, 
one inducing the expression while the other maintaining it. This dynamic switch in 
GATA2 promoter use has not been previously described. This example represents the 
power of combining a comprehensive transcriptomic analysis (i.e. RNA-seq) with a 
developmental time-course to provide insight into developmental mechanism.
In addition, RNA-Seq data indicates that there is a novel transcript which is 
transcribed by the opposite strand but which overlaps with the 5’ portion of the 
GATA2 gene (Figure 4.58), and that it has a similar expression pattern to GATA2 (i.e. 
not expressed in day 0, and gets induced during differentiation).
158
Figure 4.58: RNA-Seq peak profile of GATA2.
It gets induced during day 2 and keeps on being up-regulated. Initially a short 
transcript is expressed and around day 6 a longer transcript is transcribed.
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Figure 4.59: Different isoforms of GATA2 expressed at day 8.
At day 8, the shortest and the longest isoform of the GATA2 gene is expressed, and 
the third isoform is not. The above Figure shows the junction reads (in green), which 
joins the exons together. The junctions marked with a blue dot represent the exon - 
exon connections of the longer isoform, while the junctions marked with the black dot 
originates from the shortest isoform. In day 2, only  the junction reads from the shorter 
isoform can be seen.
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Figure 4.60: The novel transcribed region next to GATA2.
The GATA2 peaks are highlighted in blue and the novel transcribed region / transcript 
is shown in red. There is considerable overlap between the two (but coded by 
different strands) and the new transcript has a similar expression pattern to that of 
GATA2.
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4.20 Identification of novel exon - exon junctions based on RNA-Seq 
data
As described in the methods section, the mapreads aligner identified reads mapping to 
exon - exon junctions of known transcripts. This is done through aligning reads 
(which have not been aligned during the genomic alignment phase) to a sequence 
database which represents all the exon - exon junctions of RefSeq transcripts 
including the novel exon - exon junctions. 
The reads which map to exon-exon junctions are important as they act as markers 
indicating that the two exons which makes up a particular junction are connected (i.e. 
spliced in) with each other. Therefore if in a given gene, there is a significant number 
of reads mapping to a novel exon - exon junction (i.e the splice junction is not 
described in RefSeq but the exons which contribute to it are) then it  could be used as 
an indicator to show that there is a new isoform of that particular gene.
I wrote a pipeline to exploit this dataset which predicts novel exon-exon junctions of 
all the genes in RefSeq. To increase the accuracy of the method, only  the reads which 
are highly  specific for the novel junction were used. Based on the results of this 
workflow which used data from all time points, there were 6,205 genes which showed 
12615 potentially novel exon - exon junctions. Among these, there were 253 junctions 
which had at-least 10 reads mapping to it. Even though on the face of it, 10 reads per 
junction appears to be too stringent it should be noted that the reads used for this step 
of analysis showed the best possible unique alignment and that junction reads have a 
low chance of being aligned on the first place due to the short exon-exon junction foot 
print.
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The main importance of identifying novel exon - exons junctions is that a novel 
junction could completely change the function of the protein. This is demonstrated by 
using the novel exon - exon junctions identified in PTK2 and PAPOLA genes (Figures 
4.61 and 4.62).
Figure 4.61: The novel exon-exon junction of PTK2 identified by RNA-Seq and 
its influence on the protein product. 
For clarity  only the negative strand is shown in the day 8 time point. Note that the 
changes brought about by the novel junction ultimately leads to changing the domains 
contained within the protein.
NM_005607 (PTK2) - original NM_005607 with 4th exon spliced out
Length 1075 a.a 999a.a
Weight 121kDa 111kDa
Isoelc. point 6.42 9.28
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Amino acid Count Frequency
Valine (V) 36 0.036
Tryptophan (W) 23 0.023
Tyrosine (Y) 27 0.027
Aspartic acid or asparagine (B) 0 0.000
Glutamic acid or glutamine (Z) 0 0.000
Any amino acid (X) 51 0.051
Leucine or isoleucine (J) 0 0.000
1.8 Amino acid distribution histogram
1.9 Annotation table
There are no annotations.
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Amino acid Count Frequency
Valine (V) 58 0.054
Tryptophan (W) 14 0.013
Tyrosine (Y) 40 0.037
Aspartic acid or asparagine (B) 0 0.000
Glutamic acid or glutamine (Z) 0 0.000
Any amino acid (X) 1 0.001
Leucine or isoleucine (J) 0 0.000
1.8 Amino acid distribution histogram
1.9 Annotation table
There are no annotations.
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Figure 4.62: The novel exon-exon junction of PAPOLA identified by RNA-Seq 
and its influence on the protein product.
NM_032632 (PAPOLA) - original NM_032632 with 4th exon spliced out
Length 1513 a.a 1394 a.a
Weight 170 kDa 161 kDa
Isoelc. point 9.52 9.65
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Novel Junction (hg 18)
Start End
USP28 chr11 113180979 113184230
PTOV1 chr19 55049613 55052973
FBLN1 chr22 44307709 44321629
ZFP42 chr4 189153989 189157757
PALLD chr4 170082805 170083939
PBX1 chr1 163048011 163057398
FUS chr16 31101487 31103761
FMR1 chrX 146826812 146829787
MYO6 chr6 76675065 76680500
GPBP1L1 chr1 45899485 45924671
COL6A2 chr21 46364920 46367217
YAP1 chr11 101582016 101599563
OSBPL8 chr12 75368900 75405421
SYNGAP1 chr6 33517515 33518644
COBLL1 chr2 165265513 165269200
AP1B1 chr22 28054885 28056367
LTA4H chr12 94920974 94924223
ATP1A1 chr1 116737869 116743565
EPB41L3 chr18 5396968 5400565
RNF213 chr17 75942562 75977568
HISPPD1 chr5 102548345 102554442
DGUOK chr2 74007688 74027354
PTK2 chr8 141943681 141969824
SIN3B chr19 16834371 16835491
PRKCSH chr19 11419434 11419508
CCT2 chr12 68267664 68279910
HMG20A chr15 75500402 75537801
EPB41L3 chr18 5387426 5396776
COL1A2 chr7 93881524 93894256
PLD3 chr19 45546516 45563300
NTRK2 chr9 86474159 86475112
EPB41L3 chr18 5383478 5385066
EMID1 chr22 27941620 27957009
ACTN4 chr19 43888612 43904018
BAT3 chr6 31714983 31715955
PPP4C chr16 29995298 30001306
ZNF664 chr12 123038639 123061881
DMKN chr19 40688729 40692926
Table 13: Genes which have a novel exon - exon junction with more than 20 
reads mapping to it.
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4.21 Extensions to existing annotations at 3’ and 5’
One of the main advantages of RNA-Seq data is that it is not dependent on existing 
annotation. This becomes a great  asset in identifying novel transcriptomic 
phenomena. One such example is the improvement of existing annotations. The 
alignment pattern of the sequenced reads to a particular annotated region in the 
genome can be used to validate the existing annotations and make alterations if 
required. In certain cases the RNA-Seq peaks tends to ‘extend’ beyond the known 
RefSeq annotation boundary, and a workflow was developed to identify these 
extensions in a genome-wide manner.
The pipeline found that there were 1708 internal exons (all exons except  3’ and 5’ 
UTRs) which had an ‘extension’ of 100 base pairs or more on 5‘ and / or 3‘ side in 
day 0. There were 322 genes which had more than 1000bp extensions on their 3’ UTR 
while 20 genes had more than 1000bp 5‘UTR extensions. Based on distribution of 
extensions, it is clear that the 3’ UTR extensions have a longer average length (Figure 
4.63). 
The majority  of target sites of microRNA lies in the 3’ UTR region of the transcripts. 
For this reason the proper annotation of specially the 3’ UTR is vital. This study 
identifies a total of 1,575 kb extensions of 3’ UTR regions with respect to RefSeq 
annotation for the entire genome. This extension region is vital for accurate 
identification of microRNA-target transcript pairs. For example a microRNA - target 
prediction performed using the 3’ UTR extension regions identified here through 
miRANDA prediction algorithm (Enright, John et al. 2003) predicted 1000+ 
additional microRNAs which could bind to NANOG.
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Figure 4.64: UTR extensions of TAOK1 and TBC1D16 two genes with the 
highest extended 3’ UTRs. 
These extensions are much longer than the original length of the transcript itself.
To further show the superior nature of RNA-Seq and the extent of 3’ UTR extensions 
as compared to RefSeq annotation data EST BC042436 can be used as an example. 
This EST does not have a corresponding annotation in RefSeq and it  does not have an 
Illumina probe associated to it. An associated Affymatrix probe (212444_at) has no 
associated RefSeq gene annotated to  it. However RNA-Seq data clearly indicates that 
this is in fact a result of the 3’ extension of the gene GPRC5A (Figure 4.65). 
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In the preimplantation dataset both GPRC5A and the probe 212444_at gets up-
regulated during blastocyst  formation. The co-regulation of these two - seen by the 
similar expression pattern,  further validates that they are indeed from the same 
transcript.
Figure 4.65: Extension region of GPRC5A.
The EST BC042436 does not have a RefSeq annotation, and is annotated by  GenBank 
as an independent mRNA with a partial coding sequence. RNA - seq data clearly 
shows that it is actually an extension at the 3’ UTR of the gene GPRC5A.
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GeneID Chr UTRStop Strand Extension Length (Nucleotides)
HMBOX1 chr8 28966159 + 11453
SNORD108 chr15 22783233 + 10611
EIF2C2 chr8 141611433 - 10308
POU2F1 chr1 165651950 + 10050
RAB3B chr1 52158374 - 10016
HELLS chr10 96351846 + 9930
WDR86 chr7 150709765 - 9508
ZNF704 chr8 81716267 - 8461
HIST1H2AC chr6 26232897 + 7691
SESN3 chr11 94546153 - 7436
MBNL3 chrX 131341386 - 7251
DYNLL2 chr17 53522617 + 7153
HEBP2 chr6 138776275 + 7127
TBC1D16 chr17 75529501 - 7106
TAOK1 chr17 24895628 + 7099
FAM40A chr1 110398786 + 7097
PPM1L chr3 162271511 + 6752
TRIM71 chr3 32908775 + 6710
MPRIP chr17 17029598 + 6708
PANK3 chr5 167917204 - 6695
RGP1 chr9 35742871 + 6552
PTPN14 chr1 212598016 - 6469
FAM160A1 chr4 152804234 + 6241
C6orf186 chr6 110674156 - 6149
TMED8 chr14 76878084 - 6090
GRPR chrX 16081562 + 6086
CDS2 chr20 5119989 + 6060
LOC729082 chr15 39379086 + 6016
Table 14: Genes which show a maximum 3’ UTR extension of more than 6000 
nucleotides beyond the current RefSeq annotation.
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4.22 smallRNA data analysis
The focus on mRNA dynamics and technical issues such as difficulty  in designing 
primers for their small footprint and lack of sequence information has resulted in the 
low number of high throughput genome-wide studies on small RNA, specially during 
early development. 
Small RNA species include microRNA, which are regulators of mRNA. It  has been 
shown that during trophoectoderm formation in mouse, a massive removal of non-TE-
specific transcription factors takes place and that this removal is greater than the 
increase of TE specific transcription factors (Guo, Huss et al. 2010).  Therefore, it is 
logical to assume that microRNAs could play a major part in the reduction of non - 
TE specific transcription factors. Thus, study of microRNA expression during 
trophoectoderm formation could be beneficial in describing mRNA transcriptomic 
events that take place during this time.
Placental microRNA has been detected in maternal blood during pregnancy (Chim, 
Shing et al. 2008; Enquobahrie, Abetew et al. 2010). So it is vital to know the 
microRNA component which is involved in trophoblast formation so that they  can 
serve as markers for placental / trophoblast function.
Due to the above mentioned reasons it was decided to perform a small RNA-seq 
experiment for the samples of the human trophoblast differentiation protocol. Day 0 
(undifferentiated human ES cells), Day 2 and Day 4 time-points of the differentiation 
were used for this experiment and all RNA less than 200 nucleotides were studied. 
Since microRNAs are the most active among the small RNA, the emphasis of the 
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analysis was to study  the differential expression of known microRNA and to identify 
novel microRNA.
4.22.1 Differential expression of microRNA
The miRBASE annotation, containing a total of 1048 microRNAs, was used to obtain 
the footprints of known microRNA. A microRNA was considered as expressed at 
significant level when it had more than 20 reads mapping to it. Based on these criteria 
day 0 time-point (undifferentiated human ES cells) showed 350 microRNAs as being 
significantly expressed while day 2 and day 4 showed the significant expression of 
371 and 365 microRNA respectively. 
As for differential expression (day 4 vs day 0), 138 microRNA were up-regulated 2 
fold or more and 110 microRNA were down-regulated. (Figure 4.66)
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Expression dynamics of miRNA during differentiation
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Figure 4.66: The differential expression of microRNA during the trophoblast 
differentiation. 
Each point / bar of the graph on the left  shows the expression of a single microRNA. 
As can be seen, the microRNA component of the transcriptome is highly dynamic 
during the differentiation, having members which are highly up and down regulated. 
The top 10 highly up  and down-regulated genes and their expression levels are shown 
on the left.
Presence of a significant number of up and down-regulated microRNA during 
differentiation suggest that the SU5402 + BMP4 differentiation brings about a 
considerable change in the small RNA transcriptome. In order to see that this change 
leads to trophoblast like phenotype / biology seen in the differentiated cells, up-
regulated microRNAs were compared with microRNA previously  reported to be 
highly  expressed in the placenta and a considerable overlap was observed (Terauchi, 
Koi et al. 2003; Chim, Shing et al. 2008; Gilad, Meiri et al. 2008; Enquobahrie, 
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Abetew et  al. 2010). Figure 4.67 shows the up-regulated microRNAs during the 
differentiation protocol together with their expression values. The bars in red shows 
the microRNAs which, based on literature, are highly expressed in the placenta. The 
majority  of microRNA reported to be expressed in the placenta are up-regulated in the 
trophoblast differentiation. The microRNAs which are up-regulated during 
trophoblast differentiation but are not reported to be present in the placenta could be 




Figure 4.67: The expression level of all the up-regulated microRNA based on 
RNA - Seq data.
The microRNAs with the red bar are the ones reported in literature to be abundant in 
the placenta. The ones which are in blue could simply be unidentified new 
microRNAs of the placenta, or microRNAs involved in the early development of the 





















































































































































4.22.2 microRNAs involved in the regulation trophoblast lineage
Based on smallRNA - Seq data, there are 348 microRNA which are up-regulated 
during the SU5402+BMP4 differentiation. Expression levels of the highest expressed 
microRNA are shown in Figure 4.67. Since this is the first time that the microRNA 
component of the early  stages of human trophoblast  differentiation has been studied, 
there are no directly comparable data available. The closest  available datasets come 
from placental samples. Chim et al (2008) analyzed third trimester placenta for the 
expression of 157 microRNA by TaqMan analysis. 
Out of the 17 highest expressed microRNAs in placenta based on (Chim, Shing et al. 
2008), 12 are up-regulated during the trophoblast differentiation. These include hsa-
miR-373, hsa-mir-371, hsa-mir-372, hsa-mir-149, hsa-miR-34c, hsa-miR-34b, hsa-
miR-135b, hsa-miR-141, hsa-miR-200b, hsa-miR-137, hsa-miR-184 and hsa-
miR-337. 
4.22.3 Stem cell related microRNA
Next generation sequencing has been used to study the microRNA component of 
human embryonic stem cells (Bar, Wyman et  al. 2008; Morin, O’Connor et al. 2008). 
The sequencing depth used in these studies are much smaller than the amount used in 
my small RNA-Seq sequencing. Therefore it  is expected that my  dataset would yield 
additional information on the smallRNA transcriptome.
Using 20 reads per microRNA as cutoff, only 186 microRNAs are significantly 
expressed according to the dataset in Morin et al, while 331 microRNAs are 
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significantly  expressed in mine. The 145 microRNAs which were detected 
exclusively  in my  dataset  can be explained by its high sequencing depth which 
increases sensitivity. Despite this, the two datasets are highly comparable with 87% 
(164 microRNAs out of 186) expressed in  Morin et. being significantly expressed in 
mine. The difference of sequencing depth also could be a reason for the much higher 
number of novel microRNA detected using my dataset compared to that of Morin et 
al.
4.23 Identification of novel small RNA
Just like in the standard RNA-Seq analysis, the small RNA-Seq dataset was used to 
look for novel transcribed regions (NTRs). In this case the footprints of microRNAs 
in the miRBASE database was used to de-mark the known expressed regions. 12,404 
NTR regions were identified in day 0 and 15,145 NTRs were found in day 8. Again 
just like in the case of the standard RNA-Seq dataset the number of NTR regions 
showed a significant increase during differentiation.
Since most of the smallRNAs can be classified based on the size, the size distribution 
of all the identified NTRs were studied. The distribution shown in Figure 4.70, while 
having a large footprint from 16 nucleotides to beyond 200, shows a clear, very strong 
maxima of 22 nucleotides. Recall that my small RNA-seq library  was created for any 
RNA that was 200 bases or smaller. Since the average length of microRNAs is around 
22 nucleotides, this suggests that identified NTRs from the small RNA dataset are 
highly  enriched in microRNA. Due to this observation the subsequent analysis 
focussed on identification of novel microRNAs.
177
Figure 4.70 : The size distribution of small RNA NTRs expressed in day 0 and 
day 4. 
While the distribution has a broad footprint  the maxima is at 22 nucleotides - the 
average length of microRNAs. The bottom two graphs are shows the enlarged view of 
the microRNA size peak.
4.23.1 Potentially novel microRNAs
To get a reliable list of potential microRNA from all the NTRs, NTRs which map to 
known repeatmasker regions from UCSC genome browser, were removed. 
Repeatmasker contains annotations for rRNA, tRNA as well as LINEs, SINEs and 
LTRs described previously. By this step  most of the tRNA and small ribosomal RNA 
are removed. Subsequently, known snoRNAs were removed from the list. To narrow 
down the list further, the secondary  structure of these potential microRNA was 
analyzed using RNAfold. As mentioned in the methods section microRNAs have a 
unique stem loop like secondary structure with quantifiable criteria such the as 
number of complementary bases in the stem loop and a free energy cutoff. These 
criteria enabled the identification of potential microRNA with a stable stem loop 
secondary  structure. Finally  2,360 potential microRNA from day 0 and 2,924 from the 
day 4 data set were identified. Among these 150 and 180, in day 0 and 4 respectively, 
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originated from highly  conserved regions in placental mammals seen as a 80% or 
more overlap with mammal conservation track of UCSC. This suggest the possibility 
that most of the new microRNA are less conserved, meaning that they  could be either 
primate- or human- specific.
When comparing the expression pattern of these novel microRNAs, 927 microRNAs 
(including highly conserved and non-conserved) showed up-regulation (2-fold or 
more) and 473 showed a down-regulation. This suggest that these microRNA are 
affected by the differentiation treatment. As for the highly conserved microRNA they 
too show significant differential expression. On day  0 out of the 150 highly conserved 
novel microRNA, 64 show a 2 fold or more  up-regulation while only  8 shows down 
regulation of more than 2 fold.
Description Day 0 Day 4
Total peaks (min height 1, min reads per base 100) 12,404 15,145
no overlap with RepeatMasker 6,546 8,022
no overlap with RepeatMasker + 80% or more Overlap with Mammalian highly conserved regions460 589
no overlap with RepeatMasker + no overlap with snRNA 6,369 7,818
no overlap with RepeatMasker + no overlap with snRNA + miRNA criteria pass 2,360 2,924
no overlap with RepeatMasker + no overlap with snRNA + miRNA criteria pass + 80% conserved150 180
Table 15: Novel microRNA statistics.
Note the clear increase of novel microRNAs brought about by the differentiation.
Description Count
Up-regulated novel miRNA during differentiation more than 1SLR 927
Up-regulated novel miRNA during differentiation more than 2SLR 307
Down-regulated novel miRNA during differentiation more than 1SLR 473
Down-regulated novel miRNA during differentiation more than 2SLR 132
Table 16: Differential expression of novel microRNA.
The differential expression is measured between day  4 and day  0 during trophoblast 
differentiation.
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4.23.2 A typical view of a known microRNA together with its folded structure
Figure 4.71 shows the UCSC view of a known microRNA and the stem loop structure 
it produces. Note that the peak profile contains a taller peak and a shorter one. The 
taller peak represents the mature microRNA sequence while the shorter peak 
represents the star sequence. 
Figure 4.71: A typical UCSC view of the RNA-Seq  small RNA dataset. 
Here a footprint of a known microRNA is shown. The data tracks from day 0, day 2 
and day  4 respectively are arranged from top to bottom. In the insert, next to the 
peaks, the secondary structure of  of the microRNA - which shows the characteristic 
stem loop structure is shown. This is the format of all the small RNA-Seq related 








4.23.3 Examples of novel microRNA
As the alignment process discriminates between a known microRNA and a novel one, 
and since it is easier to align small RNA-Seq reads to the known microRNA footprints 
than to entire genome, the small peak representing the star sequence is not seen in 
novel microRNA. The peak seen in novel microRNA profiles represents the mature 
microRNA sequence.
The following section will contain examples of potentially novel microRNA which 
originate from  introns, intergenic regions and opposite strand of a known gene. In 
each of the cases the predicted stem-loop structure is also shown.
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4.23.4 Examples of novel miRNA which originate from the opposite 




Figure 4.72: novel microRNA which originates from the opposite strand of 
ASTN1 gene.
 This gets up-regulated during differentiation and has a stable stem loop.
Figure 4.73:  A novel microRNA coded by the opposite strand of GLTPD1.
This forms a stable stem loop and gets up-regulated during trophoblast differentiation.
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4.23.5 Examples of novel miRNA which originate from an intronic 
region.
Figure 4.74: A novel microRNA coded by an intron of MPZL1 and PZR genes.
This novel microRNA gets down-regulated during differentiation.
Figure 4.75: A novel microRNA which is coded by the intron sequence of LGR6 
and VTS20631. 
This gets down-regulated with treatment.
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4.23.6 Examples of novel miRNA which originate from an intergenic 
region of the genome.
Figure 4.76: novel microRNA coded by an intergenic region.
This gets up-regulated during differentiation.
Figure 4.77: Another novel microRNA coded by an intergenic region.
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4.23.7 Examples of novel miRNA which show an up-regulation 
during differentiation.
Figure 4.78: A highly up-regulated novel microRNA  (~180 fold).
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4.23.8 Examples of novel miRNA which show an down-regulation 
during differentiation.
Figure 4.79: A significantly down-regulated microRNA (~ 4 fold).
Figure 4.80: A 20 fold down-regulated novel microRNA.
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4.23.9 Novel microRNA cluster
A study on the proximity of  novel microRNA was carried out to identify  microRNAs 
which exist as clusters. Only  one such example was found containing 3 or more 
microRNA. Figure 4.81 shows the UCSC view of a known microRNA and Figure 
4.82 shows the novel microRNA cluster as identified by RNA-Seq.
Figure 4.81: A known microRNA cluster
Figure 4.82: The novel microRNA cluster identified by RNA-Seq.
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5.0 Discussion
Study of early human development, especially  the development of the trophoblast 
lineage, is important not only from a fundamental biological point of view but also 
from a clinical perspective.
Formation of the trophectoderm is a significant biological step, as it marks the first 
lineage commitment and the origin of the first epithelial cell type of the new 
organism. Furthermore, with the help of maternal tissues, trophoblast cells go on to 
produce the placenta, through a complex and unique differentiation sequence.
This thesis is an attempt to describe and understand the intricate dynamics of the 
transcriptome during the establishment and development of the human trophoblast 
lineage. A scarcity or non-availability of samples, ethical issues and the lack of 
differentiation protocols that  can provide realistic results, have limited the detailed 
study of this fascinating differentiation program in humans.
In this thesis, using an improved differentiation protocol which induces human 
embryonic stem cells to assume characteristics of the trophoblast lineage, I have 
attempted to create a comprehensive record of the transcriptomic dynamics during 
trophoblast differentiation. To study  the transcriptome, I have used RNA-Seq 
technology to look at both poly-adenylated RNA and small RNA dynamics. The 
poly(A) RNA data set provides information on the mRNA portion of the 
transcriptome while the RNA-Seq dataset of small RNA provides insights mainly on 
microRNA expression. 
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RNA-Seq technology  is superior to other traditional techniques employed for 
transcriptomic studies. It allows the analysis of the entire transcriptome and is 
extremely sensitive and accurate since it is based on sequencing. Furthermore, RNA-
Seq data is not based on existing annotation, which allows the identification of novel 
transcriptomic phenomena. 
At the time of the analysis there were no proper software to analyze an RNA-Seq data 
set in an in-depth manner. Therefore I developed a set  of workflows / scripts which 
enabled the extraction of useful information from an RNA-Seq dataset. These 
workflows identify  alternative splicing events, mutual exclusion events, extensions 
for existing annotations, novel transcribed regions, novel transcripts and novel 
microRNAs. 
To calculate the RNA-Seq expression levels, I first used RPKM  values, which are the 
counts of reads mapping to individual genes, normalized to the gene length and the 
sequencing depth. To check the validity of the RNA-Seq experiment I compared the 
RNA-Seq expression levels with microarray data for the same sample. The two 
datasets had a very  good correlation with a coefficient of determination (R2) value of 
0.8. 
Next I compared the gene expression dataset of the five time points of the 
SU5402+BMP4 treatment (our novel trophoblast differentiation protocol) with a large 
group of human tissues and cell lines, to identify  the organ / tissue system which has 
the closest transcriptional similarity  using hierarchical clustering. Reassuringly, it 
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turned out that  the closest organ to the outcome of the differentiation protocol is the 
human placenta and the closest cell types to it were the cytotrophoblast and 
syncytiotrophoblast cells. 
To further validate the data from the differentiated trophoblast transcriptome it  was 
compared with a published microarray dataset of early human development (Zhang, 
Zucchelli et al. 2009). This dataset only  contains information of the pre-blastocyst and 
blastocyst samples with no direct trophoectoderm sample. However by overlapping 
up-regulated genes of blastocyst formation with  those of trophoblast differentiation, I 
was able to identify genes which are exclusively involved in trophoblast formation.
Hierarchal clustering was again used to compare the trophoblast differentiated cell 
transcriptome with the above mentioned published human blastocyst microarray  data. 
Here the day 8 time point of the differentiation protocol clustered closest with the 
blastocyst sample and the day  0 (undifferentiated ES cells) was clustered with the 4 
cell stage embryo.
Then I looked at the expression dynamics of individual genes to identify  the ones 
which are involved in the initiation and the maintenance of the trophoblast  lineage. I 
looked at significantly up-regulated genes in day 2, 4, 6 and 8 time points compared 
to day  0. These genes either were induced meaning that they were not expressed in the 
human embryonic stem cells (day  0), but  expressed at significant levels during 
differentiation or were already  being expressed at  day  0, but were significantly up-
regulated during differentiation.
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Looking at  the number of expressed genes in each time point, it was clear that the 
differentiation caused an increase in the total number of expressed genes. The 
increase of expressed genes was highest in day  2. On the other hand at day  2 some of 
the pluripotency  factors are still expressed albeit  at a lower level than undifferentiated 
ES cells. Therefore day 2 time-point represents a transition phase where pluripotency 
machinery  are being suppressed while trophoblast inducing mechanisms are made 
active.
In general, the significantly up-regulated genes during trophoblast differentiation 
include a mix of pregnancy related hormones, placenta specific genes, genes 
associated with retroviral elements and genes which indicate mesenchymal to 
epithelial transition. 
A considerable number of the genes that were induced / up-regulated during 
trophoblast differentiation have already been reported to be involved in placenta 
formation. However in most of the cases these observations have been made in other 
model systems, trophoblast cell lines, mature placenta or related samples (e.g the 
uterus). RNA-Seq data confirms the fact that these genes are involved in the early 
phases of the trophoblast differentiation.
The highest up-regulated gene during trophoblast  differentiation is CGA which codes 
for one of the two subunits of human chorionic gonadropin - the “pregnancy 
hormone” and a hallmark of the trophoblast  lineage. CGA is initially detected at day 4 
and by day 8 has extremely high levels of expression (2,239 RPKM).
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Syncytin 1 and Syncytin 2 are fusogenic proteins implicated in the formation of the 
syncytiotrophoblast. They have originated from endogenous retroviral insertions and 
are induced during differentiation.
The keratin genes - KRT19, KRT23, KRT18, which are characteristic of epithelial 
cells, are significantly  induced around day 4 and their up-regulation is maintained 
throughout the differentiation. 
The Mucin gene MUC15 is induced immediately during differentiation and is highly 
expressed up to day 8. Mucins are believed to play a vital part during implantation, 
creating a sticky surface for the blastocyst to attach to the uterus. 
GCM1 is an essential transcription factor for placenta formation. GCM1 expression is 
induced during day  4 and keeps on increasing. Interestingly  the transcriptomic data 
suggest that the GCM1 regulatory machinery (which includes the genes GSK3B and 
DUSP23), evolved to keep the GCM1 levels in check, is also active.
Induction of genes during differentiation is not only limited to coding genes. The gene 
H19 which codes for a long non-coding gene which is modulated by oestrogen, is 
immediately induced during differentiation and its expression keeps on increasing.
All the genes mentioned here and the majority of the genes being significantly up-
regulated during trophoblast treatment are either placenta specific, or highly 
expressed in the placenta. 
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RNA-Seq data also identifies genes which are up to now not reported to be involved 
in trophoblast development. For example CCR7 (Chemokine receptor type 7) is a 
gene involved in adaptive immune response. Based on transcriptomics data, it is the 
second most highly up-regulated gene in the differentiation protocol. This is 
unexpected because it is thought that the trophoblast has mechanisms to suppress the 
immune reaction from the mother for a successful pregnancy. However the up-
regulation of CCR7 indicates that the trophoblast is actively producing proteins which 
has the potential to induce an immune reaction. Published data on the human 
preimplantation development of actual human embryos, also show an up-regulation of 
CCR7 in the human blastocyst compared to the 8 cell embryo. This suggest that CCR7 
is indeed a relevant gene for trophoblast function, and not a side effect of the 
differentiation. One potential explanation for this is that the human trophoblast 
secretes CCR7 to put the mothers adaptive immune systems to “overdrive” and 
therefore reducing its effectiveness. This sounds feasible, specially considering the 
extremely high number of endogenous retrovirus related transcripts seen to be 
expressed during the differentiation (discussed later), thereby providing an enormous 
amount of antigens - most of which are highly dynamic and not critical for the 
functions of the trophoblast. 
VTCN1 (V-set domain containing T cell activation inhibitor 1), which is an inhibitor 
of innate immunity  (Yi and Chen 2009). During the trophoblast differentiation 
VTCN1 is up-regulated 191 fold. This together with the CCR7 example could shed 
light on the immunosuppressive processed during early development. 
193
RNA-Seq of small RNA indicates that the smallRNA expression is significantly 
influenced by the trophoblast differentiation. However the number of induced 
microRNA during differentiation is extremely limited. This suggests that in the case 
of microRNA regulation of trophoblast differentiation, changes in microRNA 
expression level is more important than the induction of new microRNAs. 
A considerable number of microRNA up-regulated during trophoblast  differentiation, 
has shown to be expressed in the placenta suggesting that they have a sustained 
functional role, from the initiation of the trophoblast formation to its later stages of 
development. In addition to this, there is also another set of microRNA which gets up-
regulated during the differentiation protocol and have not been reported yet in 
literature to be expressed in the placenta. Since the samples used in literature are 
mostly  term placentas, this subset of microRNA can be considered to be specific for 
the earlier stages of trophoblast differentiation. 
A subset of the microRNA which gets up-regulated during trophoblast  differentiation 
has shown to be present in the maternal serum. This opens up the possibility of using 
these microRNA as biomarkers to monitor the development progress of the 
trophoblast lineage, and therefore, to an extent, the health of the fetus. 
Main issue with the currently  available data on trophoblast differentiation is that most 
of them have been originally  discovered in the mouse model and have been 
extrapolated into the human model. Considering the scarcity of clinical samples and 
ethical issues, this is understandable. However given the evolutionary difference 
between mouse and human, and the resulting differences in basic mechanisms of early 
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development, such an extrapolation could potentially  lead to misinterpretations. As an 
example, the genes for hCG, the main marker of trophoblast lineage is absent in the 
mouse model. To understand the difference between early development 
transcriptomics of human and mouse, and to isolate transcriptomic events specific to 
human, I generated a RNA-Seq dataset of early  mouse differentiation which included 
samples representing mouse 8-cell stage, E3.5 blastocyst, E4.5 blastocyst and E 4.5 
inner cell mass. The inclusion of an E4.5 inner cell mass sample enables the isolation 
of mouse trophoblast specific transcriptomic events. This dataset  was then compared 
to the RNA-Seq data from the human trophoblast differentiation. 
Major observation of this comparison was the apparent difference in the expression 
levels of genes between the human and mouse systems. Based on the expression 
levels, it  is evident that at least as far as the trophoblast lineage is concerned different 
molecular mechanisms participate in each of the two species.
For example the “classical” trophoblast related genes - Gata3 and Cdx2 are up-
regulated at extremely  high levels in the mouse trophoblast. In comparison, while 
GATA3 is expressed in the human (RNA-Seq and pre-implantation) system and CDX2 
is up-regulated during trophoblast formation, the expression levels are much lower 
compared to that of the mouse system. On the other hand transcription factors such as 
GCM1 which are highly  expressed in the human system is only faintly expressed in 
mouse. 
The species dependent divergence of trophoblast related biological mechanisms is a 
characteristic of the hourglass model of development. Briefly explained, the model 
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suggests that organisms of the same animal phylum have a particular stage, termed the 
phylotypic stage, where they  look morphologically similar to each other. Beyond this 
stage and before this stage, development is dissimilar just like the ends of an 
hourglass. The major criticism leveled against this model has been that the 
observation is based on morphological similarity alone. However two recent papers, 
characterizing the conservation of gene expression pattern within fish and fly  species 
across developmental time, have shown that the phylotypic similarities are observable 
at the molecular level as well (Domazet-Lo#o and Tautz 2010; Kalinka, Varga et al. 
2010). The phylotypic stage is considered to occur following gastrulation at 
approximately the early somite stage. Therefore the human and mouse transcriptomic 
data presented here belong to a time-point before the phylotypic stage. This explains 
the significant difference in the transcriptome of human and mouse seen by RNA-Seq.
The area of focus of this thesis falls on a very narrow region of the hourglass model 
much earlier than the phylotypic stage. Concerning that particular region, the human 
and mouse transcriptomic differences is in agreement with the hourglass model of 
development. That being said, due to the lack of information of our dataset on the 
conserved time points of the model, the data presented in this thesis cannot be used to 
support the rest of the hourglass model.
Since the differences between the human and mouse shown in this thesis is in 
alignment with the hourglass model of development, at the developmental stage the 
samples belong to, it is essential to find the cause of the divergence. In other words it 
is important to identify what factor / factors contribute to the developmental 
differences at the molecular level between the mouse and the human system. 
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This thesis presents ample examples which show that primate-specific retroviral 
elements in the human genome have an important function in trophoblast 
development. The number of expressed retroviral elements - namely  the trophoblast-
specific components of SINES, LINES and HERV-K elements of LTRs - are highly 
increased during differentiation. This increase is consistent with the increase of 
overall gene expression which peaks at day 2 during trophoblast differentiation. The 
expression of retroviral elements is widespread throughout the genome.
Syncytin 1 and Syncytin 2, both of which have origins in retroviral genes, and 
involved in placenta formation, get induced during differentiation and are among the 
most highly up-regulated.
The genes CYP19A1, EDNRB and PTN are known to have promoters which have 
originated from retroviral insertions resulting in production of placenta specific / 
enriched isoforms. These genes are highly expressed during human trophoblast 
differentiation and the major isoform in all these cases is the one under the regulation 
of the retroviral promoter. This suggests that  the retroviral elements have an important 
regulatory role in trophoblast differentiation.
One of the novel observations made during RNA-Seq analysis was where, a new 
unannotated exon, with origins of retroviral sequences, initiates expression during 
trophoblast differentiation. This is seen in a number of genes including CLDN4, 
DHX32 and ZBTB3, SCGB3A2. In the cases where the gene is a transcription factor 
the effects of retroviral expression will be amplified.
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The expression of retroviral elements in early development has also seen in other 
species including mouse. Therefore the expression of the retrotransposon elements are 
by no means a human specific event. However since the retrotransposon complement 
- both location and sequence - of each species is unique it is clear that the 
retrotransposon transcriptome is significantly different from each other. Because of 
this difference and the fact that most of them are expressed, they  have the capacity to 
regulate and create species specific transcriptomic events.
In summary, Focusing exclusively on the transcriptome of early  development, mainly 
in human and to a limited extent in the mouse I have catalogued the dynamics of 
known genes and also described novel transcriptomic phenomena. I also provide 
evidence for the hourglass model of development in human and mouse at the 
molecular level during trophoblast differentiation, and suggest that the expression of 
retroviral elements might be the driving force for species specific transcriptomic 
events. 
Be it human, mouse or any  other species, early  development is one of the most 
important and biologically fascinating field of study. Considering its importance and 
complexity, it will take quite some time for science to be able to fully  describe it. I 
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Appendix I : Python code for workflows
RPKM calculation
Input file: 
The default exon counts file produced by ABI bioscope pipeline
Command:  
python  counts2RPKM.py  <bioscope counts file>  <sequencing depth>
Code:
counts2RPKM.py
#this script takes in a counts file and produces RPKM values for individual genes.







for line in open(fName,'r'):
    temp = line.strip(`).split('\t')
    if temp[2] == 'exon':
        chr = temp[1]
        start = int(temp[3])
        stop = int(temp[4])
        length = stop - start
        hits = int(temp[5])
        geneID = temp[8].split('"')[1].split('"')[0]
        if geneID[-1:]=='P':
            geneID = geneID[:-1]
        #print line.split()
        #print chr,start,stop,hits,geneID
        if geneID in countsDic:
            #geneId has already been added
            countsDic[geneID] = countsDic[geneID]+hits
            lengthDic[geneID] = lengthDic[geneID]+length
        else:
            countsDic[geneID] = hits
            lengthDic[geneID] = length
k = countsDic.keys()
k.sort()
for gene in k:
    totalCounts = countsDic[gene]
    totalLength = lengthDic[gene]/2
    if totalCounts == 0:
        print gene, totalCounts,totalLength,0
    else:
        print gene, totalCounts,totalLength, (totalCounts/(totalLength/1000))/seqDepth 
* 1000000
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Identification of novel transcribed regions
Inputs:
1) A folder containing all the wig files for each chromosome-strand pair.(The 
naming convention should be as follows - chr<#>.<pos/neg>.wig - eg. 
chr1.pos.wig)
2) The default counts file containing RefSeq counts from the ABI bioscope output.
(The scripts can be modified to use others.)
 
Output:
 The final output will be a folder containing identified NTRs.
 There will be a seperate file for NTRs for all chromosome / strand 
combinations.
 The NTR files will be tab delimited and will have the following columns 
describing the identified NTR peak.
 [<chromosome><strand><start><stop><min height><max 
height><length><ucsc notation><total area>
Command:
 The NTR identification process includes the following steps...
 1)Processing the counts file
 2)Creating a gap file from the counts file.
 3)Identification of NTRs.
1)Processing the counts file.
The biosocpe counts file shows counts for each exon / cds / start codon of refSeq.
First remove CDS and start_codon counts.
Then sort the counts file in the following order 
     i)chromosome ASC
     ii)strand ASC
     iii)start position ASC
Name the counts file as [sampleID].exons.sorted.txt, and use it for the next step.
2)Creating a gap file from the counts file.
python gaps.py [counts file] > [gapfile.txt]
Recommended gapfile name - [sampleID].exon.gap.txt
3)Identification of NTRs.
Once the above script is run type...
python peakcall_iterate_bsub.py [wiggle file folder] [resuls folder] [gap file] 





#finds gaps in a list of annotated regions.
#Input - tab delimited file of strand specific annotated regions (e.g refseq)
#Input format - chr,start,stop,strand,Info - Sorted Ascending in the following order - 
chr,start,strand # corrction 18/8/2010 chr,strand,start
#Output - list of ranges of the 'gaps' between the given annotations.
import sys
try:
    annotfile = sys.argv[1] #The input file
except:
    print 'Incorrect input.'
    print ' python gaps.py <Inputfile>'
    




for line in open(annotfile,'r'): #reads the annotation file line by line
    
    #stripping data from the current line
    
    
    temp = line.split('\t')
    chr = temp[0].strip()
    strand = temp[3].strip() 
    starts = int(temp[1])
    ends = int(temp[2])
    #info = temp[8].split('\n')[0] #this field in unique for the refseq annotation
    
    
    
    
    #This begins the comparing process
    
    if prevstop > starts:
 #usually this cannont be the case, if this is true then either there is an overlap 
between two annotations or the annotation range is on a different chromosome / strand
        if (prevchr == chr and prevstrand ==strand): 
#checks to see if its the same chr/strand combination; if this is the case then its an 
overlap.
            
            if prevstop < ends: 
# Checks if the current seqments if fully immersed in the previous one. i.e. a 100! 
overlap.
                
                prevstop = ends 
# if ends is greater then shifts the prevstop position and does not print anything as 
there is not 'gap'
            
        else:
            #its a change in either the chromosme or the strand
            prevstop = -1 
#resets the prev position and prints the gap from start to the currenet position
            print chr,'\t',prevstop+1,'\t',starts-1,'\t',strand
            
    else:
            a=1
            #A normal sequential annotation.
            print chr,'\t',prevstop+1,'\t',starts-1,'\t',strand 
        
    
    
    prevstop = ends
    prevchr = chr
    prevstrand = strand




#(c)  Genome Institute of Singapore. 
#Input - tab delimited file; Format  - chr,start,stop,strand
try:
    import psyco
    psyco.full()
except:








dic = {} #this is the dictionary which will contain all the data from the wig file
#first the script adds the entire wig file to a dictionary. WARNING - you need a 
considerable amount of ram. This mac has 4Gig and it seems sufficient.
for line in open(wigfile,'r'): #loops through the file reading each line and adds it 
to the dictionary - dic
    temp = line.split('\t') 
    pos = temp[0]
    
    if pos.isdigit(): #prevents the header giving an error.
        pos = int(pos)
        count = int(temp[1].split()[0])
        
        dic[pos] = count #dic is the dictionary
        
line = '' #reusing line and temp variables
temp = ''
prevplace = 0
peak={} # this will act as a temporary dictionary to contain the data of a peak
for line in open(gapfile,'r'): #reads the file containing the gap positions line by 
line    
    temp = line.split('\t')
    chr = temp[0].split()[0] 
    strand = temp[3].split()[0]
    
    if chr==chromosome and strand == inputstrand: #This limits the search for only the 
given chromosome and strand.
        starts = int(temp[1])
        stops = int(temp[2]) #start and stop coordinates of the gap
        
        prevplace = starts-1 #this holds the previous stop+1 
        
        for i in range(starts,stops+1): #why use stops+1?
        
            try:
                d =  dic[i] # checks if the position contains a value in the 
dictionary. if not there will be an error.
                #ithere IS a count value for the given position
                
                
                if d > minthreshhold: #provides a threshhold value for the peaks
                    #itpiht there is a count for the position and it is more than the 
threshhold
                    
                    if (i-prevplace) == 1: #checks if the current position is adjecent 
to the  previous. i.e checks for continuity.
                        
                        peak[i] = int(d)
                        d=0
                        
                    else:
                        #itpiht there is gap i.e the peak has stopped! So showld 
display the peak.
                        q=2
                        
                        
                prevplace = i    
        
        
            except :
                q=2 #The peak has ended
                if len(peak) > minpeaksize:
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                    peakpoints = peak.values()
                    peakkeys = peak.keys()
                    #print 'max', max(peakpoints)
                    #print 'min',min(peakpoints)
                    #print 'length',len(peakpoints)
                    c = len(peakpoints)-1
                    tot = 0
                    for i in peakpoints:
                        tot = tot+int(i)
                    print chr,'\t',strand,'\t',min(peakkeys),'\t',max
(peakkeys),'\t',max(peakpoints),'\t',min(peakpoints),'\t',len
(peakpoints),'\t',chr,':',min(peakkeys),'-',max(peakkeys),'\t',tot
                    
                    
                    peak.clear() #resetting the peak dictionary
                else:
                    peak.clear()
                    
    #to run after the loop ends (this is for peaks which end with the range). i.e the 
peaks which continues throught the annotations, i.e. the extensions?
                    
    if len(peak) > minpeaksize:
                    peakpoints = peak.values()
                    peakkeys = peak.keys()
                    
                   
                    c = len(peakpoints)-1
                    tot = 0
                    for i in peakpoints:
                        tot = tot+ int(i)
                    print chr,'\t',strand,'\t',min(peakkeys),'\t',max
(peakkeys),'\t',max(peakpoints),'\t',min(peakpoints),'\t',len
(peakpoints),'\t',chr,':',min(peakkeys),'-',max(peakkeys),'\t',tot
                    
                    
                    
                    peak.clear() #resetting the peak dictionary
    else :
        peak.clear()
        
            
    #print '-----------------------------'
    peak.clear()
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Identification of novel transcripts
Steps:
Input:
1) A concatenated NTR file
2) File containing gene footprints
Command:
1) To identify NTRs which are close to a known gene
python getCloseNTRs.py <NTR file> <Genefootprint file> <max gap>
2) To get a list of NTRs which are not close to any gene
python compare.py <output of 1> <NTR file>
3) To identify transcripts





for line in open(sys.argv[1],'r'):
    list.append(line.strip())
b = 0
for line in open(sys.argv[2],'r'):
    temp = line.strip().split('\t')
    chr = temp[0].strip()
    start = int(temp[2].strip())
    stop = int(temp[3].strip())
    strand = temp[1].strip()
    #print chr,start,stop,strand
    for i in list:
        temp2 = i.strip().split('\t')
        chr1 = temp2[6].strip()
        start1 = int(temp2[8].strip())
        stop1 = int(temp2[9].strip())
    
        strand1 = temp2[7].strip()
        #print chr1,start1,stop1,strand1
        if chr == chr1 and start == start1 and stop == stop1 and strand == strand1 :
            #print line.strip()
            b = 1
    if b == 0:
        print line.strip()
    if b == 1:







#addint the NTRfile to a dictionary...
dic = {}
for line in open(NTRFile,'r'):
    temp = line.strip().split('\t')
    tID = temp[0]+temp[1]+temp[2]+temp[3]
    #print temp[4],temp[12],temp[13],temp[14],temp[15]
    dic[tID] = line.strip()
for line in open(geneFootPrintFile,'r'):
    temp = line.strip().split('\t')
    print line
    #print temp[0],temp[1],temp[2],temp[3],temp[4]
    geneID  =temp[0].strip()
    chr = temp[1].strip()
    start = int(temp[2])
    stop = int(temp[3])
    strand = temp[4].strip()
    setGene = set(range(start,stop))
    setGeneExtended = set(range(start-n,stop+n))
    for ntr in dic:
        t = dic[ntr].strip().split('\t')
        nchr = t[0].strip()
        nstrand = t[1].strip()
        if nchr == chr and nstrand == strand :
            nstart = int(t[2])
            nstop = int(t[3])
            setNTR = set(range(nstart,nstop))
            L1 = len(setGene & setNTR)
            L2 = len(setGeneExtended & setNTR)
            if L1 == len(setNTR) or L2 == len(setNTR):
                'L3','\t',line.strip(),'\t',dic[ntr].strip()
            else:
                if L1> 0:
                    print 'L1','\t',line,'\t',dic[ntr],'\t',L1
                #print geneID,chr,start,stop,strand,nchr,nstrand,nstart,nstop,'L1',L1
                if L2 > 0:
                    print 'L2','\t',line.strip(),'\t',dic[ntr].strip(),'\t',L2
                
                #print geneID,chr,start,stop,strand,nchr,nstrand,nstart,nstop,'L2',L2
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identifyTranscripts.py







for line in open(sys.argv[1],'r'):
    temp = line.strip().split('\t')
    chr = temp[0].strip()
    strand = temp[1].strip()
    start = int(temp[2].strip())
    stop = int(temp[3].strip())
    if chr == prevChr and prevStrand == strand and (start - prevStop) <=  n:
        print '@@@@@@@', start - prevStop, start,prevStop
        tempList.append(line.strip())
    else:
        if len(tempList)>= 2:
            j = 0.00
            for i in tempList:
                print i.strip()
                j = j + float(i.strip().split()[-1])
                
            print j / len(tempList)
            print tempList[0].strip().split('\t')[0],':',tempList[0].strip().split('\t')[2],'-',tempList[-1].strip().split('\t )[3]
            tempList = []
            tempList.append(line.strip())
            print '====================='
        else:
            tempList = []
            tempList.append(line.strip())
            
    prevStop = stop
    prevChr = chr
    prevStrand = strand




3UTR - bed file containing 3’ UTRs
allexonfile - bed file containing all exons
wigfile - original ABI file
Command:
python <3UTR> <chr> <strand> <wigfile> <allexonfile>
Code:
correctEnds.3prime.+.py
#this script is only for + strand.
import sys
exonFile = sys.argv[1] #exon file containing only annotated 3' exons
chr = sys.argv[2] #in the chrn format
strand = sys.argv[3].strip()
wigFile = sys.argv[4].strip() #corresponding wig file
originalExonFile = sys.argv[5] #the exon file containing all exons
oriExon = []
#loading the originalExonFile
for line in open(originalExonFile,'r'):
    temp = line.strip()
    oriExon.append(temp)
    
#loading the wiggle file into the dictionary
wigDic = {}
for line in open(wigFile,'r'):
    temp = line.strip().split('\t')
    #print temp[0],temp[1]
    wigDic[int(temp[0])] = int(temp[1]) #wigDic[pos]=count
    
for line in open(exonFile,'r'): #goes through all the 3' UTR exons one by one
    flag = 0
    temp = line.strip().split('\t')
    echr = temp[1].strip()
    estrand = temp[4].strip()
    #print echr,estrand,chr,strand
    if chr == echr and strand == estrand: #looks if the 3' UTR exon is withing the 
given chr and strand combination
        
        NM = temp[0]
        #print NM
        start = int(temp[2]) #start and stop of the 3' UTR
        stop = int(temp[3])
        geneID = temp[5]
        coverage = 0
        total = 0
        avgheight = 0
        #finding the next anootation after this so that the gap between the current 3' 
UTR and the next gene
        for exon in oriExon:
            t = exon.strip().split('\t')
            oriChr = t[0]
            oriStart = int(t[1])
            oriStop = int(t[2])
            oriStrand = t[3]
            oriGene = t[4]
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            if chr == oriChr and oriStart == start and oriStop == stop and oriStrand 
== strand: #looking for the 3' UTR from the list containing all exons
                oriIndex = oriExon.index(exon) #save the index of it
                tempgeneID = oriGene
                while tempgeneID.strip() == oriGene.strip(): #passes the other 3' UTRs 
of the same gene! ??
                    oriIndex = oriIndex +1
                    tempgeneID = oriExon[oriIndex].strip().split('\t')[4].strip()
                    flag = flag + 1
                   # print tempgeneID,oriGene 
                #print chr,strand,start,stop,geneID
                
                #print oriExon[oriIndex], 'is the gene next to it'
                nextStart = int(oriExon[oriIndex].strip().split('\t')[1].strip()) # 
this marks then begining of the next gene #nextStart is the start of the next gene 
(i.e. the 5' UTR of the next gene)
                                
                                
              
                                
                                
        tempstart = stop
        coverage = 0
        total = 0
        gaps = 0
        lastPeakStop = 0
        if nextStart - tempstart > 20000:#the maximum gap the scrpt looks for is 
10000bp
            nextStart = tempstart+20000
        #print tempstart,nextStart
        if nextStart < tempstart:
            continue #bypasses cases where the next genefootprint starts before the 
end of the 3'UTR
        gapCount = 0 
        while gaps < 200 and  tempstart < nextStart -1 : #max gap allowed is 100
            #print tempstart,nextStart
            #print gaps, gaps < 200
            if tempstart in wigDic:
                coverage = coverage +1
                total = total + wigDic[tempstart]
                lastPeakStop = tempstart
                #if gaps >  0:
                    #gapCount = gapCount+1
                    #gaps = 0
                gaps = 0
                
            else:
                gaps = gaps +1
                gapCount = gapCount+1
            tempstart = tempstart + 1
            
        
        if coverage > 10: #coverage limit
            
            #print '=========================================='
            print 
chr,start,stop,strand,geneID,coverage,total,lastPeakStop,start,gapCount,tempgeneID,fla
g
            #print '==========================================='            
                
        ## for i in range(stop,stop+1001):
##             if i in wigDic:
##                 coverage = coverage +1
##                 total = total + wigDic[i]
##         if coverage > 10:
##             print chr,start,stop,geneID,coverage,total
            
219
 Identification of genes which show a change in their splicing profile 
during differentiation.
Input:
datafile - file containing exon read counts of all samples arranged in different columns
Command:
print 'input -> python altsplice.py <datafile>  <column number of first sample> 
<column number of second sample> <minimum_adjoining peak size> <min peak 
size> <ratio of ratios>' 




#Given a list of combined exon counts sorted according the exon and start position, 
this script identifies transcripts which show potential alt splicing.
#It assumes that the ratio of expression level of individual exons whithin a single 
transcript at a single time point is the same.
#input format:
#e.g sortedQuery, tab delimited, no header, optional [ID, chromosome,start, stop, 
strand, exon, strand] level for each sample,
#import statements
from __future__ import division # this line makes python division behave like normal 
i.e with decimals
#from statlib import stats #statlib package used to do statistical calculations
import sys
#assigning command line arguments to variables
try:
    fname = sys.argv[1] # data file
    
    d0place = int(sys.argv[2]) #position of the first sample
    d8place = int(sys.argv[3]) #position of the second sample
    
    minAdj = float(sys.argv[4]) #min size of adjoining peaks
    minPeak = float(sys.argv[5]) #min size of peak under study
    mul = float(sys.argv[6]) # multiplication factor
    
except:
    
    print 'input -> python altsplice.py <datafile>  <column number of first sample> 
<column number of second sample> <minimum_adjoining peak size> <min peak size> <ratio 
of ratios>'
    exit(1)
    # Typical input python altsplice.py sortedQuery.txt 10 5 9
#variable initiation
lines = [] #array of lines belonging to the same gene and having a non zero exon count
pgenename = '' #holds the name of the previous gene








dic= {} #dictionary of lines and the start position, user for sorting








for line in open(fname,'r'): #sortedQuery.txt contains the combination of all the exon 
counts sorted according to the gene
    temp = line.strip().split('\t')
    #genename = temp[0].split(';')[0].split()[1].split('"')[1].split('"')[0]
    genename = temp[9].strip()
    #print genename
    if pgenename == genename: #The objective here is to make a list (lines) of all the 
exons belonging to the same gene.
        lines.append(line)
    else:
        #once the lines list is filled it gets processed here
        
        #sorting the lines in the exon order
        for l in lines:
            dic[int(l.strip().split('\t')[2])] = l #dictionary format startposition : 
line
            
        #sorting dic
        dk = dic.keys()
        dk.sort() #get the list of keys i.e. startpositions and then sort that.
        
        
        for l in dk:
            t = dic[l].strip().split('\t')
            d0i = int(t[d0place])
            d8i = int(t[d8place])
            d0.append(d0i)
            d8.append(d8i)
            exonStartStop.append( str(t[0]).strip()+':'+str(t[1]).strip()+'-'+str(t
[2]).strip())
            exonStart.append(int(t[1].strip()))
            exonStop.append(int(t[2].strip()))
            #print t[1],t[2]
            
        
        #now that the two lists are filled....
        #print 'sdfad'
        #print exonStart
        #print exonStop
        prevExonLength = 0
        nextExonLength = 0
        nowExonLength = 0
        for i in range(1,len(d0)-2):
        
            
            
            if len(nowSet & prevSet) == 0:
                d0prev = d0[i-1]
                d8prev = d8[i-1]
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            else:
                #print 'wishva',pgenename
                d0prev = d0[i-2]
                d8prev = d8[i-2]
            if len(nowSet & nextSet) == 0:
                
                d0next = d0[i+1]
                d8next = d8[i+1]
            else:
                #print 'wishva',pgenename
                d0next = d0[i+2]
                d8next = d8[i+2]
           
            #start code for finding exons which goes completely AWOL
            if d0now < minPeak and d0now > 0 and d8now >= minPeak and d8prev > 0 and 
d8next > 0 and d8now / d0now >= mul:
                if (d0prev / d8prev  >=  mul/2 or d0next / d8next >= mul/2):
                #potential appearance of a peak
                    if d0prev >= minAdj and d0next>= minAdj and d8prev >= minAdj and 
d8next >= minAdj:
                        print pgenename,'\t', exonStartStop[i],'\t',pratio,'\t',  
nratio,'\t',d0prev,'\t',d0now,'\t',d0next,'\t',d8prev,'\t',d8now,'\t',d8next,'\t', 
pratio >= mul\
     and nratio>= mul, int(exonStartStop[i].split('-')[1]) - int(exonStartStop
[i].split(':')[1].split('-')[0]),"Extream UP"
            if d8now < minPeak and d8now > 0 and d0now >= minPeak and d0prev > 0 and 
d0next > 0 and d0now / d8now >= mul :
                if (d8prev / d0prev  >=  mul/2 or d8next / d0next >= mul/2) :
                #potential dissappearance of a peak                                     
                                                                
                    if d0prev >= minAdj and d0next>= minAdj and d8prev >= minAdj and 
d8next>= minAdj:
                        print pgenename,'\t', exonStartStop[i],'\t',pratio,'\t',  
nratio,'\t',d0prev,'\t',d0now,'\t',d0next,'\t',d8prev,'\t',d8now,'\t',d8next,'\t', 
pratio >= mul\
     and nratio>= mul, int(exonStartStop[i].split('-')[1]) - int(exonStartStop
[i].split(':')[1].split('-')[0]),"Extream DOWN"
              #      print 'vertical','\t',pgenename,'\t', exonStartStop
[i],'\t',pROR,'\t',  
nROR,'\t',d0prev,'\t',d0now,'\t',d0next,'\t',d8prev,'\t',d8now,'\t',d8next,'\t', 
pratio >= mul and nratio>= mul, int(exonStartStop[i].split('-')[1]) - int
(exonStartStop[i].split(':')[1].split('-')[0])
            
            
            #end code for vertical 
comparison----------------------------------------------------------------------------
----------------------------------
            if d0prev >= minAdj and d0next >= minAdj  and d8prev >= minAdj and d8next 
>= minAdj:
                
                if d0now >= minPeak and d8now >= minPeak:
                    
                
                
                
                
                    d0prevratio = d0now/d0prev
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                    d0nextratio = d0now/d0next
                    
                    d8prevratio = d8now/d8prev
                    d8nextratio = d8now/d8next
                    
                    
                    
                    #previous ratios
                    if d0prevratio >= d8prevratio:
                        pratio = d0prevratio/d8prevratio
                        
                    else:
                        pratio = d8prevratio / d0prevratio
                        
                        
                    #next ratios
                    if d0nextratio >= d8nextratio:
                        nratio = d0nextratio/d8nextratio
                    else:
                        nratio = d8nextratio / d0nextratio
                    
                    
                    
                    if pratio >= mul or nratio>= mul  : # or?
                        print pgenename,'\t', exonStartStop[i],'\t',pratio,'\t',  
nratio,'\t',d0prev,'\t',d0now,'\t',d0next,'\t',d8prev,'\t',d8now,'\t',d8next,'\t', 
pratio >= mul and nratio>= mul, int(exonStartStop[i].split('-')[1]) - int
(exonStartStop[i].split(':')[1].split('-')[0]),'\t',"Normal"
                        dir = ''
                        count = count+1
                        
                    
                                  
        d0 = []
        d8 = []
        exonStartStop = []
        ratio = []
        dic = {}
        
        
            
        lines = []
        lines.append(line)
    pgenename = genename
                  
print count
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mutualExclusive.py
#Given a list of combined exon counts arranged according to the exon this script 
identifies transcripts which show potential alt splicing.
#The combined counts file MUST be sorted based on geneID
#Wishva Herath, Robson Lab, Genome Institute of Singapore, Singapore
#(C) Jan 2010.
#import statements
from __future__ import division # this line makes python division behave like normal 
i.e with decimals
#from statlib import stats #statlib package used to do statistical calculations
import sys
#assigning command line arguments to variables
try:
    fname = sys.argv[1] # combined counts file
    d0place = int(sys.argv[2]) #The index of the first sample
    d8place = int(sys.argv[3]) #The index of the second sample
    geneIDpos = int(sys.argv[4]) #The index of the geneID
    gT = float(sys.argv[5]) # this is the min of first+second / exonlength
    ratio = float(sys.argv[6]) #the ratio between the first and the second
    #minAdj = int(sys.argv[4])
    #minPeak = int(sys.argv[5])
    #mul = float(sys.argv[6]) # multiplication factor of the standard deviation
   
   
except:
    
    print "Input error"
    print "python findMutualSpliced.py <combined exoncounts file.txt> <d0> <d8> 
<geneIDpos> <normTotal> <ratio>"
    exit(1)
    # Typical input python altsplice.py sortedQuery.txt 10 5 9
#variable initiation
lines = [] #array of lines belonging to the same gene and having a non zero exon count
pgenename = '' #holds the name of the previous gene
d0 = []
d8 = []
exonStartStop = [] 
dic= {} #dictionary of lines and the start position, user for sorting
for line in open(fname,'r'): #sortedQuery.txt contains the combination of all the exon 
counts sorted according to the gene
    temp = line.strip().split('\t')
    #genename = temp[0].split(';')[0].split()[1].split('"')[1].split('"')[0] #This is 
for the combined gap files produced by accsess. 
    genename = temp[geneIDpos].strip()
    #print genename
    if pgenename == genename: #The objective here is to make a list (lines) of all the 
exons belonging to the same gene.
        lines.append(line)
    else:
        #once the lines list gets filled with exon data of a particular gene it gets 
here.
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        #sorting the lines in the exon order
        for l in lines:
            dic[int(l.strip().split('\t')[1])] = l #dictionary format startposition : 
line
            
        #sorting dic
        dk = dic.keys()
        dk.sort() #get the list of keys i.e. startpositions and then sort that.
        
        
        for l in dk:
            t = dic[l].strip().split('\t')
            d0i = int(t[d0place])
            d8i = int(t[d8place])
            d0.append(d0i)
            d8.append(d8i)
            exonStartStop.append( str(t[0]).strip()+':'+str(t[1]).strip()+'-'+str(t
[2]).strip())#contains chr:start-stop
        
        FC = []
        normGap = []
        rr = []
        rr.append(1.234)
        rr.remove(1.234)
        for i in range(0,len(d0)):
            first = int(d0[i])
            second = int(d8[i])
            gap = int(exonStartStop[i].split('-')[1]) - int(exonStartStop[i].split
(':')[1].split('-')[0])
            
            normGap.append((first+second)/gap)
            
            if ((first+second)/gap)  > gT :
                if first == 0 and  second == 0 :
                    #print 'zero'
                    rr.append(float(0))
                    FC.append('z')
                elif first == 0 and second > 1:
                    FC.append('Mu')
                    rr.append(float(0))
                elif second == 0 and first > 1:
                    FC.append('Md')
                    rr.append(float(0))
                elif first == second:
                    FC.append('e')
                    rr.append(float(1))
                elif first / second  > ratio:
                    rr.append(first/second)
                    FC.append('d')
                elif second / first > ratio:
                    rr.append(float(second/first))
                    FC.append('u')
                else:
                    FC.append('n')
                    if first > second:
                        rr.append(float(first / second))
                    else:
                       # rr = second/first
                        rr.append(float(second/first))
            else:
                FC.append('l')
                if first <> 0 and second <> 0:
                    if first > second:
                        rr.append(float(first / second))
                    else:
                        rr.append(float(second / first))
                else:
                    rr.append(float(0))
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        #print FC
        
        if 'u' in FC and 'd' in FC:
            print '------------------------------------------------'
            print 'GENEID=',pgenename
            
               
            for j in range(0,len(d0)):
                #print "Complete Mutual Exclusion!"
                print FC[j],d0[j],d8[j],exonStartStop[j],normGap[j],rr[j]
                #pass
        if 'Mu' in FC and 'Md' in FC:
            print "complete mutual exclusivitiy"
            for j in range(0,len(d0)):
                print FC[j],d0[j],d8[j],exonStartStop[j],normGap[j],rr[j]
        
                  
        d0 = []
        d8 = []
        exonStartStop = []
        
        dic = {}
        
        
            
        lines = []
        lines.append(line)
    pgenename = genename
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Appendix II: Sequences of novel transcripts
Novel transcripts were validated by designing primers to amplify the transcript, 
running PCR, performing gel purification, cloning the amplicon into a top10 vector 
and sequencing the vector. The entire sequence of the sequenced vector is given. The 
primer sequence is shown in bold and underlined text.

















































































































































































































































































































































Appendix III: Sequencing statistics
Day 0
Counts:
Reads mapped:                                               42845342    (100.0%)
Reads filtered:                                              5866117    (13.7%)
Reads with too many mappings (N > 10):                       3261829    (7.6%)
Reads with number of mappings in proper range (N <= 10):    39583513    (92.4%)
Reads uniquely aligned (score.clear.zone =  4):             26955116    (62.9%)
Reads mapped to NTR: 1703606
Day 2
Counts:
Reads mapped:                                               42203140    (100.0%)
Reads filtered:                                              4238302    (10.0%)
Reads with too many mappings (N > 10):                       3363120    (8.0%)
Reads with number of mappings in proper range (N <= 10):    38840020    (92.0%)
Reads uniquely aligned (score.clear.zone =  4):             27790743    (65.8%)
Reads mapped to NTR: 3055869
Day 4
Counts:
Reads mapped:                                               40421804    (100.0%)
Reads filtered:                                              4105623    (10.2%)
Reads with too many mappings (N > 10):                       3378454    (8.4%)
Reads with number of mappings in proper range (N <= 10):    37043350    (91.6%)
Reads uniquely aligned (score.clear.zone =  4):             26832589    (66.4%)
Reads mapped to NTR: 3283724
Day 6
Counts:
Reads mapped:                                               40218029    (100.0%)
Reads filtered:                                              5020898    (12.5%)
Reads with too many mappings (N > 10):                       3065324    (7.6%)
Reads with number of mappings in proper range (N <= 10):    37152705    (92.4%)
Reads uniquely aligned (score.clear.zone =  4):             26237091    (65.2%)
Reads mapped to NTR: 2814868
Day 8
Counts:
Reads mapped:                                               40174214    (100.0%)
Reads filtered:                                              4056325    (10.1%)
Reads with too many mappings (N > 10):                       2866193    (7.1%)
Reads with number of mappings in proper range (N <= 10):    37308021    (92.9%)
Reads uniquely aligned (score.clear.zone =  4):             26370337    (65.6%)
Reads mapped to NTR: 2642161
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3.5BL
Reads mapped:                                               63348717    (100.0%)
Reads filtered:                                              4357607    (6.9%)
Reads with too many mappings (N > 10):                       8221261    (13.0%)
Reads with number of mappings in proper range (N <= 10):    55127456    (87.0%)
Reads uniquely aligned (score.clear.zone =  4):             38227773    (60.3%)
E4.5BL
Reads mapped:                                               69274851    (100.0%)
Reads filtered:                                              4162828    (6.0%)
Reads with too many mappings (N > 10):                       9230754    (13.3%)
Reads with number of mappings in proper range (N <= 10):    60044097    (86.7%)
Reads uniquely aligned (score.clear.zone =  4):             45011450    (65.0%)
E4.5 ICM
Reads mapped:                                               65735255    (100.0%)
Reads filtered:                                              2739158    (4.2%)
Reads with too many mappings (N > 10):                      12190267    (18.5%)
Reads with number of mappings in proper range (N <= 10):    53544988    (81.5%)
Reads uniquely aligned (score.clear.zone =  4):             37920430    (57.7%)
8 cell
Reads mapped:                                               66423689    (100.0%)
Reads filtered:                                              2155598    (3.2%)
Reads with too many mappings (N > 10):                      10926984    (16.5%)
Reads with number of mappings in proper range (N <= 10):    55496705    (83.5%)
Reads uniquely aligned (score.clear.zone =  4):             37635809    (56.7%)
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